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Thesis Abstract 
 
Aims 
Columnar metaplasia in the oesophageal remnant occurring after subtotal 
oesophagectomy (neo-Barrett’s) has been proposed as a human model for the 
development of Barrett’s oesophagus.  This study aimed to assess the 
incidence of this phenomenon and it’s accuracy as a model as well as looking 
for evidence of field cancerisation in the oesophagus. 
 
Methods 
Patients underwent prospective endoscopic evaluation having previously 
undergone oesophagectomy.  The presence or absence of columnar epithelium 
above the surgical anastomosis was noted and biopsies taken.  Specimens 
were stained using H&E and, where consent was granted, with 
immunohistochemical stains for proteins which have a well described 
expression pattern in Barrett’s oesophagus.  Tumours and adjacent Barrett’s 
oesophagus from patients who subsequently developed neo-Barrett’s were 
screened for genetic mutations.  Where these were present, subsequent neo-
Barrett’s samples were evaluated for the presence of these mutatations 
 
Results 
Of 126 eligible patients, 45 (36%) had confirmed neo-Barrett’s.  Median time 
from surgery was greater for patients with neo-Barrett’s (5.7 vs 2.2yrs, 
p<0.001).  There were no cases of dysplasia.  Non-intestinalised columnar 
epithelium occurred earlier than neo-Barrett’s with specialised intestinal 
metaplasia.  Surgery for dysplastic Barrett’s or adenocarcinoma was associated 
with a similar prevalence of neo-Barrett’s to other indications (41% vs 27%, 
p=0.157).  37 samples underwent molecular analysis.  Typical, Barrett’s like 
CK7/20 staining pattern was present in 23 cases (62%).  Chromogranin A and 
trefoil factors 1 and 2 were were present in all cases.  TFF3 expression was 
significantly associated with increasing time from surgery (median 8.1yrs vs 
3.4yrs, p=0.004).  Genetic mutations identified in the resection specimen were 
not present in the neo-Barrett’s tissue. 
 
 
ii 
Conclusions 
Columnar metaplasia is common following oesophagectomy.  Cellular protein 
expression is similar to that of sporadic Barrett’s suggesting this is an accurate 
model.  Presence of intestinal metaplasia and TFF3 expression appear to 
represent later stages in the development of Barrett’s.  No evidence of field 
cancerisation was found. 
iii 
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Chapter 1. Introduction 
2 
1.1 Barrett’s Oesophagus 
Barrett’s oesophagus is a condition in which the normal squamous mucosa of 
the oesophagus is replaced by a metaplastic columnar epithelium.  Over recent 
years there has been a move away from this eponymous description towards 
the descriptive terminology ‘Columnar Lined Oesophagus’ (CLO).  The 
importance of this condition relates to the associated increased risk of 
oesophageal adenocarcinoma.  Over the past three decades, the incidence of 
oesophageal adenocarcinoma has been increasing faster than that of any other 
major malignancy in the western world.  This is felt to represent a true increase 
in disease burden, unexplained by reclassification or changing diagnostic 
practice(Pohl and Welch, 2005). 
 
1.2 Historical background 
Barrett’s oesophagus owes its name to Norman Barrett (1903-1979) an 
Australian born surgeon working in England and president of the British Society 
of Thoracic and Cardiovascular Surgeons of England.  There can however be 
few eponymous conditions with quite such a complex and intriguing history. 
 
The first descriptions of this condition pre-date Barrett’s seminal paper by 
almost fifty years. Tileston (1906) described cases of oesophageal ulcers found 
at autopsy.  He noted the ‘close resemblance of the mucous membrane about 
the ulcer to that normally found in the stomach’.  Barrett’s original paper 
(Barrett, 1950) described several cases of oesophageal ulcers which were 
surrounded by columnar epithelium.  In this paper he incorrectly hypothesised 
that this columnar lined organ was in fact stomach which had been pulled up 
into the mediastinum as a result of a congenitally short oesophagus. 
 
Allison and Johnstone (1953) reported the cases of seven patients with 
columnar lining of what they correctly recognised as being lower oesophagus 
rather than intra-thoracic stomach.  They also described the presence of goblet 
cells in one patient, the hallmark of specialised intestinal metaplasia.  Barrett 
came to accept Allison and Johnstone’s theory that the condition represented 
columnar lined oesophagus and in 1957 published a further paper recognising 
this(Barrett, 1957).  The next key debate was whether this columnar epithelium 
was congenital or acquired.  Barrett had concluded that it was a congenital 
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condition resulting from ‘a failure of the embryonic lining of the gullet to achieve 
normal maturity’, a view which was widely accepted.  Hayward (1961) 
challenged this hypothesis in a landmark paper, postulating that columnar lined 
oesophagus was a metaplastic condition, acquired as a result of gastro-
oesophageal reflux.  Evidence for this theory came from a canine 
model(Bremner et al., 1978).  This experiment showed that excision of the lower 
oesophageal lining was followed by the return of squamous epithelium unless 
acid reflux was introduced, in which case a columnar epithelium resulted. 
 
It is universally accepted today that Barrett’s or columnar lined oesophagus is a 
metaplastic condition acquired due to the injurious effects of acid and bile reflux. 
 
1.3 Diagnosis of Barrett’s Oesophagus 
The diagnostic criteria for Barrett’s oesophagus have changed several times 
and differences remain between European and American guidelines.  This 
inconsistency is important, not only for clinicians and patients, in part it explains 
the variation in reported rates both of Barrett’s and in the associated risk of 
malignancy. 
 
1.3.1 Endoscopic features of Barrett’s 
It is possible to identify columnar epithelium during endoscopic examination of 
the upper gastro-intestinal tract.  It appears redder and more velvet-like in 
texture than squamous epithelium which has a pale, almost glossy appearance.  
Where the squamo-columnar junction occurs above the gastro-oesophageal 
junction, a segment of Barrett’s is present. 
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Figure 1.1: Endoscopic view of a segment of Barrett’s oesophagus.  Single 
white arrow shows gastro oesophageal junction (GOJ), double black arrows 
show squamo-columnar junction proximal to GOJ  
 
 
The difficulty in diagnosing Barrett’s at endoscopy relates to the difficulty in 
identifying the precise location of the gastro-oesophageal junction.  The lower 
oesophageal sphincter can be readily identified during oesophageal 
mannometry but this is rarely carried out prior to endoscopy.  In the absence of 
this precise measurement various surrogates are used.  There is often a distinct 
‘flaring out’ as one enters the stomach but this feature is lost in the presence of 
a hiatus hernia.  The accepted method of identifying the gastro-oesophageal 
junction is, therefore, to note the position of the most proximal gastric folds.  
Even this method is somewhat unsatisfactory as over insufflation by the 
endoscopist will distend the lumen and obliterate the folds resulting in the 
position of the GOJ being incorrectly identified. 
 
When a long segment of columnar epithelium is present the diagnosis is 
obvious.  However when shorter segments are present the issue of precise 
location of the GOJ becomes critically important.  The endoscopist may 
incorrectly identify columnar epithelium in the gastric cardia as columnar lined 
oesophagus, especially in the presence of a hiatus hernia.  In an effort to 
prevent such false positive diagnoses, early investigators set an arbitrary 
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requirement of a 3cm segment of columnar epithelium in order to make the 
diagnosis.  Subsequent discovery that adenocarcinoma could arise in shorter 
segments of columnar epithelium led to the recognition of so-called ‘short-
segment Barrett’s oesophagus’ with a length of <3cm(Schnell et al., 1992).  In 
recent years this classification into short or long segment disease has fallen by 
the wayside.  Whilst there is evidence to show an association between segment 
length and malignant progression, a diagnostic cut-off at 3cm is not clinically 
relevant(Weston AP et al., 2004, Rudolph RE et al., 2000).  Both the British 
Society of Gastroenterology and the American College of Gastroenterology no 
longer include segment length in their definitions of Barrett’s oesophagus. 
 
The Prague C and M criteria (Prateek et al., 2006) have been proposed as a 
method of standardising endoscopic descriptions.  Segments of Barrett’s are 
described in terms of circumferential (C) and maximal (M) length from the 
gastro-oesophageal junction.  These have been demonstrated to have excellent 
inter-observer reliability between expert endoscopists with a specialist interest 
in Barrett’s and there is some evidence that this is reproducible for trainee 
endoscopists (Vahabzadeh et al.).  There is however no consideration of 
islands of columnar mucosa in these criteria. 
 
1.3.2 Histological features of Barrett’s 
Histology alone rarely proves diagnostic for Barrett’s oesophagus.  Only 
biopsies showing native oesophageal structures with juxtaposition to 
metaplastic glandular mucosa provide definitive histological proof of Barrett’s 
(British Society of Gastroenterology guidelines, 2005).  This situation is rare and 
accurate diagnosis is therefore best achieved with histological corroboration of 
endoscopic findings.  For this reason it is essential that precise descriptions of 
the site of biopsies are available to the pathologist.   
 
In their seminal paper Paull et al (1976) used manometric techniques to prove 
the oesophageal nature of biopsy samples.  They demonstrated a spectrum of 
epithelial patterns in patients with columnar lined oesophagus.  Three distinct 
types of columnar epithelium are described (figure 1.2).   
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1. Gastric fundic type epithelium with parietal and chief cells  
2. Junctional or Cardiac type epithelium with cardiac mucus glands 
3. Specialised columnar epithelium with a villiform surface mucus glands and 
intestinal type goblet cells (also termed specialised intestinal metaplasia) 
 
Gastric fundic and junctional type epithelium can be indistinguishable from the 
normal lining of the gastric fundus and cardia and hence are not diagnostic for 
columnar metaplasia unless the biopsies are known to have been taken from 
the oesophagus. 
 
 
 
 
Figure 1.2: Histological subtypes of Barrett’s oesophagus (a) Gastric fundic 
type, (b) Cardiac type, (c) Specialised intestinal metaplasia (Chandrasoma, 
2005).  Reproduced with kind permission of John Wiley and sons 
 
 
1.3.3 The intestinal metaplasia question 
The specialised columnar epithelium is often described as specialised intestinal 
metaplasia (SIM).  The importance of SIM has been debated over the years 
with many authors suggesting that the diagnosis of Barrett’s should only be 
made when this has been demonstrated.  American guidelines have historically 
a 
b 
c 
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included SIM in their definition of Barrett’s whereas European guidelines have 
not.  The most recent American College of Gastroenterology guidance 
recognises this inconsistency but continues to advise that SIM is required to 
make the diagnosis(Wang and Sampliner, 2008). 
 
It is recognised that the yield of SIM decreases as the length of the columnar 
segment shortens and fewer biopsies are taken.(Harrison R et al., 2007, Wang 
and Sampliner, 2008)  It is therefore possible that the absence of SIM in 
biopsies of a columnar segment reflects a sampling error, rather than a true 
absence of SIM in the segment.  Even where SIM is demonstrated, Barrett’s 
cannot be considered to be confirmed on the basis of histology alone as this 
could represent intestinal metaplasia of the cardia, a condition associated with a 
much lower malignant potential than Barrett’s. 
 
Until recently it was widely accepted that SIM was the epithelial type associated 
with the greatest, if not the only, predisposition to adenocarcinoma.  Data from a 
Northern Ireland based cohort study (Anderson et al., 2003) indicated that only 
patients with SIM had a significantly increased mortality from oesophageal 
cancer.  Recent work looking at the background epithelium in endoscopic 
mucosal resection specimens of small adenocarcinomas has challenged this 
belief (Takubo et al., 2009).  In over 70% of cases, small oesophageal 
adenocarcinomas were surrounded by cardiac or fundic type mucosa rather 
than SIM.  
 
1.4 Epidemiology of Barrett’s oesophagus 
The terminology used in the literature about Barrett’s is particularly confusing 
with regards to prevalence and incidence.  Prevalence is defined as the total 
number of existing cases as a proportion of the total population at one time.  
Many articles use this term but actually describe the number of new cases 
detected at endoscopy over a particular time period.  Incidence describes the 
number of new cases detected over a set time period as a proportion of the 
population at risk.  Determining the true incidence of Barrett’s is virtually 
impossible as it is largely asymptomatic and can only be diagnosed at 
endoscopy.  Patients attending for endoscopy are almost always a selected 
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group of those with upper GI symptoms and are unlikely to represent the 
population as a whole.   
 
When reviewing the literature about prevalence or incidence of Barrett’s 
oesophagus the situation is further complicated by the lack of consistent and 
enduring diagnostic criteria.  The length of columnar lined segment required for 
the diagnosis and the requirement or otherwise to demonstrate specialised 
intestinal metaplasia are examples of inconsistencies. 
 
Autopsy studies have attempted to determine the frequency of Barrett’s in the 
general population.  Cameron et al (1990) compared the rate of clinically 
diagnosed Barrett’s with the rate found at unselected autopsy in a single county 
in the United States.  The rate of clinically diagnosed Barrett’s was only 23 per 
100,000 residents.  The estimated true rate, based on the detection of 7 cases 
in 733 consecutive autopsies, was more than 10 times this at 376 cases per 
100,000 residents (0.4%). 
 
More recent estimates of the prevalence of Barrett’s come from endoscopic 
studies but the results of these vary dramatically.  A Swedish study of 1000 
random, unselected adults found a prevalence of 1.6% with diagnosis based on 
endoscopic suspicion and histological confirmation of intestinal 
metaplasia(Ronkainen et al., 2005).  A much higher prevalence of 25% was 
detected in patients attending for screening sigmoidoscopy who were invited to 
undergo upper endoscopy at the same visit(Gerson et al., 2002).  These 
patients were asymptomatic for reflux symptoms but were drawn from a 
population primarily composed of male military veterans in the United States, a 
group likely to be at higher than average risk due to age, smoking and drinking 
habits. 
 
Whilst the incidence of oesophageal adenocarcinoma has certainly increased 
over the past two decades it is difficult to know whether there has been a similar 
upward trend for Barrett’s.  The number of individuals with a diagnosis of 
Barrett’s oesophagus has definately increased but this may simply reflect 
changing diagnostic practice.  The requirement for a 3cm segment of columnar 
epithelium has been abandoned, the number of endoscopies has increased and 
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the training of endoscopists has improved all of which may contribute to the 
increased frequency of diagnosis(Prach et al., 1997a).  Despite this there is 
some evidence to suggest that there has been a real increase in cases of 
Barrett’s oesophagus.  A cohort study using a primary care database (van 
Soest et al., 2005) showed an increasing incidence of Barrett’s between 1996 
and 2003 which was independent of the number of endoscopies performed.  
Both the number of new diagnoses of Barrett’s and the number of new cases 
per 1000 endoscopies in Scottish patients was shown to have increased 
between 1980 and 1993(Prach et al., 1997b). 
 
1.5 Risk factors associated with Barrett’s oesophagus 
 
1.5.1 Age and gender 
Barrett’s is a diagnosis most often made in later life.  Cameron and Lomboy 
(1992) reviewed the records of over 50,000 patients undergoing endoscopy 
over a 13 year period.  Barrett’s was found twice as often in men than women 
with a mean age at diagnosis of 63.  The prevalence of Barrett’s increased with 
age to reach a plateau by the seventh decade.  Data from over 5000 patients on 
the UK National Barrett’s Oesophagus Registry (Caygill et al., 2003) has 
demonstrated a male to female ratio of 1.7:1, the mean age at diagnosis being 
62.0 years for males and 67.5 years for females.  The Dutch cohort study (van 
Soest et al., 2005) reported similar findings with a mean age at diagnosis of 
59.3 years for men and 65.5 years for women.  
 
1.5.2 Race 
Historically, Barrett’s was thought to be a disease of white males.  Recent 
retrospective reviews of endoscopy records have however failed to find any 
significant differences between rates of Barrett’s in different racial groups 
(Bersentes et al., 1998, Fan and Snyder, 2009). 
 
1.5.3 Gastro-oesophageal reflux disease (GORD) 
Barrett’s is believed to develop in response to gastro-oesophageal reflux 
disease and epidemiological evidence exists to support this theory.  The 
prevalence of Barrett’s has been demonstrated to be higher in patients with 
reflux symptoms compared to those undergoing endoscopy for other reasons 
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(Fan and Snyder, 2009, Johansson et al., 2007).  In addition, patients with 
Barrett’s appear to have an earlier onset and longer duration of reflux symptoms 
(Eisen et al., 1997).  A prospective, observational study of patients undergoing 
endoscopy for reflux symptoms found that prevalence of Barrett’s was strongly 
associated with the duration of reflux symptoms.  Compared to patients with 
symptoms for less than one year, the odds ratio for Barrett’s was 3.0 in those 
with symptoms for between 1 and 5 years, rising to 6.4 for those with symptoms 
dating back more than 10 years (Lieberman et al., 1997). 
 
The association between the severity of reflux symptoms and Barrett’s is less 
clear.  Winters et al (1987), in a prospective study of 97 patients with 
symptomatic reflux, noted that patients with Barrett’s tended to report fewer 
symptoms than those with oesophagitis.  One reason for this may be that 
metaplastic Barrett’s mucosa is less sensitive than squamous mucosa and the 
severity of symptoms therefore decreases once metaplasia is established. 
 
1.5.4 Obesity, smoking and alcohol 
Meta-analysis of epidemiological data (El-Serag, 2008) has shows that obesity 
is associated with a 1.5 – 2 fold increase in symptomatic GORD, the leading 
hypothesis being that obese individuals have greater pressure stress and 
anatomical disruption of the gastro-oesophageal junction.  Data relating to the 
association between obesity and Barrett’s is contradictory and it has been 
postulated that any increased risk associated with obesity may simply be a 
reflection of the increased prevalence of GORD (Cook et al., 2008). 
 
Smoking and alcohol consumption are thought to be associated with GORD but 
there is limited data concerning their association with Barrett’s.  Several case 
control studies have found no association between cigarette smoking and 
development of Barrett’s (Anderson et al., 2007, Gray et al., 1993).  These are 
relatively small studies however and in one case concerns have been raised as 
to whether there was a selection bias for non-smokers in the control group.  
Evidence linking smoking with oesophageal adenocarcinoma is stronger, 
indicating a possible role in the progression, rather than the causation of 
Barrett’s.  Both studies which failed to show an association between smoking 
and Barrett’s found a significant association with adenocarcinoma (Gray et al., 
1993, Anderson et al., 2007).  A further study (Gammon et al., 1997) has 
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reported a doubling of oesophageal adenocarcinoma risk in current and ex-
smokers compared to those who had never smoked.  In contrast a Swedish 
case control study (Lagergren et al., 2000) failed to find any significant 
association between smoking and oesophageal adenocarcinoma.  
 
Alcohol is postulated to increase GORD by causing relaxation of the lower 
oesophageal sphincter and epidemiological evidence supports an association 
between alcohol and reflux disease (Locke et al., 1999).  The evidence linking 
Barrett’s oesophagus and adenocarcinoma with alcohol consumption is 
however, even less compelling than that for smoking.  The Irish FINBAR case 
control study (Anderson et al., 2007) suggested an association between alcohol 
consumption in early adulthood and reflux disease but failed to show any 
association with Barrett’s oesophagus or adenocarcinoma.  In another study 
patients with uncomplicated Barrett’s were significantly less likely to be drinkers 
than patients with severe reflux oesophagitis (p=<0.02)(Gray et al., 1993).  In 
two case control studies, alcohol consumption has been found to be associated 
with a decreased risk of oesophageal adenocarcinoma, with odds ratios of 
0.5(Lagergren et al., 2000) and 0.6.(Gammon et al., 1997)  
 
1.6 Pathogenesis of Barrett’s oesophagus 
Damage to the oesophageal mucosa and an abnormal intraluminal environment 
during repair is required for Barrett’s to develop.  The exact mechanisms via 
which this occurs remain unclear.  In particular it remains unexplained why the 
majority of patients with reflux do not go on to develop Barrett’s.   
 
1.6.1 Role of acid in development of Barrett’s 
Canine experiments provided early evidence of the acquired nature of Barrett’s 
and the role of acid in its development.  Bremner et al (1978) demonstrated that 
acid reflux is needed for the development of Barrett’s.  Mucosal defects were 
created in the distal oesophagus of dogs divided into three groups according to 
the presence, or absence, of surgically induced gastrooesophageal reflux and 
stimulated gastric hypersecretion.  Re-epithelialisation was predominantly with 
squamous epithelium in dogs with an intact lower oesophageal sphincter while 
columnar re-epithelialisation predominated in those with reflux and gastric 
hypersecretion.  Gillen et al (1988) refined this experiment by including an 
additional circumferential deficit above an intact ring of squamous mucosa.  In 
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dogs with experimentally induced reflux disease, columnar re-epithelialisation 
was again seen to occur.  In 2 dogs, columnar regeneration was observed 
above the intact ring of squamous mucosa, effectively excluding the possibility 
of columnar replacement by proximal migration of gastric mucosa.  In the 
absence of reflux, re-epithelialisation was with squamous mucosa. 
 
Further evidence for the importance of acid reflux includes the demonstration, 
using ambulatory monitoring, of a graded increase in reflux across the GORD 
spectrum (Vaezi and Richter, 1996).  Patients with oesophagitis were compared 
with those with Barrett’s oesophagus and with healthy controls.  Those with 
complicated Barrett’s had the highest amount of acid reflux, while healthy 
controls had the least.  
 
Evidence regarding the role of gastric acid hypersecretion is contradictory.  In a 
small study (Mulholland et al., 1989), both basal and stimulated acid secretion 
was significantly greater in Barrett’s patients than controls.  In a larger study 
however (Hirschowitz, 1996), there was no significant difference in acid and 
pepsin secretion in Barrett’s patients and controls matched for age, sex and 
background gastrointestinal disease. 
  
The mechanisms by which acid refluxate exerts its damaging effects remain 
unclear.  For H+ ions to cause damage they must be able to enter the cell.  
Oesophageal epithelial apical cell membranes are relatively impermeable to 
acid.  It is thought that the cell cytosol becomes acidic only when the 
intraluminal pH is low enough to damage the intercellular junction structures 
allowing the H+ ions to enter via the basolateral membranes.  Once acid enters 
the cell it leads to cell death by necrosis, resulting in ulceration when this occurs 
over a large area (Carney et al., 1981). 
 
As well as cell damage, acid appears to trigger several acute mucosal defence 
mechanisms including cell replication and increased blood supply (Guillem, 
2005).  Development of columnar metaplasia appears to be a chronic adaptive 
process resulting from prolonged acid exposure. 
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1.6.2 Role of duodenal reflux in development of Barrett’s 
Gillen’s canine study (Gillen et al., 1988) included a bile only reflux model.  
Dogs in this group underwent refluxogenic surgery in the form of a cardioplasty, 
hiatus hernia creation and biliary diversion but were given cimetidine to 
suppress acid production.  There were no cases of columnar re-epithelialisation 
in this group indicating that bile reflux alone may be insufficient to cause 
Barrett’s.  The group however included only six dogs with 3 months of reflux.  
Case reports of Barrett’s developing after total gastrectomy, conversely, 
indicate that it is possible for columnar metaplasia to occur in the absence of 
acid reflux.(Westhoff et al., 2004, Meyer et al., 1979a) 
 
As with acid exposure, it has been shown that there is a graded response 
across the GORD spectrum for both oesophageal exposure to bilirubin and 
fasting bile acid concentrations(Vaezi and Richter, 1996).  In this study, patients 
with both complicated and uncomplicated Barrett’s had significantly higher 
(89%-100%) exposure to the simultaneous damaging effect of acid and bile 
than those with less severe forms of oesophagitis (50-79%).  This evidence 
supports a synergistic effect of bile and acid in the pathogenesis of Barrett’s. 
Whilst it is important to consider the contribution of the separate components of 
reflux it is also important to remember that in the majority of reflux episodes, 
acid and duodenogastrooesophageal reflux (DGOR) occur simultaneously.  
 
1.7 Origins of Barrett’s oesophagus 
Early papers on Barrett’s proposed that the columnar oesophageal segment 
occurred as a result of proximal migration of gastric cardiac mucosa.  The 
finding that columnar re-epithelialisation could occur above an intact ring of 
squamous mucosa (Gillen et al., 1988) provided evidence to the contrary and 
suggested that the cell of origin must lie in the oesophagus itself.  
 
There are several postulated candidates for the cells of origin in Barrett’s.  The 
first is redifferentiation of mature squamous mucosa, a process termed 
‘transdifferentiation’.  The second, increasingly popular theory, is conversion of 
pluripotent oesophageal stem cells (Fitzgerald, 2006a). 
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Stem cells are able to divide indefinitely to produce differentiated progeny.  
Under normal circumstances they divide to produce one stem cell and one 
transit cell resulting in tissue homeostasis.  It is believed that squamous 
oesophageal stem cells reside in the basal compartment of the squamous 
epithelium.  Various mechanisms for the development of Barrett’s from stem 
cells have been proposed (Jankowski et al., 2000).   
 
The de novo metaplasia theory suggests that damage may occur to exposed 
stem cells in inflamed mucosa.  This damage converts the squamous stem cells 
to Barrett’s stem cells which repopulate the oesophagus with columnar mucosa.  
The duct-cell metaplasia theory proposes that when squamous mucosa is 
damaged, stem cells in the glandular neck region of oesophageal submucosal 
ducts are able to colonise the oesophageal mucosal layer.  Less well 
recognised theories suggest that Barrett’s could originate from circulating bone 
marrow cells (Sarosi et al., 2008), from a residual population of embryonic cells 
at the gastro-oesophagaeal junction (Wang et al., 2011) or from the 
oesophageal stroma (Chang et al., 2007). 
 
The mechanism by which metaplasia spreads throughout the oesophagus is 
also poorly understood.  Recent work has sought to determine the clonality of 
Barrett’s mucosa i.e. whether it is mono or polyclonal.  It was initially believed 
that the phenotypic change occurred as a result of a single stem cell mutation 
with a selective advantage enabling it to expand to fill an entire Barrett’s 
segment.  Evidence for this came from work showing apparently clonal lesions 
of both p16 and p53 genes throughout long segments of Barrett’s (Wong et al., 
2001, Galipeau et al., 1999). Recent work by Leedham et al. (2008) has refuted 
this and suggested that Barrett’s arises from multiple independent clones.  This 
group used laser capture microdissection to enable analysis of Barrett’s 
segments at a much higher resolution than had previously been possible.   
 
1.8 Barrett’s and oesophageal adenocarcinoma 
 
1.8.1 Association of Barrett’s and oesophageal adenocarcinoma 
The importance of Barrett’s oesophagus lies in the association with 
oesophageal adenocarcinoma, a condition for which it is the major risk factor.  
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The incidence of oesophageal adenocarcinoma has risen dramatically since the 
1970s and the prognosis remains dismal(Devesa et al., 1998, Bollschweiler et 
al., 2001). 
 
The first case report of adenocarcinoma arising within a columnar lined 
oesophagus (Morson and Belcher, 1952) was published only two years after 
Barrett’s original paper.  By the 1970s it was becoming recognised that the 
condition had significant malignant potential.  Naef (1975) reported a series of 
12 adenocarcinomas arising from a cohort of 140 patients with extensive 
columnar metaplasia.  Haggitt et al (1978) reported that 12 of 14 cases of 
primary oesophageal adenocarcinoma occurred on a background of columnar 
lined oesophagus.  In 10 cases, the columnar epithelium adjacent to the 
invasive cancer showed a spectrum of abnormalities ranging from dysplasia to 
carcinoma in situ, supporting the idea of progression from metaplasia to 
dysplasia and carcinoma.  
 
It is now believed that most, if not all, cases of oesophageal adenocarcinomas 
arise on a background of Barrett’s oesophagus, albeit previously unrecognised 
in the majority of cases.  A systematic review (Dulai et al., 2002) found that only 
5% of patients undergoing resection for oesophageal adenocarcinoma had a 
diagnosis of Barrett’s preceding their cancer diagnosis.  The earliest literature 
analysed by this group dated back to the 1960s.  Whilst one might expect this 
figure to be higher for today’s patients, given the increased use of endoscopy 
and awareness of Barrett’s among clinicians, it remains the case that the vast 
majority of patients diagnosed with adenocarcinoma have no prior diagnosis of 
Barrett’s.  Where Barrett’s is not identified at the time of diagnosis it has been 
hypothesised that this is a result of tumour overgrowth beyond the area of pre-
existing Barrett’s (Chandrasoma et al., 2007).  This view is supported by the 
finding that Barrett’s can be ‘unmasked’ following neo-adjuvant chemotherapy.  
In a retrospective study of 79 patients the rate of identifiable co-existing 
Barrett’s rose from 75% to 97% following chemotherapy (Theisen et al., 2002). 
 
1.8.2 Magnitude of the risk 
Perhaps surprisingly considering the well established association between 
Barrett’s and oesophageal adenocarcinoma, the actual risk of developing 
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cancer in a Barrett’s oesophagus is unclear.  Estimates range from 0.1% to 
nearly 3% per patient year with a recent meta-analysis of European and 
American literature quoting an overall risk of 7:1000 years patient follow up 
(Thomas et al., 2007).  It is important to recognise that differing definitions of 
Barrett’s have been used and this in part must explain some of the variation in 
quoted risks.  Short segment Barrett’s for instance was not included in most 
early series and this appears to be associated with a lower risk of malignant 
progression (Thomas et al., 2007). 
 
A publication bias, with significant over-representation of the cancer risk in 
Barrett’s oesophagus has been suggested.  Shaheen et al (2000) found a 
strong inverse relationship between study size and reported cancer risk, with 
larger studies reporting much lower cancer risks.  A recent population based 
cohort study from Denmark (Hvid-Jensen et al., 2011) included data on over 
11000 patients from a comprehensive national registry, median follow up was 
5.2 years.  The incidence of adenocarcinoma was highest in the first year after 
diagnosis suggesting that prevalent cancers were initially missed.  Beyond this 
the annual risk of adenocarcinoma fell to 0.12%, much higher than the risk for 
the background Danish population (Relative risk 11.3) but much lower than the 
figures usually quoted.    
 
Whilst Barrett’s is clearly associated with a significantly increased relative risk of 
oesophageal adenocarcinoma it is important to retain some perspective on such 
matters.  Oesophageal cancer remains a comparatively rare condition with only 
8161 new cases diagnosed in the UK in 2009 (Cancer Research UK Statistics, 
2012), the last year for which figures are available.  The vast majority of patients 
with Barrett’s oesophagus never develop oesophageal cancer.  A retrospective 
cohort study of all patients identified with Barrett’s oesophagus in Northern 
Ireland between 1993 and 1999 found that overall mortality for such patients 
was not raised and that oesophageal cancer remained an uncommon cause of 
death (Anderson et al., 2003).  During 7413 person years of follow up there 
were 253 deaths, only 12 of which were from oesophageal cancer.  This figure 
was, however, significantly higher than expected, equating to a standardised 
mortality rate of 518.  When analysed by subgroup it was found that only 
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patients with specialised intestinal metaplasia had a significantly increased 
oesophageal cancer mortality rate. 
 
1.8.3 The metaplasia – dysplasia – carcinoma sequence 
It is believed that adenocarcinoma develops from Barrett’s metaplasia via a 
stepwise progression through low and high grade dysplasia (Jankowski et al., 
1999).  For individuals who progress, it has been suggested that genetic 
mutations accumulate over time.  These may confer a selective advantage on 
the abnormal cell allowing it to clonally expand, eventually forming an invasive 
cancer (Fitzgerald, 2006a). 
 
Metaplasia is defined as the transformation of one type of mature differentiated 
cell into another fully differentiated cell type.  Metaplasia often represents an 
adaptive response of a tissue to environmental stress and it is thought that the 
metaplastic epithelium is better able to withstand the adverse environmental 
changes (Underwood, 1998).  In the case of Barrett’s oesophagus it is thought 
that the columnar epithelium is more resistant to the damaging effects of reflux. 
 
1.8.4 The natural history of progression 
Epidemiological evidence suggests that Barrett’s develops rapidly to its full 
length with little subsequent change.  Review of endoscopy records of 21 
patients followed up for a mean of 7.3 years showed a mean initial length of 
8.29cm and a mean final length of 8.33cm (Cameron and Lomboy, 1992).  
Metaplasia does not necessarily progress to dysplasia but in the presence of 
ongoing environmental insult it has the potential to do so. 
 
1.8.5 Dysplasia in Barrett’s oesophagus 
Dysplasia is defined as an unequivocal neoplastic alteration of epithelium which 
has the potential to progress to invasive malignancy but remains confined within 
the basement membrane of the epithelium within which it arose (Riddell et al., 
1983).  It is the only marker of increased risk in Barrett’s which is widely used in 
clinical practice and is diagnosed on the basis of both cytological and 
architectural abnormalities.  Hameeteman and collegues (Hameeteman et al., 
1989) demonstrated an increase in both the frequency and severity of dysplasia 
in a cohort of 50 Barrett’s patients followed, prospectively for a mean of 5 
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years.(Hameeteman et al., 1989)  British Society of Gastroenterology guidelines 
(2005) recommend that Barrett’s biopsies are histologically reported according 
to a six-point scale of neoplastic change. 
 
1. Negative for dysplasia 
2. Indefinite for dysplasia 
3. Low grade dysplasia 
4. High grade dysplasia 
5. Intramucosal carcinoma 
6. Invasive adenocarcinoma 
 
Dysplasia within a Barrett’s segment occurs in patches which may be unifocal 
or multifocal.  There is great potential for sampling error and dysplasia can be 
missed if insufficient biopsies are taken.  It is therefore recommended that when 
assessing a Barrett’s segment for dysplasia, quadrantic biopsies should be 
taken every 2cm and from any macroscopic lesion within the segment.  
 
1.8.6 Low Grade Dysplasia (LGD) 
Low grade dysplasia can be difficult to distinguish from inflammatory changes 
and diagnosis should be confirmed with repeat biopsies following PPI therapy.  
In one series (Conio et al., 2003) 75% of cases of LGD were not confirmed on 
repeat biopsy.  The natural history of LGD is poorly understood.  The majority of 
patients do not appear to progress beyond this stage and regression has been 
reported in over 60% of cases (Weston et al., 2001, Skacel et al., 2000).  A 
subgroup of patients with LGD do however, progress along the metaplasia-
dysplasia-carcinoma sequence.  Weston et al. (2001) detected progression in 
10% of a cohort of 48 patients followed for a mean of 41 months.  Where there 
is agreement as to the diagnosis of LGD the risk of progression understandably 
appears to be higher.  In one study, where there was a consensus of opinion 
between 3 pathologists, 4 out of 5 patients progressed.(Skacel et al., 2000)  
The time taken to progress from onset of metaplasia is impossible to determine 
accurately as metaplasia may be present for many years prior to diagnosis.  
However in a group of seven patients who progressed sequentially from 
metaplasia to cancer, the median time from diagnosis of Barrett’s to the 
development of LGD was only 24 months (Theisen et al., 2004). 
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1.8.7 High Grade Dysplasia (HGD) 
The behaviour of high grade dysplasia is also difficult to predict.  It can progress 
to adenocarcinoma rapidly, slowly or not at all.  Schnell and colleagues (2001) 
reported 12 cases of adenocarcinoma in a series of 75 patients with HGD 
followed up for a mean of 7 years from the time of diagnosis of Barrett’s (range 
1.5-14years).  Diffuse HGD appears to represent a higher risk than focal HGD.  
Cancer rates after 3 years follow up for HGD were 56% for those with diffuse 
HGD vs 14% for those with focal HGD in one retrospective cohort study 
(p=0.002) (Buttar et al., 2001).  In the series of patients with sequential 
progression from metaplasia to adenocarcinoma, median time from the 
diagnosis of Barrett’s to the diagnosis of HGD was 33 months.  The median 
time to the diagnosis of cancer was only 3 months more at 36 months(Theisen 
et al., 2004). 
 
Regression of HGD has been reported (Weston et al., 2000).  In this study 
regression to LGD was observed in 2 out of 15 surveyed patients and 
regression to no dysplasia in 5 of the 15.  This small study followed patients 
with unifocal high grade dysplasia for a mean period of 36.8 months.  The 
original diagnosis was confirmed by a second blinded pathologist, reducing the 
chance that apparent regression reflected inter-observer variation in diagnosis 
but a second potential source of error is less completely addressed.   A failure 
to resample the original area of dysplasia could clearly result in a false finding of 
regression.  This study actually reported 8 cases of progression in the 15 
patient cohort, 4 to invasive adenocarcinoma, 3 to possible intramucosal 
adenocarcinoma and 1 to multifocal HGD  and it must therefore be regarded 
overall as providing supportive evidence for the malignant potential of HGD. 
 
There are no other studies which clearly describe spontaneous regression of 
HGD.  The presence of HGD has widely been viewed as an indication for 
oesophagectomy, or endoscopic treatment in more recent years and evidence 
regarding the natural history of untreated oesophageal HGD is consequently 
very limited.   
 
In contrast to the suggestion that HGD may regress, there is reasonable 
evidence that this finding may be associated with more advanced disease.  
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Several surgical series of patients undergoing resection for HGD report rates of 
occult adenocarcinoma of up to 40% (Heitmiller et al., 1996, Falk et al., 1999, 
Reed et al., 2005). 
 
1.9 Clinical challenges in Barrett’s oesophagus and oesophageal 
adenocarcinoma 
The incidence of oesophageal adenocarcinoma continues to increase yet there 
has been relatively little improvement in prognosis over several decades.  Neo-
adjuvant chemotherapy has been shown to confer a survival advantage and 
surgical outcomes have significantly improved with operative mortality now 
consistently less than 5% in specialist centres.(Medical Research Council, 
2002, van Lanschot et al., 2001) (National Oesophago-gastric Cancer Audit, 
2010)  Despite these advances the majority of patients present at a stage when 
curative treatment is not possible and overall 5 year survival remains poor at 
only 13% (Office for National Statistics, 2012).  It seems unlikely that there will 
be significant progress in the treatment of advanced oesophageal 
adenocarcinoma in the foreseeable future and there is therefore an impetus to 
address the issues of cancer prevention and early detection.  
 
Endoscopic screening for Barrett’s oesophagus to detect patients at elevated 
risk of oesophageal carcinoma is not routinely recommended and is unlikely to 
ever be cost-effective (British Society of Gastroenterology, 2005, (Wang and 
Sampliner, 2008)).  Given the recent studies suggesting that the absolute risk in 
Barrett’s oesophagus is much lower than previously believed, it is likely to be 
increasingly difficult to justify widespread surveillance of patients with known 
Barrett’s oesophagus in a healthcare environment with increasing pressure on 
resources.  Developments in endoscopic technologies such as narrow band 
imaging and chromoendoscopy may improve detection of areas of dysplasia 
and early adenocarcinoma within Barrett’s oesophagus and ensure that 
surveillance and index endoscopy is as accurate as possible (Spechler et al., 
2011).  
 
The greatest advances in reducing the disease burden of oesophageal 
adenocarcinoma are likely to come as a result of better understanding of the 
development and progression of the disease.  There has been interest in the 
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use of drugs to prevent the malignant progression of Barrett’s oesophagus, so 
called chemoprevention and a large randomised trial seeks to evaluate the 
efficacy of aspirin (Das et al., 2009).  There has also been significant interest in 
the identification and use of biomarkers to risk stratify patients with reflux 
disease and Barrett’s oesophagus and allow screening and surveillance to be 
more effectively targeted at high risk individuals (Kadri SR et al., 2010, Spechler 
et al., 2011).  These techniques are yet to become routine but clearly have the 
potential to affect practice.  An improved understanding of the pathogenesis of 
both Barrett’s oesophagus and oesophageal adenocarcinoma could clearly also 
open the door to new molecular treatment modalities.  
 
1.10 Models of Barrett’s Oesophagus 
Evaluation of therapeutic candidates both for the prevention of Barrett’s in those 
with reflux and the prevention of malignant progression in those with Barrett’s 
require expensive long-term randomised trials.  Insight into the timescale over 
which reflux related damage occurs would require endoscopic surveillance of 
large numbers of healthy individuals over many years which is neither ethically 
acceptable nor financially viable.  Models are therefore required in which to 
study the pathogenesis of Barrett’s oesophagus and to fast-track evaluation of 
potential therapeutic interventions. 
 
The aims of a Barrett’s oesophagus model are: 
1. To allow observation and investigation of the earliest stages of development 
of Barrett’s 
2. To allow the study of malignant progression over an accelerated timescale 
3. To allow potential therapeutic interventions to be assessed safely and over 
an acceptable timescale 
4. To allow identification of genetic or biological factors associated with the 
development or progression of Barrett’s 
 
Requirements of a good Barrett’s oesophagus model include the following: 
1. Spontaneous metaplasia should occur in the model species 
2. Model species should be genetically similar to man 
3. Model should include a lifelike model of reflux 
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4. Model should represent the complex confounding factors in humans eg. 
Ageing, lifestyle factors and genetic heterogeneity 
 
There is no perfect model of Barrett’s oesophagus but in vitro, ex vivo, animal 
and human models all have their relative strengths and weaknesses. 
 
In vitro techniques using cell lines allow straightforward experimental data to be 
obtained.  Various factors can be manipulated or introduced and the effects on 
cell viability, apoptosis and biomarker expression observed.  The drawback with 
this model is that cells grown in vitro are not subject to normal physiological 
conditions and their growth behaviour can be heavily influenced by the 
immortalisation procedures used in their creation (di Pietro M et al., 2008). 
 
Ex vivo models using biopsy samples in culture allow the study of oesophageal 
cells in their normal tissue arrangement but these can only be kept alive for a 
short period of time.  This model can therefore not be used to address complex 
temporal issues, it provides no opportunity to assess the long term effects of 
ongoing damage or to assess if potential chemotherapeutic agents are effective 
(di Pietro M et al., 2008).   
 
Animal models of Barrett’s have been used for many years; the first evidence of 
the acquired nature of columnar metaplasia came from a canine model.  Other 
widely used models utilise rats and mice.  Clearly there are genetic differences 
between animal models and the human situation they aim to represent but other 
differences are equally important (Attwood et al., 2008).  Rodents do not have 
spontaneous reflux and require surgical intervention to induce this.  This tends 
to produce supra-physiological levels of reflux and the surgical insult also has 
immunomodulatory effects.  Depending on the species there are also concerns 
about animal models with regards to the absence of submucosal oesophageal 
glands.  These glands are thought to be important in the development of human 
Barrett’s oesophagus and have been proposed as a potential site for a Barrett’s 
oesophagus stem cell (Jankowski et al., 2000).    If these glands are absent it 
may be that columnar metaplasia in these species develops via a different 
mechanism to that in humans.  In addition most animals do not naturally 
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develop oesophageal adenocarcinoma, a further divergence from the disease 
spectrum observed in humans. 
 
The recognised deficiencies of these models have led to interest in the human 
model of Barrett’s oesophagus which is observed in patients following subtotal 
oesophagectomy and reconstruction with a gastric conduit.  During this 
procedure the gastro-oesophageal junction and distal oesophagus are excised 
and the stomach is anastomosed to the proximal oesophagus to re-establish 
intestinal continuity.  A short segment of residual oesophagus remains in situ 
and is commonly referred to as the oesophageal remnant. 
 
1.11. Barrett’s in the post oesophagectomy patient – ‘Neo-Barrett’s’ 
The development of columnar metaplasia in the remnant native oesophagus 
following surgery has been described by several groups in both paediatric and 
adult populations. (Borgnon et al., 2004, Lindahl et al., 1990, Hamza et al., 
2003, O'Riordan et al., 2004, Oberg et al., 2002, Lord et al., 2004, Dresner et 
al., 2003, Franchimont et al., 2003).  In adults it has been shown to occur 
following surgery for both adeno and squamous carcinoma with an incidence of 
up to 50%.(O'Riordan et al., 2004)  This group of patients is prone to profound 
reflux providing a potential mechanism for the development of Barrett’s. 
 
1.11.1 Reflux post-oesophagectomy 
Reflux of both gastric and duodenal contents is very common following 
oesophagectomy with a gastric conduit reconstruction.  The majority of patients 
report some symptoms consistent with reflux (Aly and Jamieson).  Dresner et al. 
(2003) demonstrated abnormal amounts of oesophageal exposure to both acid 
and bilirubin over a 24 hour period in over 80% of post operative patients and 
similar findings were reported by Oberg (Oberg et al., 2002). 
  
The reasons for this high prevalence of reflux relate to the disruption of the 
normal anatomical anti-reflux mechanisms.  The lower oesophageal sphincter, 
angle of His and diaphragmatic sling are all resected or disrupted.  In addition 
reflux is promoted by the position of the gastric tube between the positive 
pressure environment of the abdominal cavity and the negative pressure of the 
thoracic cavity.  
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1.11.2 The importance of post-oesophagectomy patients as a human 
model for the development of Barrett’s 
Post-oesophagectomy patients provide an exceptionally useful model in which 
to study the early events in the development of Barrett’s oesophagus.  
Examination of the original resection specimen allows confirmation of normal 
squamous epithelium above the anastomosis at the time of surgery and enables 
a timescale for the development of metaplasia to be determined.   
 
Another important feature of this group is the relative ease with which the 
precise location of biopsies can be identified.  The surgical anastomosis is 
easily identified at endoscopy and any biopsies from above this are clearly 
oesophageal.  Any histological finding in supra-anastomotic biopsies other than 
squamous mucosa is metaplastic.  The difficulties normally associated with 
accurately identifying the gastro-oesophageal junction are therefore eliminated. 
 
Where the resection specimens have been retained, examination of the 
proximal margin and comparison with the neo-Barrett’s material from the same 
patient provides a unique opportunity to study the molecular and genetic 
characteristics associated with the phenotypic change. 
 
1.11.3 Characteristics of post-oesophagectomy neo-Barretts 
The endoscopic appearance of neo-Barrett’s tissue is essentially the same as 
that of sporadic Barrett’s.  The mucosa has a darker appearance than that of 
the adjacent squamous tissue.  Histological assessment of samples taken from 
segments of neo-Barretts has shown both cardiac type mucosa and specialised 
intestinal metaplasia.  These neo-Barrett’s epithelia have an identical 
histological appearance to their sporadic Barrett’s equivalents.   
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 Chapter 2. Comparative Literature Review 
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Clinical follow up for patients who have undergone subtotal oesophagectomy is 
highly variable.  Many units do not routinely endoscope patients and those that 
do rarely conform to a standard protocol.  In many cases endoscopy is 
undertaken to investigate symptoms and to exclude the presence of local 
recurrence of adenocarcinoma.  The endoscopist may not undertake a thorough 
evaluation of the oesophageal remnant and biopsies may be taken only where 
there is a suspicion of significant pathology.  Columnar metaplasia or ‘neo-
Barrett’s may go unrecognised by inexperienced endoscopists, particularly if 
they are unfamiliar with the post surgical anatomy.  These factors, along with 
the relatively small numbers of patients who undergo oesophagectomy go some 
way towards explaining the paucity of evidence available on neo-Barrett’s 
oesophagus. 
 
2.1 Aim of the literature review 
The aim of this review was to summarise the existing literature on the incidence 
and characteristics of neo-Barrett’s metaplasia occurring following 
oesophagectomy. 
 
2.2 Search Strategy 
Whilst this thesis uses the term ‘neo-Barrett’s’ to describe columnar metaplasia 
occurring in the oesophageal remnant following subtotal oesophagectomy this 
is not a widely recognised term.  Searches of the major scientific databases for 
this term return no relevant papers. 
 
The search strategy outlined in table 2.1 was used to search both Medline 
1946-2012 and Embase 1980-2012.  The search strategy was adapted for the 
Web of Science and Scopus databases (figures 2.1 and 2.1).  The 
bibliographies of relevant papers were hand searched for other relevant cited 
articles. 
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Table 2.1: Literature review search strategy for Medline and Embase 
 
 
 
 
 
 
 
 
 
Figure 2.1: Search strategy for Web of Science database 
 
 
 
Figure 2.2: Search strategy for Scopus database 
 
 
 
# Search term 
1 Barrett Esophagus/ 
2 Columnar metaplasia.mp. 
3 1 or 2 
4 Esophagectomy/ 
5 Esophagoplasty/ 
6 Surgical anastomosis/ 
7 4, 5 or 6 
8 esophageal remnant.mp. 
9 oesophageal remnant.mp. 
10 8 or 9 
11 3 or 7 
12 10 or 11 
(TITLE-ABS-KEY("barrett* *esophagus" OR "columnar metaplasia") AND 
TITLE-ABS-KEY(*esophagectomy OR *esophagoplasty OR "surgical 
anastomosis") AND TITLE-ABS-KEY("*esophageal remnant")) 
 
TS=("barrett* *esophagus" or "columnar metaplasia") AND 
TS=(*esophagectomy or *esophagoplasty or "surgical anastomosis") 
AND TS=(*esophageal remnant) 
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2.3 Scope of the literature review 
The topics of interest covered by the literature review are listed below: 
 
Prevalence of neo-Barrett’s in the adult surgical population 
Prevalence of neo-Barrett’s in the paediatric surgical population 
Timescale for the development of neo-Barrett’s 
Pre-disposing factors for the development of neo-Barrett’s 
Malignant progression in neo-Barrett’s 
Molecular marker expression in neo-Barrett’s 
 
 
2.4 Methods 
The studies identified in the search will be assessed for the quality of their data 
according to the criteria set out in table 2.2. 
 
Quality criteria for literature review 
 
Number of patients 
Prospective endoscopic evaluation 
Histological corroboration of neo-Barrett’s 
Histological exclusion of residual disease at time of surgery 
Inclusion criteria eg. Routine follow up of all patients, investigation of research 
volunteers or investigation of symptomatic patients 
 
Table 2.2: Quality criteria for literature review 
 
 
2.5 Prevalence of neo-Barrett’s in the adult surgical population 
Twelve studies were identified which evaluated the prevalence of neo-Barrett’s, 
these are summarised in table 2.3 below.  The quality of these studies varies, 
all are from single centres.  All studies report cases of neo-Barrett’s during the 
follow up period.  The studies will be discussed in chronological order. 
 
Öberg and colleagues (2002) published the first study which sought to evaluate 
the prevalence of columnar metaplasia in the remnant oesophagus following 
oesophagectomy and gastric tube reconstruction.  All 60 surviving patients who 
had undergone surgery in the unit were invited to participate.  Thirty two 
patients underwent prospective endoscopic evaluation and 15 cases of 
columnar metaplasia were detected (47%).  The strengths of this study include 
the histological confirmation of squamous mucosa at the resection margin at the 
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time of surgery and the routine biopsy of areas of apparent oesophagitis to 
exclude the presence of metaplasia.  One potential weakness of this study is 
the inclusion of only a subset of the group of survivors as whole.  The authors 
recognise this fact and that this may give rise to a degree of bias towards 
patients more symptomatic for reflux disease but they state that the major 
reason for decline of the study invitation was old age or medical co-morbidities 
rather than the absence of symptoms.    
 
A similar study was published by Dresner et al (2003) the following year.  Again 
all surviving patients from the authors unit were invited to participate and 20 of 
51 agreed to do so.  Nineteen cases of columnar metaplasia were identified 
(48%) and of these 9 (23%) demonstrated specialised intestinal metaplasia.  As 
in the Öberg study, endoscopy was prospective, by an endoscopist with a 
specialist research interest and there was routine exclusion of residual Barrett’s 
and histological confirmation of neo-Barrett’s.  Again there is a potential 
selection bias towards patients who had more symptomatic reflux disease.  
Both of these studies included 24 hour acid and bilirubin monitoring in addition 
to endoscopic evaluation and it is possible that patients who were asymptomatic 
were less willing to undergo this degree of monitoring. 
 
Also published in that year, a study by Franchimont and colleagues (2003), 
reported a 13.5% prevalence rate of neo-Barrett’s metaplasia amongst a cohort 
of 66 patients who had undergone subtotal oesophagectomy in a single surgical 
unit.  Unlike the previous two studies this one was based on a retrospective 
review of medical records.  The patients were drawn from a group of 87 patients 
with 21 excluded due to missing data, no upper gastrointestinal endoscopy or 
residual Barrett’s oesophagus (one case).  The authors do not state the 
indication for post operative endoscopy employed in the unit and it is therefore 
difficult to assess if there might be a selection bias in the included patients.  It is 
not clear whether the endoscopist specifically assessed for the presence of 
neo-Barrett’s.  The strength of this study is the routine use of biopsy sampling 
but the location of these biopsies was not standardised and they are simply 
described as having been taken from ‘around the oesophagogastric 
anastomosis’.  Clearly biopsies taken from below the surgical anastomosis 
would be of no use in confirming the presence of neo-Barrett’s. 
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In 2004 a further four studies were published which assessed the prevalence of 
neo-Barrett’s.  The largest of these came from the Dublin group (O'Riordan et 
al., 2004).  This was a prospective case series of 48 patients.  This included a 
consecutive series of patients invited to participate with no refusals recorded.  
Strengths of this study include the prospective evaluation by one of two 
experienced surgical endoscopists and the routine biopsies from 1-2cm above 
the anastomosis.  Additional biopsies were taken from suspected areas of neo-
Barrett’s and oesophagitis.  All resection specimens were reviewed to exclude 
residual Barrett’s oesophagus.  Interestingly this study reports 10 patients who 
had histological evidence of columnar metaplasia but no associated 
endoscopically visible metaplasia.  No explanation for this finding is given by the 
authors and this incidence of metaplasia unrecognised by endoscopists is not 
reported elsewhere. 
 
The only other prospective study published in 2004 is much smaller and 
included only 14 patients (Peitz et al., 2004b).  These appear to be a 
consecutive series of patients undergoing endoscopy for a variety of clinical 
indications rather than purely in a research setting.  Again this study benefits 
from review of histology to exclude residual Barrett’s oesophagus and the 
authors describe being able to clearly identify the anastomosis during 
endoscopy.  In one case the patient did not undergo biopsy of an endscopically 
visible area of metaplasia due to concerns about bleeding.  The main focus of 
this study was the anastomosis itself rather than the remnant oesophagus 
above this.  In all cases the anastomosis is described as being covered by 
columnar epithelium, a finding confirmed histologically in the 13 patients 
suitable for biopsy with 10 cases of cardiac mucosa and 3 of oxyntic mucosa.  
There were 10 cases of endoscopically visible columnar metaplasia above the 
anastomosis and this was confirmed histologically in 9 cases.   
 
Two further studies were published in 2004, both of which were retrospective 
case series based on existing endoscopy records.  The larger of these (Wolfsen 
et al., 2004) involved 36 patients who had undergone post operative endoscopy 
and biopsy who were identified from a series of 45 patients who had undergone 
subtotal oesophagectomy.  Surgical specimens were reviewed to ensure that 
the proximal margin was completely free of Barrett’s metaplasia, dysplasia or 
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carcinoma.  Indications for endoscopy are not stated and this series included a 
high proportion of patients who required dilatation of an anastomotic stricture 
during endoscopy (16/36, 44%).  The concern here is that examination of the 
oesophageal remnant and biopsy regime may have been less meticulous if the 
primary aim was therapeutic intervention.  Eight cases of neo-Barrett’s are 
reported (18%) at a median time from surgery of 42 months, the follow up 
period for those without neo-Barrett’s is not reported.   
 
The second retrospective case series published in 2004 was also from the 
United States (Lord et al., 2004).  The authors of this study reviewed the 
records of 100 patients who had undergone subtotal oesophagectomy and 
gastric tube reconstruction and identified 20 who had subsequent endoscopic 
biopsy of the oesophageal remnant.  In 10 cases columnar metaplasia was 
identified in the oesophageal remnant.  Endoscopic follow up was not routine in 
this unit and therefore all patients were symptomatic at the time of investigation 
for regurgitation, dysphagia, chest pain or weight loss, giving rise to potential 
selection bias as seen in many such studies.  As described above, patients 
were only included if biopsies were available.  The authors state that ‘biopsies 
were performed to conduct studies such as the present one but what is not 
clear is whether all patients undergoing post operative endoscopy underwent 
biopsy sampling.  This makes the true denominator for this series very difficult 
to determine, if biopsies were only taken when there was a suspicion of 
mucosal abnormality the true denominator might be much larger and the 
prevalence of neo-Barrett’s much lower.     
 
In 2007 a retrospective case series was published based on the records of 613 
patients who had undergone oesophagectomy and gastric tube reconstruction 
over a 10 year period (Bax et al., 2007).  The stated aims of this study were to 
determine whether gastric-type mucosa in the oesophagus is a precursor stage 
of intestinal metaplasia but the prevalence of neo-Barrett’s is also evaluated.  
The authors identified 45 patients who had undergone endoscopic evaluation 6 
months or more following surgery.  There were 18 cases of neo-Barretts giving 
a stated prevalence of 40%.  All of these had biopsy samples available for 
confirmation.  There were 7 cases of neo-Barrett’s with specialised intestinal 
metaplasia and no cases of dysplasia.  This study has a number of 
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weaknesses.  There is no evidence that residual Barrett’s oesophagus at the 
time of surgery was excluded.  Patients who underwent endoscopy did so 
primarily for dilatation of strictures or because there was a suspicion of 
recurrent malignancy.  The level of experience of the endoscopist is not 
recorded and there is no record of whether the examination included any 
specific assessment for the presence of neo-Barrett’s.  There is no record of the 
location of biopsies and the macroscopic findings at the time of endoscopy are 
poorly recorded. 
 
One of the largest series to assess the prevalence of neo-Barrett’s following 
oesophagectomy was published in 2008 (da Rocha et al., 2008)  Prevalence 
rates of 11% at 5 years, 30% at 5-10 years and 58% over 10 years are 
reported.  This study from Brazil involved a very different patient group to the 
others identified by this literature search.  All patients underwent surgery for 
advanced achalasia secondary to Chaga’s disease.  In addition to its size (101 
patients), this study benefits from a number of strengths.  Endoscopic follow up 
every two years with multiple biopsies was routine in these patients and the 
presence or absence of oesophagitis or columnar metaplasia in the 
oesophageal remnant was apparently routinely recorded.  The study also 
benefits from the longest follow up periods of any such study.  Patients were 
younger than those included in the European and North American studies and 
the indication for surgery was benign in all cases.  The study is not without 
some weaknesses however.  There is no indication that there was exclusion of 
Barrett’s oesophagus at the time of surgery although clearly this is less likely 
given the indication for surgery.  The series includes patients with follow up 
periods of up to 40 years.  Given that this precedes the first description of neo-
Barrett’s and modern high definition endoscopes there might be some concerns 
as to whether the evaluation patients early in this series is as reliable as that for 
later patients. 
 
A year later in 2009 the largest prospective study of metaplasia in the 
oesophageal remnant was published (D'journo et al., 2009).  Eighty four 
patients underwent endoscopic evaluation.  There were 21 cases of 
endoscopically visible columnar metaplasia (25%) and 42 cases of histologically 
evident columnar metaplasia (50%).  The reason for the significantly higher 
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prevalence of metaplasia is not adequately explained and this degree of 
discrepancy is not reported in other series.  The authors do report significant 
numbers of patients with endoscopic evidence of ulceration and erosions and 
whether these actually represent unrecognised columnar metaplasia is unclear.  
The indication for endoscopy for patients in this study is not clearly stated.  The 
majority of patients (64%) admitted to reflux symptoms when questioned but it is 
unclear if patients were included on the basis of their symptoms or if they were 
research volunteers.  Despite these issues this study has a number of high 
quality features.  The authors describe a meticulous technique for examination 
and biopsy sampling of the oesophageal remnant.  Surgical resection 
specimens were reviewed to exclude the presence of residual Barrett’s 
oesophagus.  The examining pathologist was blinded to the endoscopic findings 
and there was subsequent correlation between endoscopic and histological 
findings.   
 
The final study identified by the literature search was published in 2010 
(Nishimura et al., 2010).  This study predominantly considered reflux 
oesophagitis in the oesophageal remnant but there is some data on the 
prevalence of neo-Barrett’s.  Data was available for 100 patients at one year 
and a 14% prevalence of neo-Barrett’s is quoted.  Fifty eight patients had two 
year follow-up data available and 23 cases of neo-Barrett’s were identified 
(40%).  This study is one of the largest but is of relatively poor quality.  It is 
based on retrospective review of endoscopy records.  The authors identified 
289 patients who had undergone surgery, only 100 patients are included in the 
study and no inclusion criteria are stated.  The resection margins were 
apparently not reviewed to exclude the presence of residual Barrett’s 
oesophagus.  Of the 100 patients, 98 are reported to have undergone surgery 
for cancer.  The study originates from Japan and one would expect the vast 
majority of these to be squamous cell cancers where co-existing and residual 
Barrett’s is extremely unlikely but there no evidence is presented to confirm this.  
The authors describe columnar lined oesophagus in these patients but this is 
not defined and it is unclear from the paper whether any histological 
confirmation of this finding was available. 
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The most recent paper identified by this literature review was published 
sometime after the present study began (Tsiouris et al., 2011).  This was a 
retrospective study of endoscopy records and included patients who had 
undergone surgery using a variety of techniques, all of which involved resection 
of the gastro-oesophageal junction.  The authors identified 151 patients who 
had undergone endoscopy at least one year after surgery from a total surgical 
cohort of 179 patients.  The indications for endoscopy are not stated.  The aim 
of this study was to compare the outcomes following standard surgical 
techniques with a new novel technique developed by the authors for 
concomitant fundoplication.  Thirteen cases of Barrett’s in the oesophageal 
remnant were identified but in one case there was evidence of residual Barrett’s 
oesophagus when the original resection pathology was reviewed.  This study 
used an American definition of Barrett’s oesophagus and therefore only 
included patients with specialised intestinal metaplasia in the definition.  There 
is no data presented on whether other types of metaplasia were observed or the 
incidence of endoscopic Barrett’s oesophagus. 
 
In summary there is clear evidence that neo-Barrett’s occurs in a significant 
proportion of patients following subtotal oesophagectomy and reconstruction 
with a gastric conduit.  Columnar epithelium both with and without specialised 
intestinal metaplasia occurs.  The overall prevalence from the identified studies 
is 38% but the size and quality of the studies is somewhat limited and the 
largest study had to be excluded from this calculation as it did not report the 
incidence of non-intestinalised columnar epithelium.  The overall prevalence of 
specialised intestinal metaplasia is 17%.  This phenomenon can occur in 
patients who have no previous history of Barrett’s oesophagus or oesophageal 
adenocarcinoma. 
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Author, 
publication, year, 
country 
No. of 
patients 
Follow-up 
period 
mths 
Median 
(range) 
Study type Inclusion 
criteria 
Histological 
corroboratio
n of neo-
Barrett’s 
Residual 
Barrett’s 
effectivel
y 
excluded 
Incidence 
of 
columnar 
metaplasia 
Incidence of 
specialised 
intestinal 
metaplasia 
Öberg S, et al.  
Ann Surg 
2002 Sweden 
32 58 (36-125) Prospective Research 
volunteers 
Yes Yes 15 (47%) 3 (9%) 
Dresner SM, et al. 
Br J Surg 
2003 UK(Dresner et 
al., 2003) 
40 38 (13-118) Prospective Research 
volunteers 
Yes Yes 19 (48%) 9 (23%) 
Franchimont D, et al. 
Endoscopy 
2003 Belgium 
66 16 (1-39) Retrospective Not stated Yes Yes 15 (23%) 9 (13.5%) 
O’Riordan JM, et al 
Am J Gastro  
2004 Ireland 
48 26 (12-67) Prospective Consecutive 
patients in a 
research 
setting 
Yes Yes 24 (50%) 13 (27%) 
Peitz U, et al 
Gastrointest Endosc 
2004 Germany 
14 27 (3-88) Prospective Consecutive 
patients with 
clinical 
indication for 
endoscopy 
Yes (in 13 of 
14 patients) 
Yes 13 (93%) 3 (21%) 
Wolfsen HC, et al 
BMC Gastro 
2004 USA  
36 42 (7-90)* Retrospective Not stated Yes Yes 8 (22%) 8 (22%) 
Lord RVN, et al. 
Surgery 
2004 USA  
20 36 (9-504)* Retrospective Clinical 
indication for 
endoscopy and 
available tissue 
Yes Yes 10 (50%) 4 (20%) 
1 Intramucosal 
cancer 42yrs 
post-op 
36 
Bax D, et al. 
J Clin Gastroenterol 
2007 Netherlands 
45 59 (6-148) Retrospective Patients with 
clinical 
indication for 
endoscopy 
Yes No 18 (40%) 7 (16%) 
Da Rocha JFM, el 
al. 
Ann. Surg. Oncol. 
2008 Brazil 
101 Mean 126 
+/- 106 
Retrospective  All patients Yes No 36 (36%) 23 (23%) 
D’Journo XB, et al. 
Ann Surg 
2009 Canada 
84 35 (1-295) Prospective Not stated Yes 
Significant 
discrepancy 
between 
endoscopic 
findings and 
histology 
Yes 42 (50%) 17 (20%) 
Nishimura K, et al. 
Dis Esoph 
2010 Japan 
100 
 
(subgro
up of 58 
patients) 
12 
 
(24) 
Retrospective Not stated No No 14 (14%) 
 
23 (40%) 
Not assessed 
Tsiouris A, et al. 
World J Surg 
2011 USA 
151 Average not 
stated  
(6mths – 
10yrs) 
Retrospective Not stated Yes Yes Not 
assessed 
12 (8%) 
Totals 737      223 (38% of 
those 
assessed) 
108 (17% of 
those 
assessed) 
 
Table 2.3: Summary of published literature relating to post-oesophagectomy ‘neo-Barrett’s’
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2.6 Prevalence of neo-Barrett’s in the paediatric surgical population 
Oesophageal surgery in children is almost exclusively performed for benign 
disease.  In contrast to those undergoing surgery as adults, primarily for 
malignant disease, paediatric patients are expected to live for many decades 
post-operatively.  Given that these children have the same anatomical 
predisposing factors for reflux as adult patients, the oesophageal remnant can 
be expected to be exposed to prolonged, high levels of duodenogastro-
oesophageal reflux.  The concern must be that these individuals are at high risk 
of developing neo-Barrett’s and are likely to live long enough after their 
operation to progress along the metaplasia-dysplasia-carcinoma sequence.  
Five studies were identified which assessed the prevalence of neo-Barrett’s 
following paediatric surgery 
 
The first of these studies was published in 1990 by the Helsinki group (Lindahl 
et al., 1990).  The authors identified 18 long-term survivors (> 2 years) following 
gastric tube reconstruction for a variety of oesophageal pathologies.  
Retrospective analysis of patient records identified 14 patients who had 
undergone subsequent endoscopy.  Ten patients had endoscopic evidence of 
neo-Barrett’s, columnar metaplasia was confirmed on histology in 8 cases but 
there were no cases of intestinal metaplasia.  This study is limited in terms of 
size but it is important in that it represents the first description of neo-Barrett’s in 
a paediatric surgical population.  The authors state that symptoms were a poor 
indicator of pathology but the study is clearly underpowered to detect a 
significant difference. 
 
The next study to report cases of neo-Barrett’s in a paediatric population was 
published thirteen years later (Hamza et al., 2003).  This retrospective case 
series from Egypt provides only very limited data on the cases of neo-Barrett’s 
but it is by far the largest series of its type.  Children underwent surgery for 
caustic strictures and reconstruction utilised a gastric ‘pull-up’ technique.  The 
authors describe long term follow up of 75 patients with 10 cases of Barrett’s 
identified and one case of carcinoma.  The study is compromised by a lack of 
detail with regards to the follow up protocol and any statement as to whether 
there was routine endoscopic follow up.  The duration of follow up is not stated 
and the authors do not state the definition of Barrett’s oesophagus used or if 
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histological corroboration was obtained.  With regards to the reported case of 
carcinoma it is unclear whether this was an adeno or squamous cell carcinoma 
or if there was any evidence of neo-Barrett’s oesophagus in the patient 
concerned. 
 
Borgnon and colleagues (2004) published a small case series of 21 children 
who had undergone oesophageal replacement with an isoperistaltic gastric 
tube.  The surgery in this series differed from that undertaken in adults as in five 
cases of caustic stricture, the injured oesophagus was left in situ.  All patients 
did however have an anastomosis between the stomach and the cervical 
oesophagus with exclusion of the oesophago-gastric junction.  Nineteen 
patients underwent subsequent endoscopy and two cases of neo-Barrett’s were 
identified.  Unfortunately the authors of this study also fail to describe the 
diagnostic criteria used for neo-Barrett’s and the timing and indications for 
endoscopic follow up are not stated.   
 
The fourth study identified which considers neo-Barrett’s in a paediatric surgical 
population was published by Spitz and colleagues (2004).  This paper 
predominantly describes surgical techniques and outcomes but the authors 
recognise the possibility of neo-Barrett’s following gastric ‘pull-up’ 
reconstruction.  They state that they have encountered no cases in a series of 
173 patients, the majority of whom had surgery for oesophageal atresia.  The 
follow up protocol for these patients is not described and it is unclear how many 
of these children underwent endoscopy following surgery.  This information is of 
critical importance given that Barrett’s oesophagus and neo-Barrett’s can only 
be diagnosed or excluded by endoscopic examination. 
 
The most recent study available which considers Barrett’s oesophagus after 
paediatric surgery was published in 2005 (Deurloo et al., 2005).  This paper 
from the Netherlands involved children who had undergone surgery for 
oesophageal atresia.  Unfortunately the surgical techniques are not described 
and it is therefore not possible to assess if the anatomy of these patients is 
similar to that of adults who have undergone oesophagectomy.  Patients in this 
series were questioned about reflux symptoms and were invited to undergo 
endoscopic examination.  Ninety two potentially eligible patients were identified 
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and 86 questionnaires were returned at a median follow up period of 17 years.  
Forty nine patients underwent endoscopy and 2 cases of columnar metaplasia 
were identified, both of gastric type. 
 
In summary the available literature confirms that neo-Barrett’s oesophagus can 
occur in children and young adults who have undergone oesophageal surgery 
and reconstruction with a gastric tube.  The available literature is of insufficient 
quality to allow the prevalence or timing of this metaplasia to be determined. 
 
2.7 Timescale for the development of neo-Barrett’s 
One of the unique features of the post-oesophagectomy human model for the 
development of Barrett’s metaplasia is that it allows the timescale over which it 
develops to be determined.  It is also possible to study the different subtypes of 
columnar metaplasia and the temporal relationship between them. 
 
The earliest case of neo-Barrett’s identified by the literature search occurred 
only 43 days after surgery (Franchimont et al., 2003).  The authors describe a 
review of the resection specimen to exclude the presence of residual Barrett’s 
and the histological examination to confirm the presence of columnar epithelium 
with specialised intestinal metaplasia.  There are several other reported cases 
of neo-Barrett’s occurring less than a year after surgery (O'Riordan et al., 
2004)but no others at this very early stage.  It is not clear whether there was 
clear correlation of endoscopic and histological findings in order to make the 
diagnosis raising the possibility of inadvertent sampling of the gastric conduit 
below the anastomosis rather than the tubular oesophagus above.  The 
presence of intestinal metaplasia makes this less likely however, as one would 
not routinely expect to find this in a healthy gastric conduit. 
 
Four studies were identified which sought to evaluate the association between 
time from surgery and the presence of neo-Barrett’s (da Rocha et al., 2008, 
Nishimura et al., 2010, O'Riordan et al., 2004, Oberg et al., 2002).  Nishimura 
and colleagues in their study of 100 patients describe no cases of columnar 
metaplasia at one month, 14% prevalence at one year and 40% prevalence in a 
subgroup of 58 patients who were followed up for two years.  The authors state 
that this association was statistically significant quoting a p value of <0.05.  The 
40 
other study which reports a significant association between the time from 
surgery and the presence of columnar metaplasia is that conducted by Da 
Rocha and colleagues (2008).  As outlined above, patients in this study 
underwent regular endoscopic follow up and the prevalence of columnar 
metaplasia increased from 11% at 1-5 years (11/101) through to 30% between 
5 and 10 years (18/61) and 58% for those more than 10 years post surgery.  
The authors state that this relationship is statistically significant but no p values 
are quoted. 
 
Conversly, two studies report that there is no significant association between 
time from surgery and the presence of columnar metaplasia (O'Riordan et al., 
2004, Oberg et al., 2002).  Both of these studies were based on a single 
endoscopy for patients and comparison of time from surgery for those with and 
without columnar metaplasia.  Interestingly in one study, (O'Riordan et al., 
2004) median time from surgery for patients with columnar metaplasia was 
almost twice that of those with no metaplasia (39 months vs 20 months) yet this 
difference failed to reach statistical significance.  The concern here must be that 
these studies, both of which involve less than 50 patients, may be 
underpowered to detect a difference in time from surgery. 
 
Three studies were identified which address the relationship between time from 
surgery and the presence of neo-Barrett’s with specialised intestinal metaplasia 
(Dresner et al., 2003, Oberg et al., 2002, da Rocha et al., 2008).  All three of 
these found that there was a significant positive association.  Dresner et al. 
(2003) compared the time to the development of non-specialised cardiac-type 
metaplasia (median 14 months) with the time to first detection of specialised 
intestinal metaplasia (median 27 months) and found a significant difference 
(p=0.011).  Oberg et al. (2002) found that the median postoperative period was 
significantly longer in patients with intestinal metaplasia compared with those 
without (9.5 vs 4.2 years, P=0.004).  Again there are concerns about the 
reliability of these findings as this study included only 3 patients with intestinal 
metaplasia.  The third study to describe an association between time from 
surgery and the presence of specialised intestinal metaplasia is that by Da 
Rocha and colleagues (2008) but again, no statistical data is provided to 
support this claim.   
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Four studies describe progressive histological changes in individual patients 
(Lord et al., 2004, Gutschow et al., 2008, Dresner et al., 2003, D'journo et al., 
2009).  Lord describes one case where biopsies from the oesophageal remnant 
showed squamous epithelium at 15 months and cardiac type mucosa 9 months 
later.  Unfortunately this study was based on retrospective evaluation of biopsy 
material and it is not clear how carefully the oesophageal remnant was 
examined for the presence of metaplasia at the first endoscopy.  A similar case 
is described by Gutschow (2008) in which there was progression from 
squamous mucosa at 8 months to specialised intestinal metaplasia at 15 and 20 
months and adenocarcinoma at 28 months.  More convincing data of 
histological progression comes from the study by Dresner et al. (2003).  In this 
prospective study, progression from squamous mucosa to cardiac type mucosa 
was demonstrated in 10 patients.  In all cases, metaplasia was preceded by 
oesophagitis.  The final study which reports histological progression is that by 
D’Journo and colleagues (2009).  This is the only study to provide evidence that 
gastric type metaplasia might be a precursor to cardiac type metaplasia.  The 
authors describe progression to cardiac type metaplasia in 4 of 12 patients who 
initially had gastric type metaplasia and progression to specialised intestinal 
metaplasia in 8 of 16 patients with cardiac type metaplasia.   
 
In summary the data on the time to develop neo-Barrett’s is inconsistent and 
tends to come from small studies which makes statistical analysis difficult.  
There are few reported cases occurring before one year.  The available data 
tends to support the theory that the initial step is conversion to a non-
intestinalised columnar epithelium with subsequent progression to specialised 
intestinal metaplasia. 
 
2.8 Predisposing factors for the development of neo-Barrett’s 
 
2.8.1 Association with pre-operative histology 
The most widely studied potential predisposing factor for neo-Barrett’s is the 
pre-operative histology.  Both the association with the tumour type and the 
presence of pre-operative Barrett’s oesophagus have been assessed. 
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Only one study includes a multivariate analysis of potential predisposing factors 
(D'journo et al., 2009).  This study considered the following potential 
predisposing factors; gender, age, previous Barrett’s oesophagus, 
adenocarcinoma vs squamous cell carcinoma, neo-adjuvant therapy, thoracic 
anastomosis vs cervical anastomosis, anastomotic complications, proton pump 
inhibitor and prokinetic medication use.  Previous Barrett’s oesophagus was 
associated with a significantly increased risk of developing neo-Barrett’s (odds 
ration 2.667).  When this was considered using a multivariate model however, 
the threshold for statistical significance was not reached (p=0.064). 
 
Other studies have assessed the association between the presence of pre-
operative Barrett’s oesophagus and the development of neo-Barrett’s but all are 
based on univariate analysis.  Oberg et al (2002) found that the prevalence of 
columnar metaplasia was significantly higher in patients with a pre-operative 
diagnosis of Barrett’s oesophagus compared to others (69% vs 25%) but there 
were only 16 patients in each group.  Two further studies have found no 
significant association between the presence of pre-operative Barrrett’s 
oesophagus and the development of neo-Barrett’s.  One of these (Peitz et al., 
2004b) involved only 14 patients and 10 cases of neo-Barrett’s and it could be 
argued that statistical comparison of groups of this size is inappropriate.  The 
second study by Franchimont and colleagues (2003) reported 7 cases of neo-
Barrett’s in 9 patients with a pre-operative diagnosis of Barrett’s (77%) and 24 
cases in 57 patients with no pre-operative diagnosis of Barrett’s oesophagus 
(42%).(Franchimont et al., 2003)  This difference was not statistically significant.  
It is important to note that this study included 35 patients with oesophageal 
adenocarcinoma so at least 26 patients in the group with no pre-operative 
Barrett’s oesophagus actually had disease on the Barrett’s metaplasia-
dysplasia-adenocarcinoma spectrum.  
 
Three studies were identified which evaluated the association between the 
original tumour type and the development of neo-Barrett’s.(Dresner et al., 2003, 
Bax et al., 2007, O'Riordan et al., 2004)  All of these employed univariate 
analysis only and all found that there was no statistically significant association 
between tumour type and neo-Barrett’s. 
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2.8.2 Association with route of reconstruction 
The type of surgical reconstruction and site of anastomosis following 
oesophagectomy has been identified as a potentially important factor.  It has 
been suggested that a cervical anastomosis is associated with less reflux than 
an anastomosis in the chest (McKeown, 1976) and one might therefore expect 
the risk of neo-Barrett’s to be lower in patients with a cervical anastomosis.  
Two studies were identified which assessed the route of reconstruction. 
 
The study by D’Journo (2009) compared patients who had undergone an Ivor-
Lewis procedure and thoracic anastomosis (n=36) with those who had 
undergone a 3-stage procedure with cervical anastomosis (n=48).  The authors 
found that on multivariate analysis, a thoracic anastomosis was associated with 
a significantly greater risk of developing neo-Barrett’s (Odds ratio 3.05, 
p=0.018).  The second study to consider the route of reconstruction as a risk 
factor was that undertaken by Nishimura and colleagues (2010).  This study 
compared the subcutaneous, retrosternal and posterior mediastinal routes of 
reconstruction but all patients are described as having a cervical 
oesophagogastrostomy and the surgical methods are not described in detail.  
No significant difference in the prevalence of neo-Barrett’s related to the route 
of reconstruction was detected. 
 
In summary the data on possible risk factors for neo-Barrett’s is limited.  Many 
studies are too small for good quality statistical analysis and only one study has 
employed multivariate analysis.  There appears to be a trend towards an 
increased risk in patients with a pre-operative diagnosis of Barrett’s oesophagus 
but statistical proof of this is lacking.  Data from a single study suggests that a 
cervical anastomosis might be protective against neo-Barrett’s. 
 
2.9 Malignant progression in neo-Barrett’s 
The importance of Barrett’s oesophagus lies in its association with oesophageal 
adenocarcinoma.  Should neo-Barrett’s have the same association it would 
mean that this finding might have clinical relevance for the patients involved.  In 
addition this would provide further evidence that the post oesophagectomy 
model for the development of Barrett’s is an accurate one.   
 
44 
Five papers were identified which described cases of dysplasia and 
adenocarcinoma arising within the oesophageal remnant following subtotal 
oesophagectomy.  Two cases occurred more than 40 years after the initial 
surgical procedure.  In both of these cases the original indication for surgery 
was a benign stricture in childhood.  In one case progression was demonstrated 
from dysplastic neo-Barrett’s through to invasive adenocarcinoma (Dunn et al., 
2010).  In the second case, intramucosal adenocarcinoma was present within 
the area of neo-Barrett’s at the time of diagnosis (Lord et al., 2004). 
 
Three further papers describe malignant progression in neo-Barrett’s following 
surgery in adults.  Da Rocha (2008) describes two cases of high grade 
dysplasia occurring in neo-Barrett’s at 13 and 19 years following surgery.  Both 
patients were followed up and went on to develop in situ adenocarcinoma over 
periods of 1 and 3 years respectively.  This was managed with endoscopic 
mucosal resection.  A detailed case report describes a case of neo-Barrett’s 
occurring 15 months after subtotal oesophagectomy for a Barrett’s 
adenocarcinoma (Gutschow et al., 2008).  By 28 months this had progressed to 
invasive adenocarcinoma.  The original proximal resection margin was free from 
metaplasia, effectively excluding the possibility of residual Barrett’s or 
carcinoma.   
 
Of most concern to clinicians caring for patients who have undergone 
oesophagectomy is the study by Wolfsen and colleagues (2004) which reports 
an exceptionally high incidence of dysplasia and adenocarcinoma in neo-
Barrett’s.  In this study forty five patients were identified who had undergone 
oesophagectomy for Barrett’s dysplasia or adenocarcinoma.  Follow up periods 
for the cohort as a whole are not stated but the earliest patient underwent 
surgery 9 years prior to the publication of the paper.  The study identified three 
cases of neo-Barrett’s with low grade dysplasia, one case of neo-Barrett’s with 
high grade dysplasia and two cases of neo-Barrett’s in association with invasive 
adenocarcinoma.  The proximal resection margin is described as being 
composed of squamous epithelium in all cases.  Mean time to the diagnosis of 
LGD was 44 months, to HGD was 88 months and to adenocarcinoma was 13 
months.  There is clearly a marked discrepancy between the findings in this 
study and others which have reported outcomes following oesophagectomy.  
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No explanation for this is offered by the authors and there is no obvious reason 
why this cohort should differ from the others reported in the literature.  Surgical 
methods employed were similar to those in other studies included in this review 
and proton pump inhibitors are described as being routinely prescribed.  
Patients were drawn from a North American population and the only marked 
difference between this and other series appears to be the inclusion only 
patients who underwent surgery for adenocarcinoma or dysplastic Barrett’s 
oesophagus. 
 
One case report of adenocarcinoma occurring after surgery for tracheo-
oesophageal fistula (TOF) was identified (Alfaro et al., 2005).  The case 
described is of a 46 year old female who developed adenocarcinoma on a 
background of extensive Barrett’s oesophagus at the age of 46 following 
surgery as an infant.  The type of surgery involved is not described and it is 
therefore not possible to determine if this represents a situation analogous to 
that occurring after subtotal oesophagectomy.  Gastric conduits may be used in 
the repair of TOF, particularly where this is associated with long-gap 
oesophageal atresia but in other cases primary closure is the norm (Arul GS, 
2008). 
 
In summary 7 cases of adenocarcinoma arising within neo-Barrett’s were 
identified by this literature search with a further 4 cases of dysplasia.  One case 
of adenocarcinoma following surgery for tracheo-oesophageal fistula was also 
identified.  There is low grade evidence from case reports to show malignant 
progression which indicates that the metaplasia-dysplasia-adenocarcinoma 
sequence can occur in the context of neo-Barrett’s.  Given the small numbers of 
patients involved it is not possible to accurately determine the risk of malignant 
progression in neo-Barrett’s. 
 
2.10 Molecular marker expression in neo-Barrett’s 
This literature search identified four studies which involved the assessment of 
molecular marker expression in neo-Barrett’s tissue.  A variety of markers were 
evaluated and the number of samples assessed tended to be small. 
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The largest study of this type was published in 2007 (Bax et al., 2007).  
Eighteen patients with neo-Barrett’s were identified including 7 with specialised 
intestinal metaplasia (SIM).  Immunohistochemisty was used to assess for the 
presence of CDX2, MUC2 and cytokeratins 7 and 20 and CDX2 expression was 
further evaluated by polymerase chain reaction techniques.  CDX2 is a protein 
involved in intestinal differentiation, predominantly expressed in the small 
intestine and colon of adults which is also known to be present in Barrett’s 
tissue.  CDX2 expression was found in all 7 patients with specialised intestinal 
metaplasia and in a further 2 samples from patients with gastric type 
metaplasia.  The authors suggest that this indicates that gastric metaplasia is 
related to specialised intestinal metaplasia.  MUC2 is a mucin protein normally 
found in the intestine which has also been found in Barrett’s oesophagus.  In 
the neo-Barrett’s tissue studied MUC2 was observed in the goblet cell 
cytoplasm of all patients with SIM, it was not found in any patients with gastric 
type metaplasia.  Cytokeratins 7 and 20 were present in all samples of neo-
Barrett’s regardless of subtype but the exact staining pattern is not described 
and it is therefore difficult to compare this to the pattern which has been 
reported in sporadic Barrett’s oesophagus. 
 
The second largest study to assess molecular marker expression in neo-
Barrett’s involved samples from only 10 patients (Lord et al., 2004).  This study 
included a more detailed examination of cytokeratin 7 and 20 staining pattern 
using immunohistochemical techniques.  Cytokeratins are the intermediate 
filaments characteristic of epithelial cells and they occur in several different 
forms.  Sporadic Barrett’s epithelium is characterised by strong CK7 staining at 
the surface and in deep glands and weak superficial CK20 staining (Ormsby et 
al., 1999).  This study by Lord and colleagues found that CK7 and CK20 
staining patterns were similar in the neo-Barrett’s samples to what is reported in 
sporadic Barrett’s.  This held true regardless of the subtype of neo-Barrett’s.  
This study also used immunohistochemistry to evaluate the expression of 
DAS1, topoisomerase 2α, cycloxygenase 2 (COX-2) and ornithine 
decarboxylase (ODC).  The authors chose DAS1 as a further comparison 
against sporadic Barrett’s as this antibody is known to react against Barrett’s 
cells but not against normal oesophageal mucosa.  DAS1 stained the mucin in 
the goblet cells of neo-Barrett’s with SIM intensely and also faintly stained the 
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cytoplasm of some columnar cells in neo-Barrett’s without SIM.  Topoisomerase 
2α was used to assess cellular proliferation and COX-2 and ODC to assess the 
potential for dysplasia.  Overall the authors of this study conclude that the 
expression profile of neo-Barrett’s is similar to that found in Barrett’s 
oesophagus and different from that of normal oesophageal or gastric mucosa.  
The main weakness of this study is the small numbers of samples involved. 
 
Chaves and colleagues (2002) used an antibody against the enterocytic 
enzyme sucrase-isomaltase (SI) to assess for intestinal type differentiation in 
samples from 4 patients with neo-Barrett’s.  There was no direct comparison 
with Barrett’s tissue, but the authors do make reference to a previous paper 
from the same unit.  In that study this enzyme was found to be present in 8 of 
12 cases of Barrett’s oesophagus studied.  In the 4 neo-Barrett’s patients only 
one case of unequivocal SI staining was identified but really the numbers 
involved in both this study and the original study of sporadic Barrett’s are too 
small for this to be a meaningful comparison. 
 
The final paper identified which assessed molecular marker expression in neo-
Barrett’s was the case report by Gutschow and colleagues (2008).  Here the 
authors studied expression of three markers in samples from a single patient 
who progressed from squamous epithelium through to neo-Barrett’s metaplasia 
and invasive adenocarcinoma.  The markers were COX-2, BCL-2, a protein 
involved in regulating apoptosis and survivin, another protein involved in 
regulating apoptosis.  Quantitative real-time polymerase chain reaction was 
used to measure expression of these genes and a stepwise increase in each 
was found as progression to adenocarcinoma occurred. 
 
Overall there is very limited evidence available on molecular marker expression 
in neo-Barrett’s.  The evidence that has been published is from small studies 
and the markers investigated are varied.  There is insufficient data to conclude 
whether neo-Barrett’s is characterised by the same molecular markers as 
sporadic Barrett’s oesophagus. 
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2.11 Summary 
The major finding of this review is that there are very few good quality studies 
looking at neo-Barrett’s metaplasia occurring in the oesophageal remnant 
following oesophagectomy.  Most published series involve small numbers of 
patients and this has made the evaluation of potential risk factors for neo-
Barrett’s difficult.  There is insufficient data to assess the risk of malignant 
progression in neo-Barrett’s and this is critical if we are to be able to devise 
evidence based follow-up protocols for patients.  Data on molecular marker 
expression in neo-Barrett’s is extremely limited.  In order to confirm the 
accuracy of the post-oesophagectomy human model for the development of 
Barrett’s significantly more work in this area is required.    These issues provide 
the indication for the present study. 
 
2.12 Aims of the study 
The aims of this study are: 
 
1. To establish the incidence of post-oesophagectomy neo-Barrett’s in a 
large series of patients and the timescale over which this develops 
 
2. To establish whether or not neo-Barrett’s oesophagus is characterised by 
expression of the same cellular proteins as sporadic Barrett’s oesophagus 
 
3.  To establish whether or not genetic mutations present in the original 
tumour or Barrett’s oesophagus are present in post-operative neo-Barrett’s 
oesophagus 
 
 
2.13 Hypotheses 
Neo-Barrett’s metaplasia is a de novo phenomenon and is unrelated to the 
disease process in the oesophagus pre-operatively. 
 
Neo-Barrett’s metaplasia in the remnant oesophagus is an inevitable 
consequence of subtotal oesophagectomy and reconstruction with a gastric 
conduit.   
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Neo-Barrett’s metaplasia occurring after oesophagectomy is characterised by 
the same cellular proteins as sporadic Barrett’s and is an accurate model for 
this.   
 
Neo-Barrett’s metaplasia has the potential to progress to dysplasia 
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Chapter 3. A study of the incidence of post-oesophagectomy 
Barrett’s and the timescale over which it develops 
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3.1 Introduction   
In Barrett’s oesophagus the squamous epithelium of the distal oesophagus is 
replaced with metaplastic columnar epithelium.  The condition is acquired in 
response to the harmful effects of acid and bile refluxing into this region (Vaezi 
and Richter, 1996).  Whilst reflux is now well recognised as the major 
aetiological factor in Barrett’s oesophagus the precise mechanisms underlying 
the pathogenesis remain incompletely understood. 
 
Following subtotal oesophagectomy with a gastric conduit reconstruction the 
majority of patients experience reflux of gastric and duodenal contents (Aly and 
Jamieson, 2004).  In vivo ambulatory studies in Newcastle (Dresner et al., 
2003) have demonstrated abnormal oesophageal exposure to both acid and 
bile over a 24 hour period in over 80% of post operative patients.  Elsewhere, 
Öberg and colleagues (2002) have reported abnormal oesophageal acid 
exposure in 78% of patients.   The high prevalence of reflux results from the 
disruption of the normal anatomical anti-reflux mechanisms (figure 3.1).  The 
lower oesophageal sphincter, angle of His and diaphragmatic sling are all 
resected or disrupted.  Many surgeons perform a routine pyloroplasty to 
facilitate gastric emptying but this has the associated adverse effect of 
promoting duodenal reflux.  The position of the gastric tube between the 
positive pressure environment of the abdominal cavity and the negative 
pressure of the thoracic cavity further promotes reflux.  
 
Since 1977 it has been recognised that columnar metaplasia can develop 
above an oesophago-gastric anastomosis and this has been termed neo-
Barrett’s (Hamilton and Yardley, 1977).  This phenomenon is potentially 
clinically important for the patients affected.  It also provides a unique 
opportunity to study the development of Barrett’s oesophagus in a situation 
which avoids some of the pitfalls associated with observations in sporadic 
Barrett’s oesophagus.  
 
It is not normally possible to ascertain the timescale over which Barrett’s 
develops in response to reflux.  In the post-oesophagectomy patient, the 
operation date represents a baseline and allows a timescale to be determined 
for the development of neo-Barrett’s with examination of the resection specimen 
52 
confirming squamous epithelium at the site of anastomosis which is unlikely to 
have been exposed to significant reflux pre-operatively. 
 
Segments of neo-Barrett’s have the same endoscopic appearance as standard 
Barrett’s and the surgical anastomosis is easily identified at endoscopy.  Any 
biopsies from above this anastomosis are clearly oesophageal in origin and the 
difficulties normally associated with the accurate identification of the gastro-
oesophageal junction are eliminated in this group of patients. 
 
The aim of this study was to prospectively evaluate the incidence of neo-
Barrett’s in a large cohort of patients, to define the timescale over which it 
develops and to assess possible predisposing factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Anatomical features leading to reflux after subtotal oesophagectomy 
(reproduced from Minimally Invasive Esophagectomy, (Luketich et al., 2000), 
with kind permission of Elsevier) 
 
 
3.2 Patients and Methods 
 
3.2.1 Study population 
Patients for this study were enrolled from the Northern Oesophago-gastric 
cancer unit.  This unit, based in Newcastle upon Tyne, provides treatment for 
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patients with oesophageal carcinoma from across the north of England.  It is 
one of the largest such units in Europe undertaking between 60 and 75 subtotal 
oesophagectomies per year. 
 
Endoscopic evaluation of the oesophagogastric anastomosis and the remnant 
oesophagus is now a routine aspect of post-operative follow up in the unit.  The 
follow up protocol is designed to identify patients who develop neo-Barrett’s and 
to allow the option of surveillance to be considered.  The current protocol is to 
endoscope patients at around 1 year following surgery and at 5 years following 
surgery.  Early endoscopy aims to identify those with rapid development of neo-
Barrett’s who may be at higher risk of progression.  Delayed endoscopy aims to 
identify patients who are considered ‘cured’ but who have neo-Barrett’s and 
may benefit from long term follow up and surveillance.  
 
Historically follow-up endoscopy was not routine and many patients therefore 
undergo examination outside of the above protocol.  In addition patients with 
new onset upper gastro-intestinal tract symptoms undergo urgent endoscopic 
evaluation.  Very early endoscopy is occasionally undertaken when an 
anastomotic stricture is suspected.  Patients with known or suspected distant 
disease recurrence do not routinely undergo endoscopy.  Patients in whom 
endoscopy is not felt to be clinically relevant by the named consultant are also 
excluded from the above protocol.  Examples of this would be patients who are 
particularly frail. 
 
3.2.2 Surgical technique 
All surgery is performed by, or under the direct supervision of, a consultant with 
a specialist practice in oesophago-gastric surgery and the detailed resection 
techniques have been described elsewhere (Griffin SM and Raimes SA, 2006).  
The main steps of the operation include an upper midline laparotomy through 
which the stomach is mobilised based on a vascular pedicle of the right gastric 
and gastroepiploic arteries.  The lesser omentum is divided encompassing 
nodes along the lesser curve and those at the origin of the coeliac trunk.  The 
common hepatic artery and the roots of the splenic and left gastric arteries are 
also skeletonised by complete removal of the surrounding nodal tissue.  The left 
gastric artery is divided at its origin and an en bloc hiatal dissection is performed 
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removing the left and right paracardial nodal stations together with the 
respective crura.  A pyloroplasty is routinely performed to ensure adequate 
gastric drainage. 
 
Via a fifth intercostal space right thoracotomy the oesophagus is mobilised with 
any connective tissue and the encompassing mediastinal pleura dissected off 
the aorta and pulmonary veins.  A meticulous lymphadenectomy of the 
paratracheal, carinal and left and right bronchial nodes is performed followed by 
en bloc excision of the thoracic duct and para-aortic nodes.  The oesophagus is 
transected at the level of the thoracic inlet and the stomach delivered into the 
chest.  Sleeve resection of the lesser curve and the associated nodes is 
undertaken and a stapled oeosophago-gastric anastomosis fashioned.  The 
nodes in the aorto-pulmonary window are removed but neither a full dissection 
of the left recurrent laryngeal nerve chain nor a cervical lympadenectomy are 
routinely undertaken. 
 
3.2.3 Historical data 
Data from the pre-operative staging process was obtained from a prospectively 
compiled database held within the Northern Oesophago-Gastric Cancer Unit. 
 
3.2.4 Ethical approval 
Ethical approval for the study and for additional biopsies to be taken during 
routine endoscopy was sought and granted by the County Durham and Tees 
Valley 2 REC (reference number 08/H0908/25, Appendix 1).  Reseach and 
Development approval was also granted by the Newcastle upon Tyne Hospitals 
NHS Foundation Trust. 
 
3.2.5 Patient assessment 
Patients attending for endoscopy were questioned about the long-term use of 
proton-pump inhibitors, pro-kinetics, aspirin and non-steroidal anti-inflammatory 
(NSAID) medications since the time of surgery.  The presence or absence of 
reflux symptoms was noted although no attempt was made to quantify these 
symptoms.  Medical notes were reviewed in order to obtain the results of any 
previous post-operative endoscopies. 
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3.2.6 Consent and study information 
Routine informed consent for endoscopy was sought prior to examination.  After 
ethical approval to take additional biopsies for research purposes had been 
granted patients were issued with an information sheet regarding the study prior 
to their endoscopy (Appendix 2). Patients were asked whether they wished to 
participate in this study and additional written consent for this was obtained.   
 
3.2.7 Endoscopic assessment 
All patients underwent endoscopic assessment by, or in the presence of the 
same endoscopist.  A range of Olympus video-endoscopes were used with 
external diameters ranging from 9.0 – 11millimetres (XQ260, XQ240, H260, 
1T240, Olympus KeyMed, UK).  Either topical pharyngeal anaesthesia with 10% 
lidocaine (Xylocaine®, AstraZeneca, Luton, UK) or intravenous sedation with 2 - 
5 milligrams of midazolam (Hameln, Gloucester, UK) were used according to 
patient preference.  Patients were allowed to continue all usual medications up 
to and including the day of the test.   
 
With the patient in the left lateral position the endoscope was introduced and 
the distance from the incisors to the anastomotic line was measured.  The 
presence or absence of endoscopic columnar epithelium above the 
anastomosis was noted before the gastric conduit, pylorus and duodenum were 
examined.  The anastomosis was also viewed on retroflexion and the distance 
from the incisors was confirmed as the endoscope was withdrawn. 
 
3.2.8 Biopsy protocol 
Standard biopsy protocol for post oesophagectomy patients with endoscopic 
neo-Barrett’s is as follows:- 
 
2 or more biopsies from the area of columnar epithelium within the tubular 
oesophagus above the surgical anastomosis 
2 biopsies from the neo-cardia 2cm below the anatstomotic site 
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Where there is no endoscopic evidence of neo-Barrett’s biopsies are 
undertaken at the discretion of the endoscopist.  Patients who are anti-
coagulated do not undergo routine biopsy. 
Patients consenting to additional research biopsies had an additional 4 biopsies 
taken from the area of endoscopically visible columnar epithelium above the 
surgical anastomosis.  They also had an additional 4 biopsies taken from the 
neo-cardia and 2 biopsies taken from any area of endoscopically normal 
squamous epithelium above the squamo-columnar junction. 
 
All biopsies were taken using standard spiked biopsy forceps (Radial Jaw 3, 
Boston Scientific, MA, USA). 
 
The diagnosis of Barrett’s oesophagus relies upon histological corroboration of 
endoscopic findings.  The presence of the visible surgical anastomosis allows 
the endoscopist to be confident that biopsies taken from above this are 
oesophageal in origin.  No specific height above the anastomosis was set for 
biopsies as this would prevent the evaluation of short segments of columnar 
metaplasia. 
 
3.2.9 Processing of biopsy material 
All biopsy specimens were immediately placed onto strips of filter paper.  
Specimens to be embedded in paraffin were transported in 10% neutral 
buffered formalin.  Specimens to be snap-frozen were transported wrapped in 
damp gauze in universal containers.  The strips of tissue were processed for 
embedding in paraffin.  This was done in an automated tissue-processing 
machine according to the protocol described in Appendix 3.  Serial sections of 5 
micrometres were cut using the microtome and sections were de-waxed and 
rehydrated according to the protocol described in Appendix 4.   
 
3.2.10 Histopathological assessment and definitions 
Biopsies for histological assessment were stained with Haematoxylin and Eosin 
using a standard automated system.  Biopsy results were reported by the 
pathology department at the Royal Victoria Infirmary, Newcastle.  All supra-
anastomotic biopsies demonstrating columnar epithelium were reviewed by an 
experienced gastro-intestinal pathologist. 
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For the purposes of this study the definition of neo-Barrett’s epithelium included 
all types of columnar epithelium in biopsies taken from the remnant 
oesophagus.  Columnar epithelium was subdivided into 3 types as originally 
described by Paull et al. (1976). 
 
A Columnar epithelium with specialised intestinal metaplasia 
 
B Specialised gastric mucosa with parietal cells (body or fundic type) 
 
C Non-specialised gastric mucosa (cardiac type) 
 
3.2.11 Statistical analysis 
Categorical data were analysed using the chi-squared or Fisher’s exact test as 
appropriate.  Numerical data were analysed using either the independent 
students t-test or the Mann-Whitney U test. 
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3.3 Results 
 
3.3.1 Study population 
134 patients who had previously undergone subtotal oesophagectomy and 
reconstruction with as gastric conduit underwent prospective endoscopic 
evaluation during the course of the study. 
 
3.3.2 Exclusions 
Patients were excluded from the study if there was evidence of residual 
Barrett’s oesophagus at the proximal resection margin of the surgical specimen 
(7 patients).  Patients were also excluded if there was evidence of local tumour 
recurrence (1 patient). 
 
3.3.3 Demographics 
A total of 126 patients were therefore included in the study population.  The 
male to female ratio was 2.15:1.  Median age at the time of endoscopy was 67 
(range 20 – 85). 
 
3.3.4 Indications for Original Resection 
The indications for original resection are given in table 3.1.  The one case of 
benign histology relates to a patient with squamous cell carcinoma on pre-
operative biopsies.  No evidence of squamous cell carcinoma was found in the 
resection specimen but subsequent re-evaluation of the biopsies by a second 
pathologist confirmed the original pre-operative diagnosis.  One patient had 
high grade dysplasia in a small nodule at the gastro-oesophageal junction, there 
was no endoscopic or histological evidence of Barrett’s metaplasia above the 
gastro-oesophageal junction. 
 
In all cases where there was evidence of neo-Barrett’s the original resection 
specimen was retrieved and reviewed by an experienced gastro-intestinal 
pathologist to exclude the presence of residual Barrett’s metaplasia at the 
proximal resection margin. 
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Resection Specimen 
Histology 
Number of 
patients 
Clear endoscopic 
evidence of Neo-
Barrett’s 
Confirmed 
Neo-Barrett’s 
Adenocarcinoma 83 34 33 
Squamous Cell 
Carcinoma 
22 5 5 
High Grade Dysplasia 
in Barrett’s 
10 4 4 
High Grade Dysplasia 
in Squamous 
epithelium 
2 0 0 
Gastro-intestinal 
Stromal Tumour 
(GIST) 
5 1 1 
Undifferentiated 
carcinoma 
1 0 0 
Hamartoma 1 1 1 
Benign  1 1 1 
High Grade Dysplasia 
in nodule at gastro-
oesophageal junction 
1 0 0 
Total 126 46 45 
   
Table 3.1: Indications for surgery in study patients (confirmed Neo-Barrett’s 
defined as endoscopic evidence of columnar metaplasia with histological 
corroboration) 
 
 
3.3.5 Prevalence of pre-operative Barrett’s Oesophagus 
Barrett’s oesophagus was noted at the pre-operative staging endoscopy in 54 
patients.  In ten of these patients high grade dysplasia within Barrett’s 
oesophagus was the primary indication for surgery.  A further 43 patients had 
endoscopic evidence of Barrett’s oesophagus along with adenocarcinoma.  This 
equated to 52% of the 83 patients who underwent surgery primarily for 
adenocarcinoma.  Only one patient with a non-Barrett’s/adenocarcinoma 
indication for surgery was noted to have endoscopic evidence of Barrett’s 
oesophagus pre-operatively. 
 
Fifty six patients had histological evidence of Barrett’s oesophagus in the 
resected specimen.  All patients with histological evidence of Barrett’s 
oesophagus had undergone resection for either high grade dysplasia in 
Barrett’s or adenocarcinoma.  Forty six of eighty three patients (55%) with 
adenocarcinoma had histological evidence of Barrett’s oesophagus along with 
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the tumour in the resected specimen.  No patient with a non-
Barrett’s/adenocarcinoma indication for surgery was noted to have histological 
evidence of Barrett’s oesophagus. 
 
3.3.6 Timing of endoscopy 
The median time from surgery to endoscopic evaluation was 3.6 years (range 
0.3 – 13.2 years.  Twenty patients went on to have a second endoscopy during 
the study period, one patient had three endoscopic examinations. 
 
3.3.7 Endoscopic findings 
Forty six patients (37%) had clear endoscopic evidence of neo-Barrett’s 
oesophagus above the surgical anastomosis.  An additional four patients had 
possible neo-Barrett’s but either food residue or marked inflammation made the 
appearances difficult to interpret.  One patient had recurrent adenocarcinoma at 
the anastomosis 15 months after surgery. 
 
Several patterns of neo-Barrett’s were recognised: 
1. Circumferential segment 
2. Single tongue or tongues measuring at least 1cm 
3. Small encroachments of columnar epithelium less than 1cm in length 
 
The incidence of each pattern of neo-Barrett’s are shown in table 3.2.  
Examples of these patterns are shown in figure 3.2 
 
 
Pattern of neo-Barrett’s Number of cases 
Circumferential segment 19 
Tongues 17 
Small encroachment 8 
Not recorded 2 
 
Table 3.2: Incidence of each endoscopic pattern of neo-Barrett’s 
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Figure 3.2: Endoscopic patterns of neo-Barrett’s; a – Circumferential segment, b 
– Small encroachment of columnar epithelium, c – Tongues of columnar 
epithelium 
 
 
3.3.8 Histological findings 
Ninety seven patients (77%) had supra-anastomotic biopsies taken.  The 
histological findings are summarised in table 2.2.  Twenty nine patients had no 
supra-anastomotic biopsies taken.  The majority of these patients (27/29) had a 
healthy oesophageal remnant, biopsies were not felt to be clinically indicated 
and would therefore not have been covered by the ethical approval for this 
study.  The remaining two patients had endoscopic evidence of neo-Barrett’s 
but biopsy confirmation was not possible.  In one case this was due to anti-
coagulation and in the other case the procedure was poorly tolerated and 
biopsy was felt to be unsafe and inappropriate.   
c 
a b 
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Table 3.2: Histological findings in supra-anastomotic biopsies 
 
 
3.3.9 Incidence and classification of Neo-Barrett’s 
The British Society of Gastroenterology guidelines (2005) define Barrett’s 
oesophagus as a segment of columnar metaplasia of any length visible 
endoscopically above the oesophago-gastric junction and confirmed or 
corroborated histologically.  For the purposes of this study neo-Barrett’s is 
defined as a segment of columnar metaplasia visible endoscopically above the 
surgical oesophago-gastric anastomosis which is confirmed or corroborated 
histologically.  The overall incidence of Neo-Barrett’s in this study at a median 
follow up of 3.6 years was 35.7% (45/126).   
 
Many patients had more than one type of epithelium present in biopsy samples 
including fragments of squamous epithelium.  Patients with any evidence of 
intestinal metaplasia were classified as type A.  Otherwise patients were 
classified according to the predominant subtype.  All three described subtypes 
of columnar metaplasia were observed in this study.  Table 2.3 details the 
incidence of each subtype.  The incidence of Neo-Barrett’s with specialised 
intestinal metaplasia was 10%, an example of this epithelium is shown in figure 
3.3.   
 
Histological Findings Number of patients 
Columnar metaplasia 46 
Squamous epithelium 49 
Recurrent adenocarcinoma 1 
Ulcer material only 1 
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Figure 3.3 Histological image of neo-Barrett’s with specialised intestinal 
metaplasia (Type A) 
 
 
Type of columnar 
metaplasia 
N 
 
A - specialised intestinal 
metaplasia 
 
12 
B – body or fundic type 
metaplasia 
17 
C – cardiac type metaplasia 16 
 
Table 3.3: The incidence of the subtypes of columnar metaplasia in patients 
with neo-Barrett’s 
 
 
3.3.10 Length of Neo-Barrett’s segment 
At the first study endoscopy 45 patients had confirmed neo-Barrett’s.  Both 
circumferential (n=20) and non-circumferential (n=25) types of Barrett’s were 
observed.  Median maximal length of the Barrett’s segment was 1.5cm (range 
<1cm-8cm).  Where a circumferential segment was present the median length 
of this was 2.75cm (range <1 – 8cm). 
64 
During the study period 15 patients with confirmed neo-Barrett’s at first 
endoscopy underwent a second endoscopy at a median of 12 months following 
the first endoscopy (range 9-19 months).  In 13 cases (87%) neo-Barrett’s was 
also noted at the second endoscopy, in one case (initially <1cm in length) there 
appeared to have been regression of the columnar metaplasia.  In the 
remaining one case, food debris meant that accurate assessment was 
impossible.  Where a neo-Barrett’s segment was measured on more than one 
occasion there was little individual variation in maximum length and the median 
was unchanged at 3cm. 
 
3.3.11 Time following oesophagectomy 
The median post-operative period was significantly longer in patients with 
confirmed neo-Barrett’s compared to those with no evidence of neo-Barrett’s 
(5.72 vs. 2.21 yrs, p=<0.001).  The earliest confirmed case of neo-Barrett’s was 
noted at 9 months following oesophagectomy.  Figure 2.4 shows the prevalence 
of columnar metaplasia in patients with varying lengths of time between surgery 
and endoscopy.  The prevalence is seen to increase with time. 
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Figure 3.4: Prevalence of columnar metaplasia within the oesophageal remnant 
in patients with varying lengths of time between surgery and endoscopy 
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3.3.12 Association between histological subtype and time 
Mucosal biopsies were classified into one of three histological subtypes as 
detailed above.  Median time from surgery to the finding of each subtype was 
8.1 years (Type A, specialised intestinal metaplasia), 5.1 years (Type B, body or 
fundic type), 4.4 years (Type C, cardiac type) (figure 3.5).  The time elapsed 
between surgery and index study endoscopy was significantly greater for 
patients with specialised intestinal metaplasia (SIM, Type A) compared to those 
with columnar metaplasia without SIM (Types B and C), (8.1 years vs 4.8 years, 
p=0.025) (figure 3.6). There was no significant difference in the time elapsed 
from surgery to the finding of either of the two types of non-intestinalised 
metaplasia, p=0.449.   
 
 
Figure 3.5: Box plot of the time elapsed following surgery and the histological 
subtype of neo-Barrett’s 
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Figure 3.6: Box plot of the time elapsed following surgery and the presence of 
neo-Barrett’s with and without specialised intestinal metaplasia. 
 
 
3.3.13 Progression between histological subtypes 
Twenty one patients underwent a second endoscopy during the study period.  
No progression from squamous epithelium to columnar metaplasia was 
observed during the study period in the 7 patients with no neo-Barrett’s.  In 
patients with confirmed neo-Barrett’s at index endoscopy there was no evidence 
of progression from columnar metaplasia without SIM to columnar metaplasia 
with SIM.  Two patients with SIM on initial biopsies had no evidence of SIM in 
repeat biopsies. 
 
3.3.14 Association with clinical and pathological features 
Several potential pre-disposing factors for neo-Barrett’s were assessed.  In all 
cases, patients with confirmed neo-Barrett’s (i.e. endoscopic evidence with 
histological corroboration) were compared with those with no evidence of neo-
Barrett’s.  Cases where there were conflicting endoscopic and histological 
findings or where biopsy to confirm the diagnosis was not possible were 
excluded (n=6).   
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3.3.15 Association with original histological subtype 
The incidence of neo-Barrett’s following resection for adenocarcinoma or high 
grade dysplasia in Barrett’s oesophagus was 41% (37/90).  The incidence of 
neo-Barrett’s following resection for disease not on the Barrett’s metaplasia-
dysplasia-adenocarcinoma spectrum was 27% (8/30) (Figure 3.7).  This 
difference was not statistically significant (Chi square) (p=0.157). 
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Figure 3.7: Prevalence of neo-Barrett’s according to the original indication for 
surgery 
 
 
3.3.16 Association with previous Barrett’s Oesophagus 
The incidence of neo-Barrett’s in patients who had evidence of Barrett’s 
oesophagus described in the original resection histology report was 45% 
(25/55).  The incidence of neo-Barrett’s in patients with no previous evidence of 
Barrett’s oesophagus was 31% (20/65), again this difference was not 
statistically significant (p=0.098)(figure 3.8). 
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Figure 3.8: Prevalence of neo-Barrett’s according to the presence of Barrett’s 
oesophagus in the original resection specimen 
 
 
3.3.17 Patient gender and Neo-Barrett’s 
The incidence of neo-Barrett’s in male patients was 40% (34/84).  The 
incidence of neo-Barrett’s in female patients was 31% (11/36).  This did not 
represent a significant difference (p=0.304). 
 
3.3.18 Symptomatic reflux, proton pump inhibitor use and Neo-Barrett’s 
Seventy nine patients (66%) reported either intermittent or ongoing reflux 
symptoms in the post operative period or had reflux symptoms recorded in their 
notes at the time of previous clinic visits.  There was no significant association 
between the presence of reflux symptoms and the presence of neo-Barrett’s 
(p=0.518).  The majority of patients were either taking PPI at the time of their 
endoscopy or reported having taken a PPI for the majority of time following their 
surgery.  The incidence of neo-Barrett’s was significantly higher in patients with 
no history of long term PPI use 67% (12/18) vs 32% (33/103) (p=0.006). 
 
3.3.19 Height of surgical anastomosis 
The distance from the incisors to the surgical anastomosis was recorded for 106 
patients.  The median distance was identical for those with and without neo-
Barrett’s at 24cm (range 18-34cm) (figure 3.9).  Where more than one 
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endoscopy was conducted the level recorded at the first study endoscopy was 
used in analysis. 
 
 
 
Figure 3.9: Box plot showing the distance at endoscopy from the incisors 
to the surgical anastomosis in centimetres in patients with and without 
neo-Barrett’s
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3.4 Discussion 
Metaplastic columnar epithelium occurring in the oesophageal remnant 
following oesophagectomy and reconstruction with a gastric conduit is a well 
recognised phenomenon.  In the present study the overall incidence of neo-
Barrett’s was 36% (45/126) at a median follow up of 3.6 years.  This finding 
provides corroborative evidence for the high incidence of neo-Barrett’s reported 
in previous smaller studies.   
 
Sporadic Barrett’s oesophagus is generally described as a relatively rare 
condition but the true population prevalence is difficult to determine as the 
diagnosis can only be made endoscopically.  A figure of 1-2 % is most 
commonly given (Ronkainen et al., 2005, Watson et al., 2005) but figures vary 
widely and inconsistent diagnostic definitions have been used.  One study of 
asymptomatic American males attending for colorectal cancer screening found 
the incidence of Barrett’s oesophagus to be 25% (Gerson et al., 2002). 
 
Neo-Barrett’s oesophagus appears to be far more common in post-
oesophagectomy patients than sporadic Barrett’s oesophagus is in the general 
population.  Since Hamilton and Yardley’s first description (1977), several 
studies have all have found the incidence to be much higher than the generally 
accepted rate of Barrett’s oesophagus with incidence rates of 22-93% described 
(Bax et al., 2007, da Rocha et al., 2008, D'journo et al., 2009, Dresner et al., 
2003, Peitz et al., 2004b, Wolfsen et al., 2004, Lord et al., 2004, O'Riordan et 
al., 2004, Oberg et al., 2002).  This group of studies is very heterogeneous.  
The indications for surgery, follow up periods and precise definitions of neo-
Barrett’s used all vary.  These factors are likely to contribute to the wide range 
of incidences reported. 
 
Few surgical centres routinely endoscope patients during follow up making 
comparisons between data series difficult.  Retrospective review of endoscopy 
records is the basis of several studies..(Bax et al., 2007, Franchimont et al., 
2003, Wolfsen et al., 2004, Lord et al., 2004)  In these cases, endoscopy would 
seem more likely to have been undertaken in symptomatic individuals, 
potentially those with severe reflux, giving rise to a source of potential selection 
bias.   
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Prospective assessment of patients in a research setting, specifically looking for 
neo-Barrett’s has been undertaken by several groups.(D'journo et al., 2009, 
Dresner et al., 2003, O'Riordan et al., 2004, Oberg et al., 2002)  These studies 
report some of the highest incidence rates of neo-Barrett’s.  Increased 
awareness and recognition of neo-Barrett’s amongst the endoscopists involved 
in these studies may explain the higer incidence observed.  It is also possible 
that there is a degree of bias in these studies due to patient self selection, with 
those most troubled by reflux being most likely to participate in a research 
endoscopy programme. 
 
One study (da Rocha et al., 2008) has reviewed the endoscopic records of 101 
patients who underwent oesophagectomy for end stage achalasia related to 
Chaga disease.  In this study, endoscopic follow up was routine and the overall 
incidence of neo-Barrett’s remained over 30% as seen in the present study.  
 
The strength of the present study is that it is the largest to prospectively 
evaluate the incidence of neo-Barrett’s in a relatively unselected patient 
population.  Follow up was less complete than in the study of achalasia patients 
by da Rocha as one might expect given the cohort of more elderly patients with 
predominantly malignant diagnoses.  These patients are, however more 
representative of those undergoing surgery in developed countries.  The 
majority of patients underwent evaluation as part of a routine follow up 
programme rather than purely for the investigation of symptoms or having 
volunteered specifically to take part in a research project.  Whilst there were 
exclusions of patients with known metastatic disease and those who were too 
frail for endoscopy to be clinically inappropriate, the inclusion criteria remain 
some of the broadest used in this type of study and are probably as 
encompassing as is practically and ethically possible. 
 
The high incidence of neo-Barrett’s occurring after subtotal oesophagectomy is 
likely to be related to reflux disease.  Following surgery and reconstruction with 
a gastric conduit many patients experience profound duodeno-gastro-
oesophageal reflux.  In separate studies, Dresner and Öberg undertook 
manometric and 24 hour pH and bilirubin monitoring of post oesophagectomy 
patients (Dresner et al., 2003, Oberg et al., 2002).  Dresner demonstrated 
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abnormal oesophageal exposure to both acid and bilirubin in 25 of 30 patients 
(83%).  Öberg similarly demonstrated abnormal acid exposure in 25 of 32 
patients (78%) and abnormal bilirubin exposure in 12 of 32 patients (38%).  In 
both studies there was a significant association between the finding of 
pathological duodeno-gastro-oesophageal reflux and the presence of columnar 
metaplasia within the remnant oesophagus.  This finding is not universal 
however and O’Riordan (2004), using similar methods reported that there was 
no significant association between the presence of pathological reflux and the 
presence of columnar metaplasia.  The reason for this difference is unclear and 
considering the small number of patients involved it may well represent a 
statistical anomaly.  Indeed this study did report a 50% incidence of columnar 
metaplasia in a sample of 48 patients and abnormal acid and bile reflux in 63% 
and 80% of a subgroup in which this was tested. 
 
It has long been recognised that reflux disease is critical to the development of 
Barrett’s oesophagus (Bremner et al., 1978).  In order for acid to damage cells it 
is necessary for the H+ ions to penetrate the cell membrane.  In the case of 
oesophageal epithelial cells, this membrane is somewhat resistant to this 
process and it is only when the luminal acidity is sufficient to damage 
intracellular junction that H+ ions are able to enter the cell in sufficient numbers 
to cause damage (Carney et al., 1981).  Once H+ ions have entered the cell 
they cause inflammation and in severe cases, cell death by necrosis.  When this 
occurs over a large area, this process leads to denuded, ulcerated areas of 
oesophagus. 
 
Following oesophageal damage there is a process of repair and adaptation.  It 
appears that conditions within the oesophageal lumen during this process 
influence the type of epithelium which regenerates.  In the canine model, 
iatrogenic mucosal defects are repaired with squamous epithelium in the 
absence of significant ongoing reflux.  When animals have excessive amounts 
of acid reflux induced this repair is with a metaplastic columnar epithelium 
(Bremner et al., 1978).  It is thought that columnar epithelium is more resistant 
to further damage but the mechanism by which it is induced is poorly 
understood. 
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The inflammation induced by ongoing reflux is thought to have an important role 
in the induction of metaplasia.  It has been hypothesised that this exerts its 
effect via the induction of transcription factors or the activation of developmental 
signalling pathways (Wang and Souza, 2011). 
 
Transcription factors are proteins which bind to specific DNA sequences and 
control the rate of production of the protein products of these sequences.  One 
example of a transcription factor potentially implicated in the development of 
Barrett’s oesophagus is caudal related homeobox 2 (CDX2).  Induction of this 
transcription factor appears to lead to squamous cells becoming more intestine-
like, forming crypt like structures as seen elsewhere in the GI tract and 
expressing genes typical of intestinal cells.  In human oesophageal squamous 
cells exposure to a combination of acid and bile salts increases CDX2 
expression providing a potential step in the conversion to a columnar epithelium 
(Liu et al., 2006b, Hu et al., 2007). 
 
Cell signalling pathways control basic cellular activities and allow cells to 
perceive and respond to their environment including by adapting following 
tissue injury.  It is hypothesised that oesophageal damage and ongoing 
inflammation, may in some way, activate in oesophageal cells the signalling 
pathways normally involved in developing and maintaining the intestine (Wang 
and Souza, 2011).  The activation of these pathways might, in turn, lead to the 
development of the intestinal-like epithelium seen in Barrett’s oesophagus. 
 
It appears that these processes are not solely dependent on the reflux of acid 
and that duodenal contents, in the form of bile acids and bile salts also have a 
role.  Barrett’s type epithelium has been reported following total gastrectomy 
and in a rat model with a duodeno-oesophageal anastomosis, both situations 
where one would expect acid reflux to be eliminated (Lillemoe et al., 1982, 
Meyer et al., 1979b).  In the post-oesophagectomy setting there is gross reflux 
of both acid and duodenal contents, particularly when a pyloroplasty has been 
undertaken to aid gastric drainage.  The high incidence of neo-Barrett’s 
observed in the present study and other similar studies therefore may be related 
to the synergistic effects of the ongoing reflux of both acid and bile. 
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Gastro-oesophageal reflux disease is estimated to affect 10-20% of the 
Western population on a weekly basis (Dent et al., 2005), yet the estimated 
prevalence of Barrett’s oesophagus is only 1-2%.  Why some patients develop 
oesophagitis in response to reflux and others develop Barrett’s or 
adenocarcinoma has never been adequately explained 
 
Three distinct types of columnar epithelium have been noted in the oesophagus 
(Paull et al., 1976) and it is proposed that all of these are metaplastic and 
should be included in the definition of Barrett’s oesophagus (British Society of 
Gastroenterology, 2005).  This viewpoint is not universal and remains a source 
of controversy.  The present study, where all three types of columnar epithelium 
were noted in biopsies from the oesophageal remnant provides important 
evidence to support the inclusion of all three in the definition of Barrett’s 
oesophagus.    
 
Many authors argue that only columnar mucosa with intestinal metaplasia 
represents true Barrett’s oesophagus, associated with an increased risk of 
oesophageal adenocarcinoma (Wang and Sampliner, 2008).  It has been 
claimed that a short segment of cardiac type mucosa is a normal finding at the 
gastro-oesophageal junction and that a normal oesophagus can be lined by 
cardiac mucosa in the distal 2cm (Hayward, 1961).  The finding of cardiac type 
mucosa in the oesophageal remnant in this study and others provides clear 
evidence that this is a metaplastic epithelium as the whole gastric cardia and 
distal oesophagus is resected during surgery.  Further support for this 
hypothesis comes from autopsy studies suggesting that the extent of cardiac 
mucosa increases with age (Ormsby et al., 2000). 
 
A major difficulty in determining the normal histology of the gastro-oesophageal 
junction and distal oesophagus is the problem of accurately identifying the 
location from which endoscopic biopsies have been taken.  One can only claim 
that Barrett’s oesophagus is a spectrum of different types of columnar 
epithelium if it is certain that biopsies of all types have been taken from the 
oesophagus and do not represent inadvertent sampling of the gastric cardia or 
proximal stomach.  Determining the location of the anatomical gastro-
oesophageal junction in patients who have not undergone surgery can be 
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extremely difficult, especially in the presence of a hiatus hernia.  The most 
commonly used definition in the West is the proximal extent of the gastric folds 
but this is dependent on the degree of insufflation of the oesophagus by the 
endoscopist. 
 
In this study the site of the surgical anastomosis, representing the new 
oesophago-gastric junction, was clearly visible as a ring-like structure and in 
many cases, surgical staples were also visible.  This allowed the endoscopist to 
locate biopsies with a degree of confidence not possible in patients who have 
not undergone surgery.  It is far less likely, in this situation, that biopsies were 
inadvertently taken from the stomach and the finding of all three types of 
columnar epithelium strongly suggests that these can all be part of a spectrum 
of metaplastic change in the oesophagus.  In the seminal study where the three 
types of oesophageal columnar epithelium were first described (Paull et al., 
1976), manometric testing was used to ensure that biopsy material was 
obtained from above the lower oesophageal sphincter.  The present study 
usefully employs an easily visible surgical anastomosis to achieve this result. 
 
Several other studies employing endoscopic and histological evaluation in post-
oesophagectomy patients have reported a range of histological subtypes in the 
oesophageal remnant.  Some authors report the histological findings simply as 
columnar epithelium with or without specialised intestinal metaplasia but others 
list them according to either Paull’s criteria or the modification of this system 
suggested by Chandrasoma (2000).  As in the present study, Oberg (2002), 
D’Journo (2009) and Hamilton (1977) have all reported cardiac, fundic and 
specialised intestinal metaplasia columnar metaplasia in post-oesophagectomy 
patients.    In contrast Dresner (2003), Lord (2004) and Peitz (2004b) have 
described only the cardiac or specialised intestinal metaplasia subtypes 
occurring.  All three of these studies recognise the 3 subtypes described by 
Paull and state that they classified their samples according to these criteria 
suggesting that the difference is not due to the definitions used.  The reason 
why these studies failed to find any examples of body or fundic type mucosa in 
contrast to the findings of the above listed and present studies is unclear.  In the 
present study this type of mucosa accounted for 17 of 45 cases of columnar 
epithelium, in the study by Oberg it accounted for 3 of 15 cases and in 
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D’Journo’s study it accounted for 13 of 42 cases, it is therefore not an infrequent 
finding in these studies. 
 
Given the small number of cases of neo-Barrett’s in the studies by Lord and 
Peitz (10 cases in each series) it is possible that the absence of any cases of 
body or fundic type mucosa is due to chance.  The difference between the 
findings of the present study and that by Dresner et al with regards to this type 
of epithelium is particularly difficult to account for, given that these studies were 
conducted in the same unit, using similar methods and definitions with the main 
differences being the larger size and less selected nature of the cohort in the 
present study. 
 
This specialised gastric type of epithelium, (also described as body or fundic 
type) most closely resembles the mucosa of the stomach to which the 
oesophagus has been anastomosed.  The finding of this type could therefore 
represent proximal migration of this epithelium, metaplastic transformation of 
the native oesophageal mucosa or a sampling error with biopsies taken from 
the proximal gastric remnant.  This latter explanation is somewhat difficult to 
accept as a sole explanation given that it has been reported in reasonable 
numbers of cases by multiple investigators, at different sites, each of whom 
describe being able to confidently located their biopsies above the anastomosis.   
 
Results from this study effectively confirm that all three subtypes of columnar 
epithelium can develop in the previously squamous lined oesophagus and that 
all three types represent true metaplasia rather than sampling error or 
physiological columnar epithelium. 
 
The post oesophagectomy model of the development of Barrett’s is unique in 
that it allows the timescale over which metaplasia develops to be evaluated.  
Data from the present study and other similar studies suggests that Barrett’s 
oesophagus can develop much more quickly in response to reflux disease than 
was originally thought.  Sporadic Barrett’s oesophagus is most commonly 
diagnosed in patients in their seventh decade of life suggesting that many years 
of reflux damage was required to induce metaplasia.   
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Cohort studies of patients with GORD have shown a significant association 
between the duration of reflux symptoms and the presence of sporadic Barrett’s 
oesophagus.  Locke and colleagues (1999) studied a series of 1011 patients 
scheduled for endoscopy for a variety of indications.  Patients were asked to 
complete a validated symptom questionnaire, the results of which, along with 
the endoscopic findings were used to compile logistic regression models for 
conditions including Barrett’s oesophagus.  In this study duration of acid 
regurgitation was significantly associated with the presence of Barrett’s.  Those 
with a history of regurgitation for less than a year had 1.4 times the risk of 
Barrett’s compared to those with no history of regurgitation.  This risk rose to 
2.7 times for those with a history between 1 and 5 years and 5.5 times baseline 
risk for those with symptoms dating back more than 5 years.   
 
An association between duration of reflux symptoms and Barrett’s oesophagus 
was also reported by Kulig et al. (2004).  In this large prospective cohort study 
over 6000 patients completed symptom questionnaires and underwent 
endoscopic evaluation.  Patients found to have Barrett’s oesophagus were 
significantly more likely to report duration of reflux symptoms greater than five 
years compared to patients with erosive or non-erosive reflux disease.  Gatenby 
and colleagues (2009) studied a cohort of over 1000 patients with known 
Barrett’s oesophagus and found the median duration from the onset of 
symptoms to the diagnosis of Barrett’s oesophagus without intestinal 
metaplasia to be only 2.6 years and for Barrett’s oesophagus with intestinal 
metaplasia to be 5 years suggesting that metaplasia may develop more quickly 
than previously recognised and that there may be progression between 
subtypes.  The problem with all cohort studies of this type is that they rely on 
the notoriously unreliable ability of a subject to recall their symptom history 
accurately. 
 
Prior to oesophagectomy the cervical oesophagus is unlikely to have been 
exposed to significant amounts of duodeno-gastro-oesophageal reflux.  Dual 
probe oesophageal pH monitoring has shown acid exposure in the proximal 
oesophagus to occur in less than 1% of a 24 hour period (Dobhan and Castell, 
1993), sharply contrasting with the significant acid exposure seen following 
oesophagectomy.  It is therefore proposed that the date of surgery represents a 
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baseline start date for any reflux related damage.  The difficulties associated 
with using symptom history to determine the duration of reflux are therefore 
avoided. 
 
In the present study the median post-operative period was significantly greater 
in patients with confirmed neo-Barrett’s compared to those with no evidence of 
neo-Barrett’s, 5.72 yrs vs 2.21 (p=<0.001).  The earliest case of neo-Barrett’s 
detected in this study occurred only 9 months following surgery.  This data from 
post surgical patients clearly suggests that columnar metaplasia can occur 
within a few years of the onset of reflux and decades of damage are not 
required.  Whether this rapid development is unique to neo-Barrett’s, where 
patients experience particularly severe reflux is unclear but this finding certainly 
suggests that columnar metaplasia can develop more rapidly than was 
previously believed.    
 
Other studies evaluating the time to develop neo-Barrett’s have reported mixed 
results.  O’Riordan et al. (2004) reported 24 cases of columnar metaplasia 
occurring in the oesophageal remnant, with the incidence rising from 36% at 
one year to 60% three years after surgery.  Da Rocha et al. (2008) employed 
regular endoscopic evaluation in a follow up study of 101 patients who 
underwent surgery for end stage achalasia.  The mean follow up period for 
patients in this series, 10.5 years is much longer than that for other series 
involving patients undergoing surgery predominantly for malignant disease.  
Again a steady increase in neo-Barrett’s is reported with incidence rates of 11% 
at 5years, 30% for patients 5-10 years following surgery and 58% for patients 
followed up for more than 10 years following surgery.  Whilst these patients 
underwent surgery for non-neoplastic disease they effectively underwent the 
same type of procedure and reconstruction as patients undergoing surgery for 
cancer.  Post operatively they should therefore be just as susceptible to reflux 
as other patients and this would explain the similar incidence of neo-Barrett’s 
observed in the cohort. 
 
Oberg and colleagues (2002) report 15 cases of histologically confirmed 
columnar metaplasia in the oesophageal remnant at a median follow up of 4.9 
years (range 3 – 10.4 years).  In this study there was no evidence of the 
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prevalence of metaplasia increasing with time.  The earliest endoscopy in this 
series occurred 3 years after surgery suggesting that when neo-Barrett’s 
develops it tends to do so within the first 2-3 years following surgery.  In the 
present study the prevalence of neo-Barrett’s increased from 11% for patients 
0-2 years following surgery to 43% for patients 2-4 years following surgery.  The 
prevalence then remained relatively stable until patients got beyond 8 years 
post surgery.  It is possible that there is a subgroup of patients who are pre-
disposed to develop neo-Barrett’ and do so within the first few years whereas 
other patients without this pre-disposition only develop metaplasia following a 
much more prolonged period of reflux associated injury. 
 
There is some evidence to suggest that Barrett’s with specialised intestinal 
metaplasia may be a more advanced form of the condition.  In the present study 
there was a significant difference in the time that had elapsed between surgery 
and endoscopy in patients who had columnar metaplasia with specialised 
intestinal metaplasia (SIM) compared to those without (8.1 years vs 4.8 years, p 
= 0.025).  This association between the presence of SIM and time from surgery 
has been reported elsewhere in smaller studies (Dresner et al., 2003, O'Riordan 
et al., 2004, Oberg et al., 2002).  In addition progression between subtypes has 
been reported in individual patients.  Dresner (2003) reports seven patients who 
initially had cardiac type metaplasia but at a subsequent endoscopy were found 
to have columnar metaplasia with SIM  and D’Journo (2009) reports four 
patients who progressed from gastric type to cardiac metaplasia and 8 patients 
who progressed from cardiac type to SIM.  No progression between subtypes 
was observed in the present study but only 15 patients with confirmed neo-
Barrett’s underwent a second endoscopy during the study period and the 
median time elapsed before the second endoscopy was only 12 months so this 
lack of progression is perhaps not surprising. 
 
It is well recognised that the absence of SIM in Barrett’s oesophagus may 
represent a sampling error rather than a true absence.  The yield of SIM 
decreases as the segment of Barrett’s shortens and the number of biopsies 
decreases and it has been estimated that a minimum of 8 biopsies is required to 
provide an adequate assessment (Harrison R et al., 2007).  No study describes 
taking anywhere near this number of biopsies in post oesophagectomy patients 
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and sampling error may therefore partly explain the relatively low incidence of 
SIM.  This is also likely to be the explanation for the absence of SIM in follow up 
biopsies in two patients in the present study who had SIM on initial biopsies.  
Sampling error due to small biopsy numbers is however, unlikely to contribute to 
the increasing incidence of SIM over time.  There is no evidence to suggest that 
greater numbers of biopsies are taken over time, the majority of investigators 
having taken small numbers of biopsies according to a protocol in all patients as 
occurred in this study. 
 
The consistent finding that the SIM subtype of metaplasia is found in patients 
who are endoscoped later and the progression in individual patients reported in 
some series provide compelling evidence that the development of Barrett’s 
oesophagus is a stepwise process.  The initial step is conversion to a non-
intestinalised epithelium with subsequent progression to the classical 
specialised intestinal metaplasia (figure 3.10).  The time frame for this 
progression appears to be highly variable with some individuals in the present 
study demonstrating no columnar metaplasia of any type more than 10 years 
after surgery and a small number developing SIM in around a year.  Whether 
the two non-SIM subtypes represent successive steps or simply two variations 
of the initial step is unclear.  The present study suggests that they are found at 
similar times following surgery but progression from gastric type to cardiac type 
has been reported elsewhere (D'journo et al., 2009).  
 
 
 
 
Figure 3.10 – Proposed mechanism for the development of Neo-Barrett’s 
 
 
Squamous 
Epithelium 
Columnar Metaplasia 
No SIM 
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Metaplasia 
Reflux Reflux 
Median 5 yrs 
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Median 8 yrs 
(1 –13yrs) 
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Given the lack of progression between histological subtypes in the present 
study one could argue for a different model where there is development of 
different types of epithelium at different times without progression (figure 3.11).  
This would not however, be in keeping with other studies which have reported 
progression in individuals.  Given that the present study included only a small 
number of patients with neo-Barrett’s who underwent a second endoscopy and 
that median time between first and second endoscopy was only 12 months it 
does not provide good evidence against progression between histological 
subtypes and this model should be regarded as the less favoured one. 
 
 
 
Figure 3.11: Alternative proposed mechanism for the development of Neo-
Barrett’s 
 
 
In the present study the median length of Barrett’s segment was relatively short 
at only 1.5cm.  There was no evidence to suggest that segment length 
increased over time for the 15 patients who underwent more than one 
endoscopy.  Unfortunately the median time between the first and second 
endoscopy was only 12 months and no comment can therefore be made on the 
long term stability of the segment length.  Cameron and Lomboy (1992) 
suggested that when Barrett’s oesophagus develops, the columnar segment 
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forms fairly rapidly and there is subsequently little increase in the segment 
length.  They found that mean Barrett’s segment length was similar for patients 
of all age groups studied and that there was no significant change in segment 
length for a subgroup of 21 patients with Barrett’s oesophagus followed up for a 
mean of 7 years.  Dresner et al. (2003) also found the area of columnar 
epithelium to be stable in post-oesophagectomy patients.  Oberg (2002) 
describes a single patient with an increase in segment length from 1cm to 2cm 
between endoscopies at 13 and 52 months.  Differences in segment 
measurements can vary according to observer and patient movements 
including retching and inspiration and a difference of 1cm is certainly within the 
margin of error for this type of measurement.  Overall evidence from post-
oesophagectomy patients is very limited but the few studies which have 
described segment length appear to support the hypothesis that Barrett’s 
segments rapidly grow to their full length with little subsequent progression. 
 
There are no clear predisposing factors for the development of neo-Barrett’s 
following subtotal oesophagectomy.  It has been proposed that pre-operative 
Barrett’s oesophagus or adenocarcinoma might be important, as might surgical 
technique and demographic factors implicated in sporadic Barrett’s such as 
male gender (D'journo et al., 2009, Dresner et al., 2003, O'Riordan et al., 2004) 
but consistent, high quality evidence is lacking. 
 
In the present study neo-Barrett’s was observed to develop following surgery for 
indications other than adenocarcinoma and high grade dysplasia in Barrett’s.  
This finding confirms that neo-Barrett’s represents de novo metaplasia rather 
than recurrent or residual disease.  The incidence of neo-Barrett’s was higher in 
patients who underwent surgery for disease on the Barrett’s 
dysplasia/adenocarcinoma spectrum compared to others and in those with a 
pre-operative diagnosis of Barrett’s compared to those without but neither 
difference was statistically significant.  In common with this study, smaller 
studies by both Dresner and O’Riordan have reported no significant association 
between pre-operative histology and the development of neo-Barrett’s.  In 
contrast Oberg found that patients with a previous history of sporadic Barrett’s 
were significantly more prone to developing neo-Barrett’s (69% vs 25%, 
p=0.032) (Dresner et al., 2003, O'Riordan et al., 2004, Oberg et al., 2002).  
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D’Journo and colleagues (2009) found an association between a history of 
Barrett’s and the occurrence of neo-Barrett’s but this failed to reach significance 
on multivariate analysis.  These findings serve to highlight the difficulties in 
defining significant risk factors in what are always going to be relatively small 
groups of patients.   
 
Whilst statistical proof and a full understanding of pre-disposing factors remains 
elusive it is still possible to draw some useful conclusions from the present 
study.  The presence of neo-Barrett’s in patients with no previous history of 
Barrett’s implies that these individuals do not have inherent infallible protective 
factors.  This data suggests that any protective genetic or environmental factors 
against the development of metaplasia can be overwhelmed in the context of 
severe acid and bile reflux such as that which occurs following oesophagectomy 
and reconstruction with a gastric conduit.  Patients with no previous history of 
Barrett’s may simply never have experienced the ‘critical’ amount of reflux 
required to trigger metaplastic transformation prior to surgery.  The present 
study did not attempt to assess pre-operative reflux and this could be an 
interesting area for future study. 
 
The incidence of neo-Barrett’s was similar for men and women in this study 
(40% vs 31%, p=0.304).  This is despite the fact that that only 44% of women 
underwent surgery for dysplastic Barrett’s or adenocarcinoma compared to 88% 
of men which as discussed previously has been suggested as a pre-disposing 
factor in some series.  In non-surgical groups the incidence of Barrett’s has 
consistently been found to be higher in men with ratios of 2:1 described in an 
autopsy study in the United States (Cameron and Lomboy, 1992) and 1.7:1 in 
the United Kingdom Barrett’s registry (Caygill et al., 2003).  Again the roughly 
equivalent incidence of neo-Barrett’s in men and women following surgery 
suggests that severe reflux is the critical factor in the development of 
metaplasia and outweighs any potential protective gender influences. 
 
In patients who have not undergone surgery there appears to be a correlation 
between symptomatic gastro-oesophageal reflux disease and the development 
of Barrett’s oesophagus.  In the present study 66% of patients had either 
intermittent or ongoing reflux symptoms but there was no statistically significant 
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association between this symptomatic reflux and the development of neo-
Barrett’s.  Pathological gastro-oesophageal reflux has been shown to be almost 
universal following subtotal oesophagectomy and reconstruction with a gastric 
conduit (Dresner et al., 2003, O'Riordan et al., 2004, Oberg et al., 2002).  
Where a pyloroplasty has been undertaken the refluxate generally contains 
abnormally high levels of bile which has also been implicated as a causative 
factor in the development of columnar metaplasia.  It is therefore likely that even 
patients who did not report symptomatic reflux in this study were likely to 
experience pathological levels of reflux, albeit asymptomatically and this may 
explain the absence of an association between symptomatic reflux and neo-
Barrett’s.  Many patients in the present study were taking proton pump inhibitor 
medication which is likely to have affected their experience of reflux. The 
medication may have diminished or abolished the typical symptoms of GORD 
recognised by patients and led to a negative response when questioned. 
 
A potential weakness of the present study is the failure to use a validated 
questionnaire to assess reflux.  This would not have overcome all of the 
problems outlined above but might have improved the accuracy of symptom 
assessment.  Unfortunately even detailed questionnaires rely on the ability of 
patients to recall a symptom history.  Such questionnaires can be very useful in 
assessing current or recent symptoms but assessing reflux since surgery 
requires recalling symptoms over a number of years in some cases.  Only 
prospective collection of this data in all patients might significantly improve the 
quality of this data. 
 
O’Riordan and colleagues (2004) did employ a more robust validated 
questionnaire and demonstrated an association between reflux symptoms and 
the degree of supine acid reflux in post oesophagectomy patients suggesting 
that symptoms may be a marker of reflux (O'Riordan et al., 2004).  
Unfortunately some patients in this study with low symptom scores had high 
levels of bile reflux and some patients with low symptom scores also had neo-
Barrett’s.  Taken with the findings of the present study it can be concluded that 
reflux symptoms provide neither an accurate assessment of the presence of 
duodeno-gastro-oesophageal reflux nor an assessment of the risk of columnar 
metaplasia.   
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Several groups have suggested that the type of surgical anastomosis is 
important in controlling reflux and reflux related damage in the oesophageal 
remnant (De Leyn et al., 1992, D'journo et al., 2009, Shibuya et al., 2003). 
 
Although a standard surgical approach was used in all patients in this study 
there was variability in the measured distance from the incisors to the surgical 
anastomosis at the time of endoscopy, recorded values being between 18 and 
34cm (median 24cm).  Traditional surgical teaching advises that constructing 
the anastomosis more proximally reduces the severity of reflux.  With the 
exception of the patient with an anastomosis measured at 34 cm this variability 
most likely reflects variations in the height and build of patients and in the extent 
of dissection related to the site of the primary tumour.  In the case of the patient 
with an anastomosis at 34cm one must wonder whether the surgical approach 
was as described or if there were particular intra-operative difficulties.  There is 
no evidence in the present study that it is possible to reduce the risk of neo-
Barrett’s by siting the oesophago-gastric anastomosis as high as possible using 
the trans-thoracic approach. 
 
The best evidence for the importance of surgical technique comes from a recent 
paper by D’Journo et al. (2009) comparing symptoms and endoscopic findings 
in 84 oesophagectomy patients, 36 of whom had an anastomosis in the right 
upper chest and 48 of whom had an anastomosis in the left neck.  Patients with 
a right intra-thoracic anastomosis were more likely to experience reflux 
symptoms (81% vs 52%, p=0.007) and were more likely to have developed 
columnar metaplasia in the oesophageal remnant despite having a shorter 
median follow up period (66% vs 37%), this difference remained significant on 
multivariate analysis, p=0.018.  Other studies have found the incidence of 
oesophagitis to be higher when an intra-thoracic anastomosis is employed 
compared to a cervical anastomosis (Shibuya et al., 2003, De Leyn et al., 
1992). 
 
In contrast to clinical studies which suggest that a cervical anastomosis may 
decrease reflux, the only study which has used ambulatory pH monitoring 
suggested that acid exposure in the oesophageal remnant is higher in patients 
with a cervical anastomosis.(Johansson et al., 1999)  In this study, no patient 
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had undergone a pyloroplasty and no absolute or statistical values are quoted 
to support this finding making it difficult to draw conclusions from the findings.  
The absence of any relation between the presence of neo-Barrett’s and the 
height of the anastomosis in the present study may simply reflect the fact that 
all patients had very similar surgical procedures.  Differences in the height of 
the anastomosis having simply reflected the differences in patient build and the 
inevitable minor inaccuracies in measuring the distance from the incisors rather 
than a true significant difference in the anatomical position of the anastomosis. 
 
The present study failed to identify any statistically significant predisposing 
factors for neo-Barrett’s.  It is likely that the origins of the condition are multi-
factorial and might be revealed only by multivariate analysis of large numbers of 
patients.  Whilst the present study is the largest of its kind, the numbers of 
patients remain too small and the number of potential pre-disposing factors too 
large for a multivariate analysis of these risk factors to be appropriate.  
 
Neo-Barrett’s oesophagus following subtotal oesophagectomy may have 
important implications for affected individuals.  Should it have the same 
potential for malignant progression as sporadic Barrett’s oesophagus this would 
need to be factored in to treatment decisions and follow up protocols.  
 
In the present study there were no cases of neo-Barrett’s oesophagus with 
dysplasia.  There are case reports of dysplasia and adenocarcinoma occurring 
in the context of neo-Barrett’s suggesting that it has some malignant potential 
but the numbers are small and the magnitude of the risk difficult to determine.  
There are 2 reported cases of adenocarcinoma occurring more than four 
decades after the original surgery, one from the Northern Oesophago-gastric 
cancer unit and one from the United States (Dunn et al., 2010, Lord et al., 
2004).  In both of these cases, surgery was undertaken for benign strictures 
occurring in childhood.  Two cases of neo-Barrett’s with high grade dysplasia 
have been reported following surgery for achalasia (da Rocha et al., 2008).  In 
these cases the time from surgery to the development of dysplasia was shorter, 
13 and 19 years respectively.  In both cases there was progression to invasive 
adenocarcinoma within 2 years supporting the potential for progression along a 
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metaplasia-dysplasia-adenocarcinoma sequence as is seen in sporadic 
Barrett’s oesophagus.   
 
Median follow up in the present study at 3.6 years (range 0.3 – 13.2) was much 
shorter than would be required for cases of the above type to be detected.  
There is a single detailed case report describing a case of neo-Barrett’s in a 
patient within the time that might have been observed in the present study 
(Gutschow et al., 2008).  Dysplasia was detected 15 months after subtotal 
oesophagectomy for a Barrett’s adenocarcinoma and by 28 months this had 
progressed to invasive adenocarcinoma.  The original proximal resection 
margin representing the residual oesophagus is reported as being free from 
metaplasia but the reason why this individual should have developed such early 
dysplastic neo-Barrett’s is unexplained.  The absence of any cases of dysplasia 
in a cohort the size of the present study provides some reassurance that such 
cases are rare.  With the majority of patients undergoing surgery in later life the 
numbers whose natural life expectancy is such that they might be at risk of 
malignant progression in neo-Barrett’s is even smaller given that in all but one 
case it appears to take more than a decade to develop.    
 
In summary, the present study has demonstrated that over a third of patients 
will develop neo-Barrett’s in the oesophageal remnant following subtotal 
oesophagectomy and reconstruction with a gastric conduit.  All three subtypes 
of columnar epithelium are confirmed as being metaplastic having developed in 
previously squamous epithelium.  The findings of this study suggest that the first 
step in the development of Barrett’s oesophagus is conversion to a non-
intestinalised columnar epithelium with subsequent conversion to specialised 
intestinal metaplasia in the presence of ongoing reflux.  The timescale over 
which this occurs is variable but appears to be measured in years.  The 
presence of neo-Barrett’s cannot be predicted on the basis of clinical 
symptoms, demographic details or the original indication for surgery. 
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Chapter 4: Cellular protein expression in metaplastic columnar 
epithelium in the remnant oesophagus following subtotal 
oesophagectomy 
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4.1 Introduction 
Barrett’s oesophagus is defined as the replacement of the normal stratified 
squamous epithelium of the oesophagus with a metaplastic columnar 
epithelium.  Only columnar epithelium in which deep oesophageal glands are 
present is viewed as incontrovertible evidence of Barrett’s oesophagus yet very 
few endoscopic biopsies demonstrate these features.  The majority of biopsies 
show columnar epithelium with no deep oesophageal glands.  In these cases, 
knowledge of the exact location from which the biopsies were taken is essential 
in confirming the diagnosis.  Biopsies from the oesophagus, which demonstrate 
columnar epithelium, corroborate a diagnosis of Barrett’s.  It is however, 
important to recognise that the precise location of the gastro-oesophageal 
junction may be difficult to locate, particularly when a hiatus hernia is present.  
An endoscopist attempting to take a biopsy from just above the junction may 
easily and inadvertently sample the gastric cardia.  In this case the biopsies 
would have a columnar epithelium but a diagnosis of Barrett’s oesophagus 
would be inaccurate.  Even where specialised intestinal metaplasia is present, it 
is unclear if this carries the same malignant potential when it originates in the 
gastric cardia as when it originates in the distal oesophagus in Barrett’s. 
 
.A diagnosis of Barrett’s oesophagus can have significant implications for an 
individual.  There can be elevated levels of anxiety and insurance premiums 
may be increased.  Patients may be enrolled on a Barrett’s oesophagus 
surveillance programme which commits them to repeated endoscopic 
evaluation.  On a population basis, overdiagnosis of Barrett’s oesophagus 
would have significant cost implications associated with unnecessary 
endoscopic surveillance.  For these reasons there has been considerable 
interest in developing a more robust diagnostic test to confirm and endoscopic 
diagnosis of Barrett’s. 
 
Immunohistochemical techniques employ antibodies to visualise substances in 
tissue sections.  Antibodies bind to a specific substance of interest if this is 
present within the cell or its membrane.  The bound antibody can subsequently 
be visualised using one of a variety of techniques.  As different biomarkers are 
expressed by different tissues types, this technique can be used to identify 
tissues especially when conventional histology is inconclusive.  
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Immunohistochemistry is widely used to type poorly differentiated tumours 
according to their tissue of origin (Dennis et al., 2005). 
 
Immunohistochemistry has been considered as a diagnostic tool for use in 
Barrett’s oesophagus and numerous studies have tried to identify sensitive and 
specific markers.  An ideal marker could be used to confirm the diagnosis and 
to differentiate metaplastic columnar epithelium of oesophageal origin from non-
metaplastic proximal gastric epithelium (Ormsby et al., 1999).  Several potential 
markers have been studied, the most widely reported of these being 
cytokeratins.  The clinical role of this technique in the diagnosis of Barrett’s 
oesophagus remains a source of controversy but there is increasing evidence 
on the presence and pattern of various markers within Barrett’s tissue. 
 
The post-oesophagectomy neo-Barrett’s theory suggests that the columnar 
metaplasia seen following surgery is a good model for the development of 
Barrett’s oesophagus.  The aim of this study was to determine if the same 
cellular proteins seen in sporadic Barrett’s oesophagus are present in post 
oesophagectomy neo-Barrett’s thereby supporting its role as an accurate 
model.    
 
4.1.1 Cytokeratin Immunostaining 
Cytokeratins (CKs) are a family of structural proteins that, along with 
microfilaments and microtubules, are constituents of the cytoskeleton of 
epithelial cells.  The cytoskeleton is responsible for maintaining the mechanical 
integrity of the cell.  It is also important in cell division, motility and cell to cell 
contact.  Cytokeratins are encoded for by a large family of genes but they each 
exhibit a similar structure with a central helix-rich rod and non-helical N and C 
terminal domains (Barak et al., 2004).   
 
More than 20 different types of CK are known and their expression is highly 
variable depending on the type and location of the epithelium.  Even within the 
gastrointestinal tract the cytokeratin expression pattern varies along its length.  
The mouth and oesophagus express CK6, a cytokeratin typically associated 
with stratified squamous epithelia (Chu and Weiss, 2002).  CK20 is generally 
considered a marker of intestinal differentiation and is expressed by the surface 
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foveolar epithelium of the stomach and by the surface and crypt epithelium of 
the small intestine and colon.  CK7 is associated with ductal differentiation and 
is expressed by the epithelia of bile and pancreatic ducts.  In addition CK7 
expression has been reported in the gastric cardia although it is consistently 
absent from the gastic body and antrum (Jovanovic et al., 2002).  
 
 In malignancy, the cytokeratin patterns associated with the original tissue type 
are usually maintained, a property which has allowed cytokeratins to be used as 
tumour markers (Chu and Weiss, 2002).   As the expression of individual 
cytokeratins is not organ specific a panel of markers are usually assessed and 
evaluated along with the morphology of a haematoxylin and eosin stained 
section of a specimen. 
 
In 1999 Ormsby and colleagues (1999) described a distinctive pattern of 
cytokeratin 7 and 20 staining in Barrett’s oesophagus.  This classical Barrett’s 
pattern is outlined in figure 4.1. 
 
 
 
 
Figure 4.1: Classical Barrett’s cytokeratin (Ormsby et al., 1999) 
 
 
This pattern was found to be present in 29/30 (94%) of resection specimens of 
long segment Barrett’s oesophagus and 34/34 biopsies from long segment 
Barrett’s oesophagus   The authors defined long segment Barrett’s oesophagus 
as being greater than 3cm in length.  Histologically the definition required the 
presence of columnar epithelium with specialised intestinal metaplasia. 
 
In this study Barrett’s specimens from the oesophagus were compared to 
gastric specimens also demonstrating intestinal metaplasia.  Endoscopic 
biopsies were obtained from the gastric cardia within 5mm of an apparently 
 
 
CK7 Diffuse moderate to strong staining of both superficial and deep 
glands 
 
CK20 Band-like staining of surface epithelium and superficial glands 
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normal squamo-columnar junction and gastrectomy specimens were used to 
obtain samples of gastric intestinal metaplasia originating at least 3cm distal to 
the gastro-oesophageal junction.  The CK7/20 pattern described above was 
highly specific for Barrett’s oesophagus as this pattern was not seen in any of 
the gastric samples.  The exceptionally high specificity seen in this study has 
not been replicated elsewhere but other authors have confirmed the presence 
of this staining in the majority of cases of Barrett’s oesophagus (deMeester et 
al., 2002, Glickman et al., 2001) and it was therefore felt to be a useful marker 
pattern to explore in neo-Barrett’s.  
 
4.1.2 Chromogranin A Immunostaining 
Neuroendocrine cells are responsible for the uptake and release of 
neurotransmitters and neuropeptide hormones and are an integral part of the 
intestinal epithelium (Voutilainen et al., 2002).  Neuroendocrine differentiation is 
well described in gastric adenocarcinomas where it may be associated with a 
slightly better prognosis and in colonic adenocarcinomas where the association 
with prognosis is uncertain (Rogers and Murphy, 1979) (Smith and Haggitt, 
1984, Grabowski and Schindler, 2001).  The presence of neuroendocrine 
differentiation within areas of Barrett’s oesophagus has been reported by a 
number of authors (Koppert et al., 2004, Hamilton et al., 2000, Griffin and 
Sweeney, 1987, Jaskiewicz et al., 1994).  The presence of these cells is notable 
because it suggests that Barrett’s arises from a multipotential stem cell capable 
of differentiating into more than one cell type (Koppert et al., 2004).   
 
Chromogranin A is regarded as a general marker of neuroendocrine 
differentiation.  It is stored in the secretory granules of neuroendocrine cells and 
participates in vesicle aggregation , granulogenesis and hormone secretion 
(Koppert et al., 2004).  Other markers of neuorendocrine differentiation include 
synaptophysin and neuron-specific enolase (NSE) but these are less widely 
studied in the oesophagus.  There are no reports of the use of synaptophysin or 
NSE to detect neuroendocrine cells in Barrett’s oesophagus and only one study 
describes the use of synaptophysin to detect neuroendocrine cells in 
oesophageal adenocarcinoma (Wang et al., 2006).  Chromogranin A was 
therefore selected as the marker of neuroendocrine differentiation in this study. . 
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The present study sought to establish whether there was evidence of 
neuroendocrine differentiation within neo-Barrett’s oesophagus similar to that 
reported in Barrett’s oesophagus. 
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4.2 Methods 
Inclusion criteria for the study were as follows: 
 
1.  Confirmed neo-Barrett’s (endoscopic evidence of columnar epithelium above 
the surgical anastomosis with histological corroboration. 
 
2.  No evidence of Barrett’s oesophagus at the proximal resection margin at the 
time of surgery i.e. residual Barrett’s oesophagus. 
 
3.  Informed consent given by the patient either via a specific consent form for 
this study or via a generic consent form used in the endoscopy department for 
tissue to be used for research purposes. 
 
4.2.1 Biopsy technique 
As detailed in the previous chapter biopsies were taken from above the level of 
the surgical anastomosis.  Histological analysis was undertaken as previously 
described and the columnar epithelium classified as one of three subtypes. 
 
4.2.2 Immunohistochemistry Technique 
Unstained 5µm tissue sections of formalin fixed paraffin-embedded tissue were 
cut according to the protocol described in appendix D.  Staining was undertaken 
using the Ventana Benchmark XT automated staining system (Roche 
diagnostics, Sussex, UK), protocols used are outlined in appendices E and F.  A 
primary antibody raised in rabbits was used for cytokeratin 20 (Ventana, 
Tucson, Arizona, USA), primary antibodies raised in mice were used for 
cytokeratin 7 and chromogranin A (Dako UK Ltd, Ely, Cambridgeshire).  In all 
cases the ultraView Universal DAB detection kit (Ventana, Tucson, Arizona, 
USA) was used to visualise positive binding. 
 
4.2.3 Analysis 
Slides were evaluated by the author and any equivocal slides were reviewed by 
an expert gastrointestinal pathologist.  Many patients had examples of more 
than one type of columnar epithelium within the biopsy samples.  Where 
intestinal metaplasia was present, this was always assessed.  In other cases 
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the most representative areas of the predominant histological subtype were 
scored. 
 
Cytokeratins 
 
CK 7 and 20 staining was evaluated for both the superficial and deep 
compartments (table 4.1). 
 
Classification Description 
Diffuse Staining of all representative columnar epithelium 
Patchy Staining of some, but not all representative columnar 
epithelium 
 
Absent No staining of representative columnar epithelium 
 
Table 4.1: Scoring system for cytokeratin staining 
 
 
Patients with band-like CK20 staining of the surface epithelium and superficial 
glands and diffuse moderate to strong staining of both superficial and deep 
glands as described by Ormsby were classified as demonstrating a classical 
Barrett’s phenotype. 
 
Chromogranin A 
 
Staining for Chromogranin A utilised a semi-quantitive scoring system (table 
4.2) 
 
Score Description 
0 No staining 
1+ Very rare staining, scattered single cells 
2+ More frequent individual cells 
 
3+ Small clusters of cells 
 
4+ Nodule formation 
 
Table 4.2: Semi-quantitive scoring system for Chromogranin A 
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4.2.4 Statistics 
Fisher’s exact test was used for comparisons of proportions.  The Mann-
Whitney U test was used to compare continuous data between groups with the 
Kruskal-Wallis test used for comparisons between multiple groups.   
Correlation was analysed using the Spearman correlation coefficient. 
 
 
4.3 Results 
 
4.3.1 Study population 
The study population comprised a total of 37 patients, 31 males and 6 females.  
Median time following surgery was 6.6 years (range 1.0 – 13.2 years).   
 
Thirty five patients were endoscoped prospectively by, or in the presence of the 
author.  The remaining two patients were identified retrospectively and had 
clear documentation and picture evidence of columnar epithelium above the 
anastomosis from which biopsies had been taken. 
 
All three subtypes of columnar epithelium were represented in the study as 
summarised in table 4.3. 
 
 
Barrett’s Subtype Number of patients 
A (specialised intestinal metaplasia) 12 
B (body or fundic type) 16 
C (cardiac type) 9 
 
Table 4.3: Histological subtypes of patients included in the study 
 
 
4.3.2 Cytokeratin 7 and 20 immunostaining  
Fragments of normal squamous epithelium were frequently seen alongside 
columnar epithelium in the biopsy samples from individual patients.  In all 
cases, areas of squamous epithelium were negative for both CK7 and CK20. 
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Cytokeratin 7 
Of the two cytokeratins studied, CK 7 was the more widely expressed 
throughout the epithelium (figure 4.2).  In the superficial compartment, diffuse 
staining was seen in 27 cases (73%) and patchy staining was seen in 9 cases 
(24%).  One case of the type B subtype had no CK7 immunostaining in the 
superficial compartment.  All cases demonstrated CK7 immunostaining in the 
deep compartment, in 27 cases (73%) this was diffuse and in 10 cases (27%) 
this was patchy.  The case with no superficial staining demonstrated diffuse 
deep staining. 
 
 
 
Diffuse
Patchy
Absent
 
Figure 4.2a: Extent of CK7 staining of the superficial compartment 
 
Diffuse
Patchy
Absent
 
Figure 4.2b: Extent of CK7 staining of the deep compartment 
 
 
Cytokeratin 20 
Strong band-like superficial CK20 staining was seen in 36/37 cases (97%).  In 
the remaining case there was patchy staining.  In all cases CK20 staining was 
absent from the deep compartment (figure 4.3). 
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Figure 4.3a: Extent of CK20 staining of the superficial compartment 
 
Diffuse
Patchy
Absent
 
Figure 4.3b: Extent of CK20 staining of the deep compartment 
 
 
Classical Barrett’s Pattern Staining 
The classical Barrett’s CK7/20 staining pattern was seen in 23/37 cases (62%).  
The band-like staining of the surface epithelium and superficial glands for CK20 
and the diffuse superficial and deep staining for CK7 are shown in figure 4.4. 
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Figure 4.4a: CK7 - Diffuse staining of both superficial and deep glands 
 
 
 
 
Figure 4.4b: CK20 – Band like superficial staining for CK20 
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The proportion of each histological subtype of columnar metaplasia which 
stained with a classical Barrett’s pattern is shown in figure 4.5.  The proportion 
of patients with this classical Barrett’s type CK7/20 staining pattern was greater 
in the group with intestinal metaplasia (Type A) compared to those without 
intestinal metaplasia (Types B and C) but this difference failed to reach 
statistical significance (p=0.084). 
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Figure 4.5: Typical Barrett’s staining according to histological subtype 
 
 
The median time that had elapsed between surgery and endoscopic biopsy was 
7.8 years for patients with a classical Barrett’s CK7/20 staining pattern and 5.1 
years for those that did not demonstrate this pattern.  This difference was not 
statistically significant (p=0.578) (figure 4.6). 
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Figure 4.6:  Box plot showing the association between time elapsed since 
surgery and the presence of a classical Barrett’s CK7/20 staining pattern.  
There was no significant difference (p=0.340) 
 
 
4.3.3 Chromogranin A immunostaining 
All 37 neo-Barrett’s samples demonstrated expression of chromogranin A to 
some extent.  Table 4.4 shows the frequencies of the different staining 
intensities and examples of these staining intensities are shown in figure 4.7.  
The most frequent pattern of chromogranin A expression seen was that of rare, 
scattered single cells (1+). 
 
Chromogranin A Score Number of samples (%) 
 0  0 
1+ 22 (59%) 
2+ 7 (19%) 
3+ 8 (22%) 
4+ 0 
 
Table 4.4: Staining intensities for Chromogranin A in neo-Barrett’s samples 
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Figure 4.7a: An example of 1+ Chromogranin A staining with infrequent staining 
of single scattered cells 
 
 
 
 
Figure 4.7b: An example of 2+ Chromogranin A staining with more frequent 
staining of individual cells 
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Figure 4.7c: An example of 3+ Chromogranin A staining with small clusters of 
positive cells 
 
 
The Chromogranin A staining intensities for the three histological subtypes of 
columnar metaplasia are given in table 4.5.  There was no significant difference 
in the staining intensity for the different subtypes (p=0.180) 
 
 
 
Histological 
subtype 
1+ 2+ 3+ Mean score 
A (specialised 
intestinal 
metaplasia) 
5 5 2 1.75 
B (body or 
fundic type) 
9 2 5 1.75 
C (cardiac type) 8 0 1 1.22 
 
 
Table 4.5: Chromogranin A staining intensity according to subtype of columnar 
epithelium 
 
 
There was no correlation between the time since surgery and the Chromogranin 
A staining intensity (p=0.697) (figure 4.8). 
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Figure 4.8: Scatter plot of time since surgery and Chromogranin A score 
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4.4 Discussion 
The columnar metaplasia occurring in the oesophageal remnant following 
subtotal oesophagectomy has been proposed as a suitable human model in 
which to study the development of Barrett’s oesophagus.  For this model to hold 
true it is important to be certain that this mucosa is molecularly similar to 
Barrett’s oesophagus in addition to being endoscopically and histologically 
similar.   
 
The diagnosis of sporadic Barrett’s oesophagus represents a significant clinical 
challenge, particularly in cases where only a short segment may be present.  
Few biopsies show the combination of deep oesophageal glands and columnar 
epithelium required to confirm the diagnosis of Barrett’s oesophagus.  In 
addition, specialised intestinal metaplasia, which is sometimes considered a 
hallmark of Barrett’s, can occur in the gastric cardia and the clinical significance 
of this intestinal metaplasia of the cardia is uncertain.  For these reasons much 
work has focused on finding molecular markers which are specific for Barrett’s 
oesophagus.  The most widely studied potential markers are cytokeratins 7 and 
20. 
 
A cytokeratin pattern that might be specific for Barrett’s oesophagus was first 
described by Ormsby and colleagues (1999).  They performed cytokeratin 7 and 
20 staining on biopsy samples and surgical resection specimens and compared 
the cytokeratin staining pattern in patients with Barrett’s oesophagus to those 
with intestinal metaplasia of the gastric cardia.  The classical CK7/20 staining 
pattern of superficial CK20 staining and strong CK 7 staining for both superficial 
and deep glands was found to be present in 29 of 31 (94%) of oesophageal 
resection specimens and all of 34 oesophageal biopsy specimens from patients 
with long-segment Barrett’s oesophagus.  In contrast this pattern was not seen 
in any of the gastric cardia biopsies or gastric resection specimens.  On the 
basis of these results the authors suggested that cytokeratin staining could be 
used to reliably distinguish Barrett’s oesophagus from intestinal metaplasia of 
the stomach. 
 
The present study, looking at supra-anastomotic biopsies from the oesophageal 
remnant in patients who had undergone sub-total oesophagectomy found the 
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classical CK7/20 staining pattern in 62% of cases and in 83% of a subgroup of 
patients with columnar metaplasia with specialised intestinal metaplasia.  This 
prevalence is clearly less than that reported by Ormsby and the potential 
reasons for this warrant further exploration.  
 
Following the Ormsby paper, several groups undertook studies evaluating 
cytokeratin staining of both normal and metaplastic tissues from the region of 
the oesophago-gastric junction with mixed results.  There is therefore some 
suggestion that the original paper may overestimate the prevalence of this 
CK7/20 staining pattern in sporadic Barrett’s oesophagus.   
 
Several groups have reported similar findings to Ormsby with the classical 
CK7/20 staining pattern observed in over 90% of cases of Barrett’s oesophagus 
(deMeester et al., 2002, Glickman et al., 2001, Jovanovic et al., 2002, Shearer 
et al., 2005).  These studies include cases of both long and short-segment 
Barrett’s oesophagus but all have included the presence of specialised 
intestinal metaplasia in the definition of Barrett’s oesophagus.  In contrast, El-
Zimaity and Graham (2001), in a study of biopsy samples from long-segment 
Barrett’s oesophagus found the classical pattern in only 45% of 29 patients.  A 
further study by Mohammed and colleagues (2002) also found only moderate 
sensitivity for Barrett’s oesophagus using the classical CK7/20 staining pattern.  
In this retrospective study involving 49 cases of both long and short-segment 
Barrett’s oesophagus the classical pattern was seen in 65% of cases, when 
subdivided into patients with long and short segment Barrett’s, the figures were 
54% and 81% respectively.  The findings in the present study of a 62% 
prevalence of the classical CK7/20 staining pattern overall and an 83% 
prevalence in patients with SIM are therefore similar to the literature reported 
prevalences. 
 
Technical differences and inter-observer variability are a possible explanation 
for the discrepancies seen in the various studies.  Slightly different 
immunohistochemical staining protocols have been used by investigators along 
with antibodies provided by different suppliers which may affect the appearance 
of the stained slides and the subsequent interpretation of the staining pattern.  It 
is known that the fixative used can affect staining.  Glickman et al. (2005) 
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showed poor inter-institutional agreement (71%) in the presence of the classical 
Barrett’s CK7/20 pattern in patients with Barrett’s oesophagus with specialised 
intestinal metaplasia.  They identified that the major source of disagreement 
was in the interpretation of weak or variable CK7 staining of deep intestinalised 
mucosa of biopsies fixed in Hollande’s solution but not those fixed in formalin.  
After new criteria were established, taking into account the effect of the different 
fixatives, inter-institutional agreement improved.  The present study used 
formalin fixative throughout, as did the studies by El-Zimaity and Mohammed, 
but there may be other, unidentified technical differences affecting these studies 
which could explain the lower prevalence of the typical CK7/20 pattern.  
Specimens in the current study were assessed against a criteria described in a 
published paper,  The paper included pictorial examples of the classical staining 
pattern but interpretation may have varied between the authors of the original 
paper and the present study, particularly in equivocal cases.   
 
In the present study, all patients with neo-Barrett’s in the oesophageal remnant 
were included provided they had given consent for biopsies to be used for this 
purpose.  The advantage of this approach was that it maximised the amount of 
neo-Barrett’s tissue to be studied but it may also contribute to the somewhat 
lower prevalence of the classical staining pattern observed when compared to 
other studies.  Biopsies from the oesophageal remnant can be technically 
difficult to obtain.  The areas of neo-Barrett’s were, by definition, never long-
segments and on occasion it was difficult to obtain reasonable sized samples 
whilst ensuring the accurate placement of the biopsy forceps.  The principle 
concern being to ensure that there is no inadvertent sampling from the gastric 
side of the anastomosis which could lead to overdiagnosis of columnar 
metaplasia.  Personal observations suggest that endoscopic biopsy in the 
cervical oesophagus can occasionally be poorly tolerated by patients due to the 
increased amount of retching when the endoscope is in this region.  Despite the 
fact that pyloroplasty was routine for patients in this series, there was some 
evidence of delayed gastric emptying with food residue seen in the gastric 
conduit in many cases.  On occasion food residue was present within the 
oesophageal remnant causing further problems with obtaining biopsy samples.  
These problems together meant that a number of samples in the present study 
were either small or demonstrated crush artefact making assessment of 
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immunohistochemical staining more challenging than for larger, better 
orientated specimens.  It seems likely that in other retrospective studies, 
particularly those involving oesophagectomy specimens and long-segment 
Barrett’s, the specimens to be assessed would have been of better quality.  
Indeed the seminal study by Ormsby reports that tissue blocks for the study 
were selected as they were felt to be the most representative. 
 
In many cases in the present study the biopsy samples from individual patients 
contained more than one type of epithelium.  In some cases there were 
differences between the various biopsy fragments and in other cases there was 
more than one type of epithelium within a single biopsy.   Typical patterns seen, 
included biopsies with both squamous and columnar mucosa and biopsies with 
a small focus of intestinal metaplasia, within predominantly non-intestinalised 
columnar epithelium.  This situation implies that neo-Barrett’s in the 
oesophagus may be composed of a relatively heterogeneous epithelium, 
perhaps with different areas at different stages of development.  Alternatively it 
may be that these differences simply reflect the problems with obtaining 
accurate biopsies given the technical difficulties outlined above.  In either case 
the presence of heterogeneous samples undoubtedly led to problems assessing 
staining patterns.  The scoring system employed suggested that the most 
representative areas of epithelium should be used to assess the staining pattern 
for the patients.  Assessment of which area was most representative, however, 
introduces a further element of subjectivity to the scoring process.  Patients with 
specialised intestinal metaplasia were assessed as a single group regardless of 
whether this was the predominant subtype of epithelium.  It is possible that for 
patients with only a small focus of specialised intestinal metaplasia, this may 
have ‘cut out’ between the level of the slides cut for H&E assessment and those 
cut for immunohistochemistry assessment.  In the two cases of type A Barrett’s 
which did not stain with the classical Barrett’s type cytokeratin pattern, the area 
of intestinal metaplasia identified on the H&E stained slide took the form of a 
small single focus. This suggests that intestinal metaplasia may not have been 
evident on subsequent slides which in turn could explain the lower prevalence 
of classical Barrett’s pattern staining in this study compared to others. 
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The present study used the current British definition of Barrett’s oesophagus, a 
segment of columnar metaplasia of any length visible endoscopically and 
confirmed or corroborated histologically.  All of the major studies looking at 
cytokeratin expression in Barrett’s oesophagus have used an American 
definition requiring the presence of specialised intestinal metaplasia (deMeester 
et al., 2002, El-Zimaity and Graham, 2001, Glickman et al., 2001, Jovanovic et 
al., 2002, Mohammed et al., 2002, Ormsby et al., 1999, Shearer et al., 2005).  
This difference could be an important explanation for the lower presence of a 
typical Barrett’s staining pattern seen in the present study.   
 
Despite the limitations of the samples in the present study outlined above, the 
prevalence of a typical Barrett’s CK staining pattern was 83% in patients with 
Barrett’s with intestinal metaplasia, higher than the prevalence for those without 
intestinal metaplasia.  Squamous oesophageal epithelium does not normally 
express CK7 or CK20 which suggests that oesophageal cells must start to 
express these proteins at some point along the pathway of transformation to 
columnar metaplasia and Barrett’s oesophagus.  All 14 of the samples in the 
present study which did not stain with a typical Barrett’s pattern exhibited some 
degree of CK7 and CK20 positivity.  All but one demonstrated Barrett’s like 
strong staining of the superficial epithelium for CK20 and the remaining sample 
demonstrated patchy staining.  All samples demonstrated some degree of CK7 
expression but this tended to be more patchy than is seen in the classical 
Barrett’s pattern.  Evidence from the present study outlined in the previous 
chapter suggests that Barrett’s oesophagus with specialised intestinal 
metaplasia is a more advanced stage of the metaplasia-dysplasia-
adenocarcinoma sequence than that without.  It is therefore proposed that the 
samples in the present study represent relatively early stage Barrett’s 
oesophagus which in some cases has not yet achieved the mature CK7/CK20 
expression pattern but which is in the process of developing this. 
 
Despite the above considerations, it is important to consider two other potential 
explanations for why the present study may have shown a lower prevalence of 
a classical Barrett’s oesophagus cytokeratin staining pattern.  These are namely 
that there could have been sampling errors, with biopsies taken from incorrect 
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anatomical conditions or that post-oesophagectomy neo-Barrett’s is, in fact a 
different entity from sporadic Barrett’s oesophagus. 
 
As previously described, the site of the surgical anastomosis is clearly visible at 
endoscopy in the majority of cases making determination of the site of the 
gastro-oesophageal junction much easier than for other patients.  Biopsies were 
taken by experienced endoscopists with a specialist interest in neo-Barrett’s 
thereby minimising the risks of sampling errors.  If errors in the site of biopsies 
were made however, one would expect tissue samples to resemble either 
normal oesophagus, above an area of neo-Barrett’s or gastric body tissue from 
which the gastric conduit is fashioned. 
 
Proximal sampling error, where biopsies are taken from above the segment of 
neo-Barrett’s can be easily discounted by the presence of columnar epithelium.  
In addition the cytokeratin staining pattern described in squamous oesophagus 
is markedly different from that seen in the neo-Barrett’s samples of the present 
study.  Both Shearer and Ormsby report uniform absence of CK20 (Ormsby et 
al., 1999, Shearer et al., 2005).  Shearer also reports uniform absence of CK7, 
although Ormsby reports a more varied picture with some cases showing a 
complete absence of CK7 and others exhibiting strong reactivity, particularly in 
areas adjacent to Barrett’s epithelium. 
 
Distal sampling error is more difficult to discount, but here too there are 
differences in the cytokeratin expression in the neo-Barrett’s samples and those 
reported in gastric tissue.  The comparison to be made is with the gastric body 
rather than the cardia which is removed in its entirety at subtotal 
oesophagectomy.  In Ormsby’s original study cytokeratin expression was 
studied in normal control tissues including gastric body samples.  This showed 
surface and foveolar staining for CK20 but no staining for CK7.  The study by 
Shearer et al included 20 gastric biopsy samples as controls and again surface 
and foveolar staining with CK20 and negative staining for CK7.  In the present 
study all but one sample demonstrated CK7 staining in the superficial 
compartment and all samples demonstrated CK7 staining in the deep 
compartment.  These results therefore strongly support the claim that the 
columnar epithelium of our neo-Barrett’s samples, regardless of subtype, is 
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different from that of the adjacent normal tissues and does not simply represent 
a sampling error. 
 
One further molecular marker was evaluated in the present study to assess the 
similarity of post-oesophagectomy neo-Barrett’s to sporadic Barrett’s 
oesophagus.  Chromogranin A, a marker of neuroendocrine differentiation was 
present in all neo-Barrett’s samples tested.  The presence of neuroendocrine 
cells in sporadic Barrett’s oesophagus has been described by several authors.  
Griffin and Sweeney (1987) detected neuroendocrine cells in 90% of biopsies 
and resections of Barrett’s mucosa.  Two later studies have assessed 
neuroendocrine differentiation in Barrett’s using Chromogranin A 
immunohistochemistry (Hamilton et al., 2000, Koppert et al., 2004).   
 
Hamilton demonstrated Chromogranin A expression in 21 of 34 cases (62%) of 
Barrett’s oesophagus, again in a combination of biopsy and resection 
specimens whilst Koppert demonstrated Chromogranin A expression in 38 of 56 
oesophagectomy specimens (68%) containing Barrett’s mucosa.  As in the 
present study both Hamilton and Koppert describe Chromogranin A positive 
cells as being infrequent and scattered with very occasional small clusters of 
cells.  
 
There is clearly some discrepancy between the finding in the current study of 
universal Chromogranin A expression and the findings of Hamilton and Koppert 
which suggests that this is present in around two thirds of cases of sporadic 
Barrett’s oesophagus.  Unlike the present study, all samples in the previous 
studies were obtained from patients with adenocarcinoma of the oesophagus or 
oesophago-gastric junction.  Adjacent areas of Barrett’s could therefore be 
thought of as being at an advanced stage within an unstable oesophageal 
epithelium.  In the neo-Barrett’s patients of the current study there were no 
cases of dysplasia of any type and the mucosa of the oesophageal remnant 
was proven to have been squamous at a median of only 6.6 years previously. 
 
There is some evidence from the studies of Hamilton and Koppert to suggest 
that Chromogranin A expression in Barrett’s may be lost as the condition 
progresses.  Hamilton describes 3 cases where Chromogranin A expression 
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was lost in areas of high grade dysplasia in patients with Chromogranin A 
positive areas of low grade dysplasia or non-dysplastic Barrett’s.  In Koppert’s 
study it was observed that neuroendocrine cells were found more often in 
Barrett’s with no dysplasia or low grade dysplasia compared to that with high 
grade dysplasia although this difference was not statistically significant.  It may 
therefore be the case that the increased rate of Chromogranin A expression 
seen in the present study represents the fact that this is relatively early stage 
columnar metaplasia with no evidence of progression to dysplasia. 
 
An alternative explanation may relate to the high levels of proton pump inhibitor 
(PPI) use in the present study as there is a reported association between PPIs 
and neuroendocrine proliferation.  These drugs act by blocking the action of the 
proton pump of gastric parietal cell membranes.  This pump directly secretes 
hydrogen ions into the gastric lumen in exchange for potassium ions and 
inhibition of this process therefore results in profound acid suppression.  
Gastrin, secreted by the gastric antral G cells is involved in the secretion of 
gastric acid and is part of the feedback mechanism for controlling acid 
production.  Gastrin secretion is inhibited in the presence of high levels of 
gastric acid and profound acid suppression, such as that induced by PPIs 
suppresses this negative feedback process resulting in hypergastrinaemia 
(Laine et al., 2000).  In addition to its secretory effects, gastrin has a trophic 
effect on the oxyntic mucosa in general and on neuroendocrine cells called 
enterochromaffin-like (ECL) cells in particular (Bakke et al., 2000).  In rats, both 
surgically and proton pump induced acid suppression has been shown to result 
in hypergastrinaemia, ECL hyperplasia and formation of ECL carcinoid tumours 
(Mattsson et al., 1991, Havu, 1986).  In humans the evidence is more 
contradictory, PPI induced hypergastrinaemia has been shown to be associated 
with ECL hyperplasia but there is no convincing evidence that there is a 
significant association with carcinoid tumours (Lamberts et al., 1993 , Brunner 
et al., 2012). 
 
Of the 37 patients in the present study, 27 (73%) reported current or long-term 
proton pump inhibitor (PPI) use.  In addition to the association between PPI use 
and ECL hyperplasia it has been shown that long term PPI use is associated 
with elevated serum Chomogranin A levels (Sanduleanu et al., 1999).  It is 
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possible that the widespread presence of neuroendocrine cells as evidenced by 
chromogranin A staining in the present study is, at least in part, related to the 
high prevalence of PPI use in the study population.  
 
Very few other studies have evaluated molecular marker expression in neo-
Barrett’s tissue and those that have involved much smaller numbers of patients.  
As in the present study however, the limited data which has been published 
suggests that neo-Barrett’s is characterised by the expression of the same 
molecular markers as is seen in sporadic Barrett’s oesophagus.   
 
Lord and colleagues (2004) used immunohistochemical techniques to evaluate 
cytokeratin 7 and 20 expression.  This study included 10 samples of cardiac 
type neo-Barrett’s and 4 samples of neo-Barrett’s with specialised intestinal 
metaplasia.(Lord et al., 2004)  As in the present study, there was superficial 
staining for both of these cytokeratins with deep glandular staining for 
cytokeratin 7 also present.  This pattern was seen in neo-Barrett’s tissue of both 
types but staining was observed to be more intense in areas of intestinal 
metaplasia.  Bax et al (2007) also studied cytokeratin 7 and 20 expression in 23 
patients with neo-Barrett’s and found CK7 and CK20 to be present in a Barrett’s 
like pattern in all samples(Bax et al., 2007). 
 
Barrett’s epithelium is characterised by the presence of goblet cells and 
expression of intestinal markers including MUC2 (a secretory mucin), alkaline 
phosphatase and isomaltase.  There is increasing evidence that neo-Barrett’s 
epithelium is characterised by the presence of the same intestinal markers.  The 
enterocytic enzyme isomaltase was identified in samples from 2 out of 4 
patients with neo-Barrett’s by Chaves and collegues (2002).  More recently Bax 
(2007) described similar expression of the mucin gene product MUC2 in neo-
Barrett’s samples as is seen in Barrett’s.  The antibody DAS1 reacts with goblet 
cells.  Immunhistochemical staining with this antibody is positive in Barrett’s but 
not squamous oesophageal mucosa.  Neo-Barrett’s mucosa with intestinal 
metaplasia, stains strongly for DAS1, providing further evidence of phenotypic 
similarity to sporadic Barrett’s (Lord et al., 2004).  CDX2, a protein involved in 
intestinal differentiation, predominantly expressed in the small intestine and 
colon of adults is also known to be present in Barrett’s tissue.  In neo-Barretts 
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tissue CDX2 expression appears frequently in samples with intestinal 
metaplasia and infrequently in samples with gastric-type metaplasia perhaps 
providing further evidence that non intestinalised columnar epithelium is an 
early form of columnar metaplasia (Bax et al., 2007).  
 
In summary the cytokeratin 7 and 20 staining pattern seen in the neo-Barrett’s 
biopsy samples in the present study was similar to that reported in sporadic 
Barrett’s oesophagus.  A typical Barrett’s like pattern was seen in 62% of cases, 
and whilst this prevalence is lower than that reported in some studies it is within 
the range of values reported in the literature for sporadic Barrett’s oesophagus.  
In addition the pattern is different from that expected in the adjacent tissues.  
Chromogranin A expression is seen in neo-Barrett’s tissue in a similar pattern to 
that described in sporadic Barrett’s oesophagus although it is seen more 
frequently.  These findings together suggest that neo-Barrett’s oesophagus is 
molecularly similar to sporadic Barrett’s oesophagus and support the hypothesis 
that post-oesophagectomy neo-Barrett’s is an appropriate model for the 
development of Barrett’s oesophagus.  
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Chapter 5. Expression of Trefoil Factors in neo-Barrett’s 
epithelium 
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5.1 Introduction 
Trefoil factors are a family of proteins which contain the three-loop trefoil 
domain.    TFF1 and TFF3 are able to form dimers and an example of the 
structure is shown in figure 5.1.  Three human trefoil factors have been 
identified.  The predominant site of expression of all three is within the 
gastrointestinal tract however there are differences in the precise locations of 
expression. 
 
 
 
Figure 5.1: Structure of human TFF1 dimer.  Note the three loops in each 
globular trefoil domain creating a three-leafed structure.  The red region 
indicates the short region of α-helix that is present in the second loop of the 
trefoil domain (Kjellev, 2009) reproduced with kind permission of Springer 
Science) 
 
 
The function of trefoil proteins remains far from certain.  They are relatively 
resistant to heat, acid and enzymes and it has been proposed that they may 
interact with mucin molecules in order to stabilise the mucus gel which protects 
the epithelium of the gastrointestinal tract (Wong et al., 1999). 
 
In addition to their proposed protective role, it has been suggested that trefoil 
proteins may have a role in the repair of damaged tissue.  They have been 
identified in what has been termed the ulcer associated cell lineage (Hauser et 
al., 1993).  This cell lineage forms a unique glandular structure at sites of 
chronic gastrointestinal ulceration including those seen in Crohn’s disease and 
peptic ulcers (Wright et al., 1990).  Trefoil proteins appear to be able to 
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stimulate the migration of cells from the healthy epithelium at the edge of a 
wound (Playford et al., 1995, Dignass et al., 1994).  These cells are stimulated 
to move to cover the damaged area allowing rapid repair and protection from 
further damage. 
 
In addition to their role in mucosal protection and repair there is evidence to 
suggest that trefoil proteins have a role in carcinogenesis.  Mice lacking the 
gene for TFF1 expression are prone to gastric adenomas and adenocarcinomas 
and there is increasing evidence that abnormal TFF expression is a common 
feature of many types of tumour (Lefebvre et al., 1996) (Kjellev, 2009) (Regalo 
et al., 2005).    
 
The finding of an association between the trefoil factors and both ulceration and 
cancer within the gastrointestinal tract has led to interest in the study of trefoil 
proteins in Barrett’s oesophagus.  Barrett’s is believed to develop in response to 
chronic gastroduodenal reflux and the resultant inflammation.  It has been 
suggested that the columnar metaplasia seen in Barrett’s is an adaptive 
response to this reflux related injury with the metaplastic columnar epithelium 
being more resistant to acid than the native oesophageal squamous mucosa.  
This metaplastic epithelium may be able to secrete protective mucins as 
happens elsewhere in the gastrointestinal tract and trefoil proteins could clearly 
have a role in this.  In addition, secretion of trefoil proteins in the distal 
oesophagus could potentially aid mucosal repair following reflux, where damage 
has occurred.  A small number of studies have demonstrated expression of 
trefoil factors in Barrett’s oesophagus providing some evidence for these 
theories (Hanby et al., 1994, Warson et al., 2002, Labouvie et al., 1999, Fox et 
al., 2005, Van de Bovenkamp et al., 2003).   
 
The stage of the metaplastic process at which trefoil factors start to become 
expressed is unclear as is the expression pattern for the different subtypes of 
Barrett’s oesophagus.  Expression of trefoil factors has never been specifically 
studied in the proximal oesophagus or in a post oesophagectomy neo-Barrett’s 
population.   
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The aim of the present study was to assess the expression of the three human 
trefoil factors in neo-Barretts tissue.  As outlined in previous chapters the 
oesophageal remnant following surgery potentially provides a unique 
opportunity to study the early stages of Barrett’s oesophagus.  By evaluating the 
expression of trefoil proteins in this environment it was hoped to gain some 
insight into their role in the development of Barrett’s oesophagus and also to 
compare their expression here with what has been observed in sporadic 
Barrett’s oesophagus. 
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5.2 Methods 
Patients and inclusion criteria for the study were as outlined in the previous 
chapter.  All had confirmed neo-Barrett’s with evidence of a squamous lined 
oesophageal remnant at the time of surgery. 
 
Thirty five patients were endoscoped prospectively by, or in the presence of the 
author.  The remaining two patients were identified retrospectively and had 
clear documentation and picture evidence of columnar epithelium above the 
anastomosis from which biopsies had been taken.  Biopsy technique and initial 
processing was as outlined in the previous chapter. 
 
5.2.1 Trefoil factor immunohistochemistry 
Monoclonal antibodies raised in mice (a gift from F. May) were applied to the 
biopsy sections according to the protocol described in appendix G.  An avidin-
biotin-peroxidase method was used with 3,3’-diaminobenzidine as a chromogen 
to view positive binding. 
 
5.2.2 Assessment and scoring of samples 
Histological classification was determined by an expert gastrointestinal 
pathologist.  Where more than one type of epithelium was present, classification 
was based on the predominant type with the exception of samples containing 
intestinal metaplasia.  Samples containing any areas of intestinal metaplasia 
were classified as type A.  In these cases immunohistochemical scoring was 
based only on representative areas of epithelium.   
 
Staining for all three trefoil factors was assessed for both the superficial surface 
epithelium and the deeper glandular structures, only epithelial cells were 
considered.  Immunohistochemical scoring was carried out by the author using 
a semi-quantitive scoring method as described in table 5.1.     
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Score Description 
0 Staining absent 
1 Staining in 0 – 25% of cells 
2 Staining in 25 – 50% of cells 
3 Staining in 50 – 75% of cells 
4 Staining in 75 – 100% of cells 
. 
Table 5.1: Semi-quantitative scoring system used to assess trefoil staining 
 
 
5.2.3 Statistical analysis 
Comparisons of proportions were undertaken using the Fisher’s exact test or 
Mann-Whitney U tests as appropriate. 
 
5.2.4 Ethical approval 
Ethical approval was sought and granted by the County Durham and Tees 
Valley 2 REC as outlined previously. 
 
5.3 Results 
5.3.1 Study population 
The study population comprised a total of 37 patients, 31 males and 6 females.  
Median time following surgery was 6.6 years (range 1.0 – 13.2 years).   
 
5.3.2 TFF1 
Normal stratified squamous epithelium was usually seen in the sections of the 
biopsies, often continuous with the columnar epithelium.  TFF1 was not 
expressed by any of the normal squamous epithelium. 
 
TFF1 was extensively expressed by the columnar epithelium, predominantly in 
the superficial compartment.  All samples demonstrated extensive 4+ staining of 
the superficial epithelium (figure 5.2).  Within the surface epithelium, two distinct 
patterns of staining were seen.  In one there was equal staining throughout the 
cytoplasm and in the other the staining had a clear apical predominance (figure 
5.3).  Twenty two specimens (60%) demonstrated the predominantly apical 
staining phenotype. 
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TFF1 was expressed by the deeper glandular tissues in the majority of cases 
but the extent of this staining was much less than in the superficial compartment 
(figure 5.2). 
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Figure 5.2: Extent of Trefoil factor staining within superficial and deeper 
glandular tissues of columnar epithelium 
 
 
 
 
Figure 5.3a: TFF1 Staining where there is equal staining throughout the 
cytoplasm 
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Figure 5.3b: TFF1 staining where there is an apical predominant pattern 
 
 
There was a trend towards more extensive expression of TFF1 in specimens 
with intestinal metaplasia compared to those without (figure 5.4) but this just 
failed to reach statistical significance (p=0.058). 
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Figure 5.4:  Extent of TFF1 in deeper glandular tissues according to subtype of 
columnar metaplasia 
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5.3.3 TFF2 
 
There was no expression of TFF2 in the areas of normal stratified squamous 
epithelium present within the specimens. 
 
TFF2 was the most widely expressed of the three trefoil factors with the majority 
of specimens demonstrating strong (4+) superficial staining in addition to 
marked staining of the deeper glandular structures (figure 5.2).  There was no 
difference in either the superficial or deep staining for TFF2 according to the 
presence of intestinal metaplasia (p=1.000 and p=1.000 respectively (figures 
5.5 and 5.6). 
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Figure 5.5: Extent of TFF2 in superficial epithelium according to subtype of 
columnar metaplasia 
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Figure 5.6: Extent of TFF2 in deeper glandular tissue according to subtype of 
columnar metaplasia 
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5.3.4 TFF3 
 
There was no expression of TFF3 in areas of normal stratified squamous 
epithelium present within the specimens. 
 
TFF3 was the least widely expressed of the three trefoil factors with only 1 
specimen demonstrating more than 50% staining in the superficial epithelium 
and no samples demonstrating more than 50% staining in the deeper glandular 
tissues (figure 5.2).  When present, the staining was diffuse and cytoplasmic 
with no cases of an apical predominant pattern.   
 
There was no significant difference in the staining intensity for TFF3 in either 
the superficial or deep compartments for columnar metaplasia with intestinal 
metaplasia compared to columnar metaplasia without intestinal metaplasia 
(p=0.074 and p=0.081 respectively) (figures 5.7 and 5.8).  Only one specimen 
of type A and one specimen of type C columnar epithelium demonstrated a 
complete absence of staining for TFF3.  There were 6 specimens of type C 
columnar epithelium which demonstrated no TFF3 staining however this 
difference did not reach statistical significance. 
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Figure 5.7: Extent of TFF3 in superficial epithelium according to subtype of 
columnar metaplasia 
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Figure 5.8: Extent of TFF3 staining in the deeper glandular tissue according to 
subtype of columnar metaplasia 
 
 
5.3.5 Time from surgery and TFF expression 
There was a significant association between the time that had elapsed since 
surgery and the presence of TFF3.  Patients whose samples expressed TFF3 
were endoscoped at a median of 8.1 years following surgery compared to a 
median of 3.4 years for those with no TFF3 expression (p=0.004).  This 
association was not seen for the other 2 trefoil factors (figure 5.9).  In the case 
of TFF2, all samples demonstrated some staining regardless of time from 
surgery.  There was greatest variability in the expression of TFF1 and TFF2 in 
the deeper glandular tissue and it was therefore decided to assess whether 
there was any correlation between the extent of expression of these trefoil 
factors in the deeper tissues and the time from surgery.  There was however no 
significant correlation (p=0.292 and p=0.084 respectively) (figure 5.10).  For the 
other staining scores the variability was too limited for correlation analysis to be 
relevant. 
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Figure 5.9a: Association between time from surgery and the presence of TFF1 
staining p=0.696 (Mann-Whitney) 
 
 
Figure 5.9b: Association between time from surgery and the presence of TFF3 
staining p=0.004 (Mann-Whitney). 
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Figure 5.10a: Association between time from surgery and the staining score for 
TFF1 in deeper glandular structures.  There was no significant correlation 
(p=0.292) 
 
 
 
Figure 5.10b: Association between time from surgery and the staining score for 
TFF2 in deeper glandular structures.  There was no significant correlation 
(p=0.084) 
 
 
5.3.6 Pattern of staining 
In a proportion of specimens the trefoil factor staining took a distinctive form 
with circular areas of strong staining within goblet cells (figure 5.11).  Where this 
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appearance was noted it was present for all 3 trefoil factors in the majority of 
cases (table 5.2). 
 
 
 
Figure 5.11a: High powered view of strong circular areas of staining for TFF3 in 
goblet cells in a specimen with specialised intestinal metaplasia 
 
 
Figure 5.11b: Low powered view H&E stained neo-Barrett’s with corresponding 
slide showing TFF3 staining in goblet cells 
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Patient 
Distinct goblet 
cell staining for 
TFF1 
Distinct goblet 
cell staining for 
TFF2 
Distinct goblet 
cell staining for 
TFF3 
1 No No No 
2 Yes No Yes 
3 Yes Yes Yes 
4 Yes Yes Yes 
5 Yes Yes Yes 
6 Yes Yes Yes 
7 No No No 
8 No No No 
9 No Yes Yes 
10 Yes Yes Yes 
11 Yes Yes Yes 
12 No No No 
 
Table 5.2: Distinctive staining of goblet cells for trefoil factors in patients with 
neo-Barrett’s with specialised intestinal metaplasia 
 
 
130 
5.4 Discussion 
Trefoil factors are a family of proteins which bear the three-loop trefoil domain.  
There are three human trefoil factors, TFF1, TFF2 and TFF3.  The first trefoil 
protein to be identified was TFF1.  Initially named pS2, it was identified in a 
breast carcinoma cell line and was first described in the early 1980s 
(Masiakowski et al., 1982).  TFF2 was identified around the same time having 
been extracted from porcine pancreas (Jorgensen et al., 1982).  It was several 
years later, in 1989 that the similarity between these proteins was appreciated 
and the trefoil domain identified (Thim, 1989).  TFF3 was the last of the trefoil 
factors to be discovered, initially described in the rat it was first termed intestinal 
trefoil factor (Suemori et al., 1991).  The genes for the three human trefoil 
factors are clustered together on chromosome 21q22.3.  The predominant 
physiological site of expression of all three is the gastrointestinal tract where 
they are expressed in a site specific pattern.  Physiological expression has 
however been described in several sites outside the gastrointestinal tract 
including salivary gland, respiratory tissues and breast (Madsen et al., 2007). 
 
The physiological function of trefoil proteins is relatively poorly understood but it 
is believed that they have an important role in the protection and repair of 
mucosal surfaces.  Studies have shown that trefoil proteins are located within 
the mucin granules in mucous secreting epithelial cells and it has been 
suggested that trefoil proteins interact with the mucin molecules to stabilise the 
mucous gel present on gastrointestinal mucosal surfaces (Ahnen et al., 1994) 
(Wong et al., 1999).  Longman and colleagues (Longman et al., 2000) used 
immunofluorescent co-labelling to demonstrate that each trefoil protein co-
localises with a specific mucin and that the expression of these varies according 
to location within the gastrointestinal tract.  TFF1 is highly expressed in the 
surface epithelial cells of the stomach and has also been reported to be 
expressed in the upper ducts and surface cells of Brunner’s glands in the 
duodenum(Hanby et al., 1993b) (Hanby et al., 1993a).  TFF2 is also mainly 
expressed in the stomach.  In normal gastric mucosa high levels of expression 
have been observed in the mucous glands of the body and antrum as well as in 
the Brunners glands of the duodenum.  In contrast TFF3 is predominantly 
expressed in the intestine by the goblet cells (Podalsky et al., 1993).  It is also 
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more widely expressed than either TFF1 or TFF2 in non-gastrointestinal tissues 
including breast, uterus, hypothalamus and pituitary gland (Regalo et al., 2005). 
 
There has been significant interest in the role of trefoil proteins in mucosal 
repair.  All three trefoil factors have been found to be expressed in what is 
termed the ulcer associated cell lineage (UACL).  This novel cell lineage was 
first described by Wright and colleagues (1990) and is found in proximity to 
ulcers in Crohn’s disease and peptic ulceration.  The acinar structures of the 
UACL are thought to arise as a direct result of the ulceration.  They are able to 
secrete a number of molecules which are thought to be important in epithelial 
repair including trefoil proteins and epidermal growth factor.  Trefoil proteins 
appear to be motogens, able to promote cell migration without affecting cell 
division.  In vitro studies using wounded monolayers of cells have shown that 
addition of trefoil proteins results in a marked increase in the rated of epithelial 
migration into the wound (Dignass et al., 1994, Playford et al., 1995).  This 
evidence suggests that trefoil proteins have an effect on ulcer healing by 
stimulating the migration of surviving cells from the edge of the damaged region 
to cover the damaged region itself. 
 
In vivo data on the role of trefoil proteins comes from studies of ‘knockout’ mice.  
TFF1 knockout mice exhibit decreased mucous secretion and develop gastric 
antral adenomas and multifocal intramucosal adenocarcinomas (Lefebvre et al., 
1996).  TFF3 knockout mice in contrast do not appear to have an obvious 
alteration in phenotype but have an impaired response to intestinal damage.  
Administration of dextran sulphate sodium, an agent which causes mild 
epithelial injury in wild type mice, resulted in much more severe damage in 
TFF3 knockouts where poor mucosal healing and death secondary to colitis 
were observed (Mashimo et al., 1996).  More recent work involving TFF2 
knockout mice has suggested that TFF2 is able to down-regulate gastric acid 
secretion and that absence of TFF2 results in a susceptibility to non steroidal 
anti-inflammatory drug (NSAID) induced gastric ulceration (Farrell et al., 2002).  
The prevalence of gastric adenocarcinomas in TFF1 knockout mice has 
resulted in the hypothesis that the gene encoding for TFF1 may have a role as 
a tumour suppressor gene. Immunohistochemical studies of gastric tissue have 
suggested that whilst TFF1 is almost universally present in samples of normal 
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gastric mucosa, expression is lost in up 50% of gastric adenocarcinomas 
(Henry et al., 1991, Muller and Borchard, 1993, Machado et al., 1996). 
 
Barrett’s oesophagus is believed to develop in response to chronic mucosal 
injury in the presence of duodeno-gastro-oesophageal reflux.  Given this 
proposed mechanism of epithelial damage, inflammation and attempted repair 
there is interest in the potential role of trefoil factors in the development of 
columnar metaplasia.  Similarly the potential role of genes encoding for trefoil 
proteins as tumour suppressor genes raises the question of whether these 
molecules might be important in the malignant progression of Barrett’s and the 
development of oesophageal adenocarcinoma.  Trefoil proteins have also been 
proposed as potential biomarkers to assist in the diagnosis of Barrett’s 
oesophagus (Lau-Sirieix et al., 2009). 
 
In the present study, many specimens included areas of squamous epithelium 
alongside the metaplastic columnar epithelium.  There was no evidence of 
trefoil protein expression in any of the squamous epithelium.  This finding is 
similar to that of other studies which have assessed trefoil expression in 
squamous oesophageal mucosa (Hanby et al., 1994, Warson et al., 2002, 
Kouznetsova et al., 2007).  A single study has found evidence of TFF3 
expression within the squamous lined oesophagus.  This study identified TFF3 
messenger RNA (mRNA) in surgical resection specimens (Kouznetsova et al., 
2007).  Laser capture dissection and immunofluorescence localisation 
suggested that the TFF3 was expressed in the submucosal glands and not in 
the superficial stratified squamous epithelium likely to be sampled by plain 
biopsy, potentially explaining the absence of TFF3 noted elsewhere.  In the 
present study the fragments of squamous mucosa came from areas directly 
adjacent to the columnar epithelium and must therefore have been exposed to 
the same luminal conditions.  The absence of trefoil expression in this situation 
suggests that TFF1 and TFF2 cannot be secreted by squamous oesophageal 
mucosa in response to injury and the only way the protective and reparative 
effects of these trefoil proteins can be utilised in the oesophagus is via the 
adaptive metaplastic process seen in Barrett’s oesophagus. 
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TFF1 expression is well described in Barrett’s oesophagus, including the 
cardiac and fundic types (Hanby et al., 1994, Warson et al., 2002).  TFF1 is 
predominantly found in the superficial epithelial compartment but some staining 
of deeper glands is described (Hanby et al., 1994).  In the present study 
examining neo-Barrett’s, extensive TFF1 staining (>75% of cells) was found in 
all samples of columnar metaplasia.  The majority of the deeper glands also 
expressed TFF1 but staining was less extensive than in the superficial 
compartment.  These findings are in agreement with what has been reported in 
cases of sporadic Barrett’s oesophagus and also closely resembles the 
expression found in normal gastric tissue (Hanby et al., 1994, Warson et al., 
2002, Labouvie et al., 1999, Fox et al., 2005) (Longman et al., 2000, Rio et al., 
1988). 
 
The TFF1 gene is recognised as a tumour suppressor gene in gastric 
adenocarcinoma however its role in oesophageal adenocarcinoma is less 
clearly defined.  One study (Fox et al., 2005) has assessed TFF1 expression in 
adenocarcinomas of the oesophagus (n=31) and the gastro-oesophageal 
junction (n=72).  This study found negative to weak TFF1 expression in tumours 
which contrasted with the abundant expression seen in Barrett’s oesophagus 
tissue.  The authors suggest, on this basis, that loss of TFF1 expression may be 
important in the malignant transformation of Barrett’s oesophagus.  In the 
present study all samples demonstrated abundant expression of TFF1, which 
may therefore indicate that these patients are at low risk of developing Barrett’s 
carcinomas in the near future.  The role of TFF1 in the malignant progression of 
Barrett’s however remains to be fully elucidated and temporal studies and 
validation are required before this can be considered as a clinical biomarker. 
 
TFF2 was the most extensively expressed trefoil factor in this study with 
extensive expression in the superficial compartment and much greater 
expression than TFF1 in the deeper glands (figure 4.2).  In sporadic Barrett’s 
oesophagus, studies of TFF2 expression have produced inconsistent results.  
Warson et al (2002) undertook immunohistochemical evaluation of Barrett’s 
oesophagus biopsies and demonstrated similar results to the present study with 
TFF2 expression present throughout the surface epithelium and the deeper 
glandular structures.  Hanby and colleagues (1994) demonstrated expression of 
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TFF2 mRNA in both the superficial and deeper tissues but found TFF2 protein 
to be predominantly located within the deeper compartment.  They suggest that 
the discrepancy may to due to low levels of protein being made in the superficial 
epithelium under normal circumstances or it’s rapid secretion although if this 
were the case it is unclear why this problem was not experienced in either the 
present study or in that by Warson.  Labouvie et al. (Labouvie et al., 1999) 
failed to demonstrate any TFF2 expression in 21 biopsy samples of Barrett’s 
metaplasia despite requiring staining of only 5% of cells to define positivity.  In 
the context of disagreement with other studies and a lack of data regarding the 
positive controls used in this series concern remains that the reported absence 
of TFF2 is simply an anomalous result.   
 
TFF3 was the least widely expressed of the trefoil factors in the present study 
with no cases of extensive (>75% of cells) staining.  Two distinct patterns of 
staining were observed, one being a weak cytoplasmic pattern and the other 
being strongly positive staining associated with goblet cells in areas of intestinal 
metaplasia.  Goblet cell associated TFF3 expression is described in the 
intestine and this type of strong round staining associated with goblet cells has 
been described in Barrett’s oesophagus by others (Podalsky et al., 1993) (Lau-
Sirieix et al., 2009).  In contrast, the study by Warson et al. (Warson et al., 
2002) found TFF3 to be absent from the goblet cells of intestinal metaplasia in 
Barrett’s.(Warson et al., 2002)  The authors also found no association between 
TFF3 expression and the presence of intestinal metaplasia in individual 
patients.   
 
This paper also details the expression of mucins in Barrett’s oesophagus.  
Mucins are glycosylated proteins which are produced and secreted in large 
amounts by epithelial cells in the gastro-intestinal tract (Kim and Ho, 2010).  Up 
to 20 different types of mucin are recognised, each encoded for by a gene given 
the prefix MUC and numbered according to the order of discovery.  Mucins can 
be broadly classified into two groups, secretory and membrane associated and 
they are produced in a tissue specific fashion.  The structure of mucin 
molecules, with cysteine-rich domains allows them to form bonds with each 
other and with other molecules to form a highly viscous gel.  In the 
gastrointestinal tract, mucins are the major component of the protective mucus-
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gel layer which provides a defence against damage from ingested food and 
microbes and the acid and enzymes secreted as part of the digestive process.  
This gel layer also helps to lubricate the gut, assisting with transit of its 
contents.  Abnormalities in mucin secretion are observed in several disease 
states including intestinal infections, inflammatory bowel disease and mucinous 
adenocarcinomas (Kim et al., 2005).   
 
Warson and colleagues (2002) studied the expression of 4 major secretory 
mucins  in Barrett’s oesophagus including MUC2.  MUC2 is considered to be a 
marker of intestinal differentiation associated with the presence of goblet cells.  
It is found in the normal intestine and has been found in intestinal metaplasia of 
the stomach (Chang et al., 1994, Reis et al., 1999).  Despite the authors finding 
no significant association between TFF3 expression and intestinal metaplasia in 
individual patients they did show a correlation between the extent of MUC2 and 
TFF3 expression as determined in individual patients.  This potentially provides 
circumspect evidence of a link between intestinal metaplasia and TFF3 
expression in these samples.  
 
A model for the secretory phenotype changes associated with the development 
of Barrett’s metaplasia in the distal oesophagus has been proposed (Van de 
Bovenkamp et al., 2003).  In this model the first step involves a change from the 
normal stratified squamous epithelium to a single layer of columnar epithelium 
forming glandular structures.  At this stage virtually all cells produce secretory 
mucins and associated trefoil proteins suggesting that this metaplastic mucosa 
has an increased capacity for protection and repair in the face of ongoing reflux 
injury.  In the next phase intestinal metaplasia with goblet cells develops, MUC2 
expression increases dramatically and TFF3 expression increases in 
conjunction with this.   
 
The present study has confirmed that a similar process is possible in the tissue 
of the proximal oesophagus following sub-total oesophagectomy.  All types of 
columnar epithelium present in this area express trefoil proteins, whereas these 
proteins were never seen in residual areas of squamous epithelium.  TFF3 
expression was more common in neo-Barrett’s of intestinal and cardiac types 
compared to that of gastric type.  This difference failed to reach statistical 
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significance (p=0.129) but the numbers of each subtype were relatively small.  
There was however a statistically significant difference in the average time from 
surgery of patients demonstrating TFF3 expression compared to others.  
Median time from surgery was 8.1 years for patients expressing TFF3 
compared to 3.4 years for patients with no TFF3 expression. This, along with 
the finding that the presence of intestinal metaplasia was associated with 
increasing time from surgery provides evidence to support the model outlined 
above.  Ideally prospective studies collecting biopsy samples from the same 
patients over a prolonged period of time would be required to confirm this 
process however, on a practical level it is difficult to justify repeated 
endoscopies in this population without a good clinical indication. 
 
TFF3 is present in the human stomach in very limited amounts only in the 
absence of intestinal metaplasia (Hauser et al., 1993).  Peitz and colleagues 
(2004a) assessed TFF3 mRNA expression in the gastric cardia and compared 
this to the gastric body and the oesophageal columnar epithelium in patients 
with Barrett’s with intestinal metaplasia.  They found that TFF3 expression was 
significantly more frequent at the cardia (n = 15/24) than in the body of the 
stomach(n = 2/26).  In addition, TFF3 at the cardia was more common in 
patients with gastro-oesophageal reflux disease compared to those without, 
although this difference was not significant.  Patients with evidence of intestinal 
metaplasia at the cardia were excluded so, as in the present study, it appears 
that TFF3 expression can occur in the absence of intestinal metaplasia and 
goblet cells.  Biopsies from the cardia included both cardiac-type and fundus-
type mucosa.  The authors found TFF3 expression less commonly in fundus-
type mucosa than in cardiac-type but TFF3 was present in all cases of 
oesophageal intestinal metaplasia.  Combining these results with those of the 
present study and others it is clear that TFF3 expression can occur in cardiac-
type mucosa of both gastric and proximal and distal oesophageal origin.  This 
supports the concept of cardiac mucosa being metaplastic, occurring in 
response to reflux and being a precursor to intestinal metaplasia.  In the 
oesophagus the earliest metaplastic step may be conversion to a gastric fundic-
type mucosa with only rare expression of TFF3.    
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One group has proposed TFF3 as a potential biomarker to be used in screening 
for Barrett’s oesophagus (Lau-Sirieix et al., 2009).  This group used microarray 
datasets to identify markers which were present in Barrett’s oesophagus but 
absent in normal oesophagus and gastric mucosa.  Validation was then 
performed using immunohistochemistry on biopsy samples.  As predicted, TFF3 
protein was expressed extensively at the luminal surface of Barrett’s 
oesophagus and was absent in normal oesophagus and gastric mucosa.  Of 
interest the gastric samples in this study were taken from the cardia, an area 
where Peitz (2004a) suggests that TFF3 expression is not uncommon in the 
presence of reflux.  Despite this TFF3 expression in cells captured using an 
oesophageal sponge capsule technique does appear to have excellent 
specificity for Barrett’s oesophagus and further studies of this technique are 
underway. 
 
In summary the current study has demonstrated expression of trefoil factors in 
neo-Barrett’s epithelium in a pattern similar to that seen in sporadic Barrett’s 
oesophagus.  The finding that TFF3 expression was associated with time from 
surgery suggests that evidence of this trefoil may indicate a more advanced 
stage of Barrett’s.   
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Chapter 6. Genetic mutations in Barrett’s oesophagus, 
associated oesophageal adenocarcinoma and subsequent neo-
Barrett’s oesophagus 
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6.1 Introduction 
The normal adult oesophagus is lined by a stratified squamous epithelium which 
undergoes continuous renewal.  As with other rapidly proliferating tissues the 
epithelium is maintained by a limited number of stem cells (Seery and Watt, 
2000, Nicholson et al., 2012).  These stem cells are able to divide to self-renew 
and to produce transit cells which differentiate to produce cells characteristic of 
the particular epithelium (Hall and Watt, 1989).   The location of both normal 
oesophageal stem cells and Barrett’s oesophageal stem cells remains unclear.  
Squamous stem cells are thought to be located in the interpapillary basal layer 
and possibly also in the glandular neck region of oesophageal submucosal 
gland ducts (Seery, 2002).  There are several theories as to the origin and 
location of Barrett’s stem cells but the evidence for these is even less 
conclusive. 
 
There are five main theories as to the origins of Barrett’s oesophagus: 
 
1. Gastric cardia migration with subsequent intestinal metaplasia 
2. A metaplasia of the oesophageal squamous epithelium 
3. Circulating bone marrow stem cells which are multipotent and able to 
colonise a damaged oesophagus 
4. A residual population of embryonic cells that persist at the gastro-
oesophageal junction  
5. Stem cells in oesophageal submucosal gland ducts 
 
A summary of each theory is outlined below: 
 
1. Gastric cardia migration with subsequent intestinal metaplasia 
 
This was one of the earliest theories as to the origins of Barrett’s oesophagus.  
In the canine experiments of Bremner et al. (1970) a columnar epithelium, 
similar to human cardiac epithelium, was observed to replace surgically excised 
oesophageal squamous epithelium in the presence of gastro-oesophageal 
reflux.  Cardiac epithelium was thought to be more resilient and capable of 
migrating proximally to repair the denuded area of oesophagus (Bremner et al., 
1970).  This theory does not explain the presence of goblet cells in Barrett’s 
oesophagus as these are not present in cardiac epithelium.  The absence of 
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goblet cells in the normal gastric cardia does not however rule out this theory as 
intestinal metaplasia can occur in the stomach and the development of Barrett’s 
via this mechanism could be explained by a two stage process of proximal 
migration with subsequent intestinalisation (Eda et al., 2003).  Against this 
theory is the fact that cardiac type metaplasia has been observed above an 
intact ring of squamous epithelium in dogs (Gillen et al., 1988) and following 
subtotal oesophagectomy in humans where the gastric cardia is resected 
(Dresner et al., 2003).   In the second case Barrett’s could be explained by 
proximal migration of gastric body epithelium rather than gastric cardia 
epithelium and this theory would perhaps be better described as gastric 
migration with subsequent intestinal metaplasia.   
 
2. Conversion of the stem cells of the oesophageal squamous epithelium 
 
This theory has been the pre-eminent one for many years (Oh and deMeester, 
2010).  It suggests that the stem cells of the oesophagus undergo a metaplasia 
from a squamous to a columnar phenotype.  Despite the predominant nature of 
this theory over recent years there is surprising little hard evidence to support 
the hypothesis.   
 
The metaplasia process is believed to occur as a result of the chronic 
inflammation and damage associated with duodeno-gastro-oesophageal reflux.  
In vitro experiments using cell culture models and biopsy specimens have 
suggested that chronic exposure of oesophageal cells to acid and/or bile can 
result in the induction of genes associated with differentiation to an intestinal 
phenotype (Liu et al., 2006a, Hu et al., 2007).  Experiments of this nature have 
not however demonstrated that goblet cells can be produced in this manner, 
merely that cells can demonstrate upregulation of genes and gene products 
associated with goblet cells.  Animal experiments where oesophago-
duodenostomy or oesophago-jejunostomy have been used to induce reflux into 
the oesophagus have shown that Barrett’s like epithelium can develop above 
such an anastomosis (Melo et al., 1999, Pera et al., 1989, Clark et al., 1994).  
Whilst these experiments have resulted in the presence of goblet cells in the 
oesophagus they do not prove the oesophageal origin of these cells.  It is 
possible that these result from proximal migration of duodenal or jejunal cells.  
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In addition whether this is situation is representative of the situation in humans 
remains open for debate (Nicholson et al., 2012). 
 
3. Circulating bone marrow stem cells able to colonise a damaged oesophagus 
 
Lethal irradiation of female rats followed by rescue with bone marrow from male 
donor rats allows the Y chromosome to be used as a marker for the fate of the 
transplanted bone marrow cells.  Rats which have undergone this process 
followed by oesophagojejunostomy to induce reflux have been found to have 
both oesophageal squamous and columnar cells with a Y chromosome as the 
oesophagus heals (Sarosi et al., 2008).  This suggests that cells from the bone 
marrow are able to migrate to the oesophagus and divide to produce more than 
one phenotype of cell to repair mucosal damage.  Recently there have been 
some concerns that these results are inaccurate and that the presence of Y 
chromosomes in cells of the gastrointestinal tract may be the result of fusion 
between a bone marrow cell and a gastrointestinal (GI) cell rather than 
differentiation of a bone marrow cell to become a GI cell (Ferrand et al., 2011).  
The evidence for the role of bone marrow stem cells in the development of 
Barrett’s oesophagus therefore remains highly speculative. 
 
4. A residual population of embryonic cells that persist at the gastro-
oesophageal junction  
  
This theory has received much less attention than those outlined above.  In the 
human embryo, the foregut is thought to arise from a common progenitor cell 
which expresses the p63 protein.  In the mature oesophagus the cells of the 
superficial layers are p63 negative but it has been suggested that populations of 
embryonic type p63 positive cells persist at the squamo-columnar junction 
(Wang et al., 2011).  In the presence of oesophageal damage the authors of 
this paper suggest that these embryonic cells are able to migrate towards the 
squamous epithelium and give rise to both squamous and columnar epithelial 
cells.  As with other theories the evidence comes from animal models and is 
therefore subject to the usual concerns with regards to extrapolation to humans.  
This model is also unable to explain the occurrence of neo-Barrett’s epithelium 
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after surgery where the proposed site of these embryonic cells has been 
removed.   
 
5. Stem cells in oesophageal gland ducts 
 
Submucosal glands are present in the wall of the human oesophagus.  These 
glands are composed of individual mucus producing acini which lead into ducts 
which open onto the surface epithelium (Coad et al., 2005).  Proximally these 
ducts are lined by columnar epithelium but the distal third is lined by squamous 
epithelium.  This theory for the origin of Barrett’s oesophagus proposes that 
these ducts contain multipotential stem cells (Barbera and Fitzgerald, 2010).  
Nicholson et al. (2012) used mitochondrial DNA mutations as clonal markers to 
study the development of Barrett’s oesophagus.  They found that oesophageal 
gland ducts can contain clonal patches of cells with a mitochondrial DNA 
mutation.  This indicates a stem cell from which these mutant cells are derived 
should reside somewhere within the duct.  The authors of this study were 
unable to identify a clonal mutation incorporating both columnar and squamous 
cells.  Previous studies have however suggested that stem cells in either 
oesophageal ducts or glands are capable of producing both columnar and 
squamous epithelium (Leedham et al., 2008).   
 
This theory would sit comfortably with evidence from the early animal studies 
where columnar metaplasia was observed to develop above a ring of intact 
squamous epithelium (Gillen et al., 1988).  This suggested that Barrett’s was 
not occurring as a result of proximal migration of columnar cells but that the cell 
of origin might lie within the oesophagus itself. 
 
In addition to uncertainty about the cell of origin of Barrett’s oesophagus the 
mechanism by which large areas of the oesophagus become lined with 
metaplastic epithelium is poorly understood.  The selective ‘sweep to fixation’ 
model proposes that a single mutated stem cell with a selective advantage is 
able to clonally expand to fill an entire Barrett’s segment (Maley et al., 2004).  
An alternative theory suggests that Barrett’s oesophagus arises from multiple 
independent mutated clones (Leedham et al., 2008).  According to this 
hypothesis there is no single founder mutation which is present throughout a 
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Barrett’s segment.  Instead mutations occur in multiple progenitor cells 
throughout the length of the oesophagus.  These give rise to multiple distinct 
clones of metaplastic epithelium which then compete to colonise the 
oesophagus resulting in a mosaic pattern of clones across the segment. 
 
Certain genetic mutations are known to occur relatively frequently in Barrett’s 
oesophagus and oesophageal adenocarcinoma and are therefore useful targets 
to study.  Mutations are thought to occur sequentially and to confer a biological 
advantage on the cells involved allowing them to grow and divide at an 
abnormal rate (Fitzgerald, 2006b).  During the later stages of carcinogenesis 
genetic changes are believed to result in decreased apoptosis and increased 
angiogenesis allowing tumours to grow and metastasise. The presence, 
location and extent of spread of genetic mutations can be tracked within a 
segment of Barrett’s oesophagus and this principle has been utilised to study 
the development and malignant progression of Barrett’s oesophagus.  Genes 
which have been widely studied in Barrett’s oesophagus include CDKN2A 
which encodes for the p16 ink4a protein, Tp53 which encodes for the p53 
protein and KRAS which encodes for the Kras GTPase.  
 
The CDKN2A (p16) gene acts as a cell cycle inhibitor and regulates the 
progression of cells from the first gap (G1) phase of the cell cycle through to the 
second DNA synthesis (S) phase.  This is the major point of regulation for cell 
proliferation and the protein which acts as the master controller at this point is 
the retinoblastoma (Rb) protein (Wang and Souza, 2011).   p16 inhibits cyclin 
D4/6 mediated phosphorylation of Rb preventing the cell proceeding through 
the cell cycle.  Where mutation or methylation, results in inactivation of p16, 
cells are able to pass unhindered into the DNA synthesis (S) phase of the cell 
cycle and cell proliferation is increased. 
 
The TP53 gene is a tumour suppressor gene which has a central role in the 
induction of apoptosis, the process of programmed cell death which typically 
occurs after significant cellular damage has occurred (Wang and Souza, 2011, 
Meek, 2009).  Like p16, p53 also has a role as an inhibitor of the cell cycle.  In 
this respect it acts via target genes including p21 cyclin-dependent kinase 
inhibitor 1A (CDKN1A), 14-3- 
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3σ, and growth arrest and DNA damage-inducible gene (GADD45α) (Reinhardt 
and Schumacher, 2012).  Loss of p53 consequently results in abnormalities of 
both the apoptosis pathway and the cell cycle. 
 
The KRAS oncogene encodes for a protein which has a major role in cell 
proliferation.  RAS-mediated signals regulate the function of proteins which 
promote passage from the G1 phase into the S phase of the cell cycle and 
proteins that influence apoptosis (Wang and Souza, 2011).  KRAS is part of a 
kinase pathway which mediates cellular response to extracellular growth 
factors.  This pathway is complex and it has been proposed that it is also 
disrupted by methods other that mutation of the KRAS gene (Jankowski et al., 
1991).  Mutation of the KRAS gene is rare in non-dysplastic Barrett’s.  In this 
early stage of Barrett’s carcinogenesis, Ras pathway activation appears to 
occur as a result of increased levels of growth factors including epidermal 
growth factor receptor (EGFR) and transforming growth factor alpha (TGF-α).  
Increased levels of both of these growth factors have been found in biopsy 
samples of non-dysplastic Barrett’s oesophagus (Jankowski et al., 1991).  In the 
later stages of Barrett’s carcinogenesis mutations of the KRAS gene become 
more common along with those of the BRAF gene which is part of the same 
pathway.  Sommerer and colleagues (2004) found that around one third of 
Barrett’s adenocarcinomas have either a KRAS or BRAF gene mutation.  
 
Dysfunction of the RAS pathway is also a key factor in angiogenesis, the 
process by which cells are able to synthesise new blood vessels which is critical 
if tumours are to grow.  The process is mediated via the Ras signalling pathway 
and is initiated by the binding of vascular endothelial growth factors (VEGFs) to 
their receptors (Wang and Souza, 2011).   
 
Wong et al (2001) demonstrated that at least one CDKN2A allele was silenced 
either by mutation, loss of heterozygosity (LOH) or methylation in over 85% of 
patients with Barrett’s oesophagus.  They also found that mutated p16 glands 
underwent extensive clonal expansion to involve long (up to 17cm) segments of 
Barrett’s oesophagus.  The mechanism of expansion is unclear but gland fission 
(where one Barrett’s gland bifurcates to form two daughter glands) has been 
shown to occur in Barrett’s (Nicholson et al., 2012).  Galipeau and colleagues 
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(1999) similarly demonstrated a high prevalence of abnormalities of both the 
p16 and p53 tumour suppressor genes in patients with Barrett’s oesophagus 
with high grade dysplasia.  Again these abnormalities were found to occupy 
long segments of the Barrett’s oesophagus in some cases.  More recent work 
by Leedham et al (2008) has suggested that Barrett’s oesophagus comprises 
multiple independent clones (each with independent mutation profiles indicating 
a separate ancestry) rather than being the result of the expansion of a single 
clone.  Marked genetic heterogeneity was observed between different glands of 
samples from the same patients.   
 
In the context of neo-Barrett’s oesophagus, these theories about the origins of 
metaplasia and malignant progression are particularly interesting.  At the time of 
surgery these patients appear to have normal mucosa in the oesophageal 
remnant (Personal observations L Dunn and A D Burt).   Despite this, a high 
proportion proceed to develop metaplasia over a relatively short period of time 
(D'journo et al., 2009, Dresner SM and Griffin SM, 2000).  This raises the 
question of whether this simply reflects the high frequency and severity of reflux 
in this group or if there is an underlying susceptibility of the oesophageal 
epithelium to develop metaplasia and possibly subsequent dysplasia. 
 
The theory of field cancerisation has been gaining credence over recent years.  
Initially proposed as a mechanism for the development of tumours of the oral 
squamous epithelium, this theory suggests that there can be widespread 
replacement of the normal cell population of an epithelium by a histologically 
non-dysplastic mutant clone that is predisposed to tumour development 
(Slaughter et al., 1953).  Tumours subsequently occur as a result of further 
mutation events within the mutated field.  This theory therefore proposes that 
tumour development begins sometime before there are any overtly visible 
histological changes.  Field cancerisation has been described in the lung 
(Franklin et al., 1997), colon (Galandiuk et al., 2012, Leedham et al., 2009, 
Nosho et al., 2009) and skin (Hafner et al., 2010) and there is increasing 
recognition that it may also occur in the oesophagus (Zeki et al., 2011).  
Potentially this process could contribute to the development of neo-Barrett’s 
after subtotal oesophagectomy.  Whilst the residual oesophageal epithelium 
appears endoscopically and histologically normal there may be residual genetic 
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changes present within the cells of this epithelium which result in a 
predisposition to the development of metaplasia.   
 
The aim of this study was to look for evidence of field cancerisation in the 
context of neo-Barrett’s.  Tumours and adjacent Barrett’s oesophagus from 
patients who subsequently developed neo-Barrett’s were screened for genetic 
mutations.  Where mutations were present the aim was to determine if these 
same mutations were present in the post operative neo-Barrett’s. 
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6.2 Methods 
Patients were eligible for inclusion in this study if they had samples of neo-
Barrett’s oesophagus taken at endoscopy under the terms of the ethical 
approval granted by the County Durham and Tees Valley 2 REC.  This work 
was conducted as a collaborative project involving the author and Dr Stuart 
Macdonald’s team at the Cancer Research UK laboratories in London.  Laser 
capture microdissection and polymerase chain reaction and sequencing 
practical work were divided equally between the author and Dr Shabuddin 
Khan, a fellow research student. 
 
6.2.1 Tissue  
Paraffin-embedded oesophagectomy blocks from 10 patients were obtained 
from the pathology archives of the Royal Victoria Infirmary, Newcastle-
uponTyne.  Slides were reviewed by an expert gastrointestinal pathologist to 
identify representative areas of oesophageal adenocarcinoma and, where 
possible, co-existing Barrett’s oesophagus from the same patient. 
 
Serial sections were cut at 5µm thickness and one sample was stained with 
haematoxylin and eosin (H&E). 
 
6.2.2 Macrodissection of Specimens 
Suitable areas of oesophageal adenocarcinoma and Barrett’s oesophagus were 
confirmed using the H&E slide.  Serial sections containing these areas were 
dewaxed and rehydrated by soaking in xylene and decreasing concentrations of 
alcohol through to water.  Following de-waxing the identified representative 
areas from 5 serial slides were macrodissected using a sterile 21-guage needle. 
 
Scraped samples were incubated in 30 µl of proteinase K solution (Picopure, 
Arcturus Bioscience, Mt View, California, USA) at 65°c overnight.  Following 
incubation a 10 minute incubation at 95°c was used to denature the proteinase 
K. 
 
6.2.3 Screening polymerase chain reaction and sequencing 
The macro-dissected specimens were screened for mutations in the mutable 
regions of CDKN2A (exon 2) and TP53 (exons 5 – 8).  In the case of KRAS the 
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specimens were screened for mutations in the whole gene sequence as the 
gene is much smaller. 
Primers were designed using the Primer 3 website 
http://frodo.wi.mit.edu/primer3/input.htm).    A nested PCR protocol was used 
for each primer sequence.  Briefly 1 µl of extracted DNA was added to a 25 µl 
PCR reaction mixture containing 0.25 µl each of forward and reverse gene 
specific primers, 0.5 µl dNTP (Life Science, Buckinghamshire, UK), 0.2 µl of 
Taq polymerase (Qiagen, Crawley, UK), 2 µl of PCR template along with 
magnesium chloride, Q solution (Qiagen, Crawley, UK) and water in the 
quantities outlined in appendix H.  First round PCR was prepared in a UV hood 
to minimise contamination and then subjected to 37 cycles of denaturing, 
annealing and extension.  Annealing temperatures are provided in appendix F.  
1 µl of first round PCR product was then subjected to a second round of PCR.  
Details of individual primer reactions for this round are detailed in appendix I.  
To ensure successful amplification prior to sequencing, 2nd round PCR products 
were electrophoresed through a 1.5% agarose gel (Sigma, UK). 
   
PCR products were sequenced using BigDye terminator cycle sequencing on 
an ABI 3100 DNA sequencer (Applied Biosystems, Foster City, California, 
USA).  Sequences obtained were reviewed for the presence of mutations and 
directly compared to the ensemble database.  Identified possible mutations 
were correlated against the COSMIC database of somatic mutations in cancer 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/).  Single nucleotide 
polymorphisms were excluded by sequencing DNA extracted from either 
muscle or distant stroma. 
 
Specimens identified as having mutations on the initial screen were put forward 
for laser capture dissection and further analysis on a gland-by-gland basis to 
assess how widespread the mutation was within the specimen.  Where a 
mutation was present in either the original tumour or Barrett’s oesophagus, the 
neo-Barrett’s specimen from the patient was screened for the presence of the 
same mutation.  In this case the neo-Barrett’s biopsy specimen was sectioned, 
microdissected and sequenced for the identified mutation using the techniques 
described above. 
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6.2.4 Laser capture microdissection 
5µm serial sections were cut from blocks identified as having a mutation on the 
initial screen.  Six serial sections were mounted onto P.A.L.M. membrane slides 
(P.A.L.M., Microlaser Technologies, Benried, Germany) which had been UV 
treated to minimise contamination.  In addition a further serially cut section was 
mounted onto a standard slide and stained with H&E.  The P.A.L.M. mounted 
sections were stained with methylene green which was applied for 30 seconds, 
rinsed with tap water and allowed to dry thoroughly. 
 
Suitable individual crypts for dissection were identified using the H&E slide.  
Each selected crypt was dissected out using the P.A.L.M. system and 
catapulted onto adhesive capped eppendorfs which had been UV treated in 
preparation.  The process was repeated for the same crypt on each of the 
remaining 5 serial slides.  Once the final sample had been catapulted, 14 µl of 
proteinase K solution (Picopure, Life Technologies) was added to the combined 
samples. 
 
Eppendorfs were centrifuged at 3000rpm for 30 seconds, sealed with paraffin 
film and incubated at 65°C overnight.  Following overnight incubation, a 10 
minute incubation at 95°C was used to denature the proteinase K.  Extracted 
DNA was then subjected to PCR sequencing as described above. 
 
6.3 Results 
 
6.3.1 Oesophagectomy samples 
Samples were available from 10 patients as detailed below.   
 
Paired Tumour and Barrett’s oesophagus samples  6 patients 
Tumour sample only      3 patients 
Barrett’s oesophagus only      1 patient 
 
The samples of Barrett’s oesophagus were obtained from the same en-bloc 
oesophagectomy specimen as the samples of tumour but from an area not 
exhibiting frank malignancy. 
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Analysis of the initial screening of the macro-dissected specimens revealed 
mutations in the samples from 4 patients (table 6.1).  In each of these four 
cases the mutation was present in the specimen of adenocarcinoma.  In one 
case the same mutation was present in both the sample of adenocarcinoma 
and the sample of Barrett’s oesophagus. 
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Patient Specimen 
type 
TP53 
Exon-5 
TP53 
Exon-6 
TP53 Exon-
7 
TP53 
Exon-8 
KRAS CDKN2A 
Exon-2 
ACA WT WT WT WT WT WT 1 
BO WT WT WT WT WT WT 
ACA WT WT WT WT c.35G>A WT 2 
BO WT WT WT WT WT WT 
ACA WT WT WT WT WT WT 3 
BO WT WT WT WT WT WT 
4 ACA WT WT WT WT WT WT 
5  ACA WT WT WT WT WT WT 
6 ACA WT WT c.743G>A WT WT WT 
ACA WT WT WT WT WT WT 7 
BO WT WT WT WT WT WT 
8 ACA WT WT WT WT WT WT 
ACA WT WT WT WT WT c.238C>T 9 
BO WT WT WT WT WT WT 
ACA c.451C>T WT WT WT WT WT 10 
BO c.451C>T WT WT WT WT WT 
  
Table 6.1: Results of initial screen of macro-dissected oesophagectomy specimens (ACA – Adenocarcinoma, BO – Barrett’s 
oesophagus, WT – Wild type). 
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6.3.2 Post oesophagectomy neo-Barretts biopsies 
Neo-Barrett’s biopsies from the 4 patients with an identified mutation in their 
resection specimen showed no evidence of this mutation.  In addition no new 
mutation was identified in any of the studied exons, all were wild type.  
 
6.3.3 Laser capture microdissection 
The four samples found to contain mutations were subjected to laser capture 
microdissection of individual crypts with the intention of determining how 
widespread the identified mutation was within the tissue.  Only exons identified 
as containing mutations in the original screening process were sequenced in 
this case.  
 
Patient 2 
 
Eight areas were dissected from this sample (figure 6.1).  The KRAS mutation 
identified in the initial macrodissection was present in every microdissected 
sample.   
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Figure 6.1: Specimen from patient 2 stained with (a) Haematoxylin and Eosin 
and (b) methylene green showing laser captured areas 
 
 
Dissected area Tissue phenotype KRAS 
1 Adenocarcinoma c.35G>A 
2 Adenocarcinoma c.35G>A 
3 Adenocarcinoma c.35G>A 
4 Adenocarcinoma c.35G>A 
5 Adenocarcinoma c.35G>A 
6 Adenocarcinoma c.35G>A 
7 Adenocarcinoma c.35G>A 
8 Adenocarcinoma c.35G>A 
 
Table 6.3: Results of sequencing of laser captured areas of oesophagectomy 
block from patient 2 (WT – Wild type) 
 
 
Patient 6 
 
Five areas were dissected (figure 6.2).  Areas 3 and 5 were from deeper within 
the tissue.  The mutation identified in the initial macrodissection was a 
c.743G>A substitution in exon 7 of TP53. 
1 
8 
2 
3 
4 5 6 
7 
a. 
b. 
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Figure 6.2: Specimen from patient 6 stained with (a) Haematoxylin and Eosin 
and (b) methylene green showing laser captured areas 
 
Dissected area Tissue phenotype TP53 Exon 7 
1 Adenocarcinoma c.743G>A 
2 Adenocarcinoma c.743G>A  
3 Stroma WT 
4 Adenocarcinoma c.743G>A  
5 Stroma WT 
 
Table 6.4: Results of sequencing of laser captured areas of oesophagectomy 
block from patient 6 (WT – Wild type) 
 
 
 
3 
1 
2 
4 
5 
b. 
a. 
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Patient 9 
 
Five areas were dissected, four areas from the malignant epithelium and one 
from the adjacent squamous epithelium.  The c.238C>T substitution in CDKN2A 
exon 2 was present in all of the areas of malignant epithelium which were 
microdissected.  The squamous mucosa microdissected was wild type. 
 
Figure 6.3: Specimen from patient 9 stained with (a) Haematoxylin and Eosin 
and (b) methylene green showing laser captured areas 
4 
3 5 2 1 
a. 
b. 
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Dissected area Tissue phenotype CDKN2A Exon 2 
1 Adenocarcinoma c.238C>T 
2 Adenocarcinoma c.238C>T  
3 Adenocarcinoma c.238C>T  
4 Squamous WT 
5 Adenocarcinoma c.238C>T  
 
Table 6.5: Results of sequencing of laser captured areas of oesophagectomy 
block from patient 9 (WT – Wild type) 
 
 
Patient 10 
 
Nine areas were dissected, areas 1-7 were taken from the malignant epithelium 
and areas 8 and 9 were from the area of adjacent squamous epithelium 
contained within the same block.  The mutation identified in the initial 
macrodissection was a c.451C>T in TP53. 
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Figure 6.4: Specimen from patient 10 stained with (a) Haematoxylin and Eosin 
and (b) methylene green showing laser captured areas 
 
 
Dissected area Tissue phenotype TP53 Exon 5 
1 Adenocarcinoma c.451C>T 
2 Adenocarcinoma c.451C>T  
3 Adenocarcinoma c.451C>T  
4 Adenocarcinoma c.451C>T  
5 Adenocarcinoma c.451C>T  
6 Adenocarcinoma c.451C>T  
7 Adenocarcinoma c.451C>T  
8 Squamous WT 
9 Squamous WT 
 
Table 6.6: Results of sequencing of laser captured areas of oesophagectomy 
block from patient 10 (WT – Wild type) 
 
 
2 
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a. 
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6.4 Discussion 
The origins of neo-Barrett’s are unknown.  It is a common condition in post-
oesophagectomy patients but we do not know if it is a de novo lesion or whether 
it arises from an unresected area of the original Barrett’s.  The resection 
margins are typically sufficient for all salmon-pink mucosa (the macroscopic 
phenotype of Barrett’s) to be removed however, field cancerisation (the process 
by which an epithelial field becomes predisposed to cancer development) 
frequently is indistinguishable from non-cancerised areas (Slaughter et al., 
1953).  It is therefore important to screen neo-Barrett’s and the original 
oesophagectomy in an attempt to ascertain putative genetic relationships 
between the two.   
 
There is some evidence to suggest that mutated progenitor cells which are able 
to give rise to Barrett’s metaplasia are also able to give rise to apparently 
normal squamous epithelium.  Paulson and colleagues (2006) studied 20 
patients who had islands of neo-squamous epithelium which had appeared 
within segments of Barrett’s oesophagus following either medical or surgical 
acid reducing treatment.  All patients included in this study had evidence of a 
clonally expanded population of cells with a mutation of either the CDKN2A or 
TP53 genes.  In 19 cases the neo-squamous epithelium was wild type but in 
one case there was evidence of the same CDKN2A mutation in the both the 
Barrett’s oesophagus and the neo-squamous epithelium.  The authors propose 
that this is evidence of a common precursor cell that is capable of generating 
both types of epithelia.  In the context of neo-Barrett’s the same process might 
occur in reverse, a mutated precursor cell in the proximal oesophagus might be 
giving rise to squamous epithelium at the time of surgery but following surgery 
when this area is exposed to reflux, this precursor cell might begin to produce 
neo-Barrett’s epithelium.  In this case one would expect there to be a clonal link 
between the neo-Barrett’s epithelium and any Barrett’s oesophagus present at 
the time of surgery.  
 
In the present study, samples were initially macrodissected and known 
‘hotspots’ in genes commonly mutated in oesophageal adenocarcinoma were 
sequenced.  Macrodissection of either a whole biopsy specimen or of a relevant 
section of an oesophagectomy block allows an effective screening process for 
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genetic mutations to be undertaken.  This process is relatively crude but it is 
time efficient.  Where mutations are detected, samples can be subjected to 
further, more detailed analysis but in the relatively high number of samples 
where there are no mutations detected, time and reagents are not wasted by 
microdissecting and sequencing multiple individual crypts. 
 
The limitation of the macrodissection screening process is that low copy number 
mutations can be missed either due to contamination by wild type stromal tissue 
or wild type adjacent crypts.  Effectively the predominant wild type tissue masks 
a mutation only present in a tiny proportion of the sequenced tissue.  In the 
current study a single KRAS mutation was detected in one sample using the 
macrodissection process but subsequent laser capture work by colleagues 
using the same original specimen revealed a mutation in exon 5 of TP53 which 
was not evident in the macrodissected specimen even when sequencing was 
repeated. 
 
The present study did not sequence the entire coding sequence of TP53 and 
CDKN2A but instead sequenced selected exons.  It is well recognised that the 
majority of mutations in these genes occur in certain ‘hotspots’ of the gene, 
exons 5-8 in the case of TP53 and exon 2 in the case of CDKN2A.  By 
sequencing these known ‘hotspots’ one would expect to pick up the majority of 
mutations which might be present in these genes.  Whilst mutations in other 
parts of the gene would be missed using this approach the number of these is 
likely to be extremely small.  The gene for KRAS is much smaller and it is 
possible to sequence the whole gene using a single round of PCR and it is 
therefore unnecessary to select mutation hotspots. 
 
In the current study genetic mutations were found in samples from 4 out of 10 
patients (40%).  One sample contained a mutation of the KRAS gene, one 
sample contained a mutation of CDKN2A and 2 samples contained mutations of 
TP53.  Analysis of the COSMIC database of somatic mutations in cancer 
suggests that 9% of oesophageal adenocarcinoma specimens contain a KRAS 
mutation, 10% contain a CDKN2A mutation and 51% contain a TP53 mutation.  
The incidence of mutations detected in this study are therefore similar to what 
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would be expected for both KRAS and CDKN2A but lower than might be 
expected for TP53.   
 
Patients were included in the present study as they had gone on to develop 
neo-Barrett’s oesophagus.  Schneider and colleagues (2000) detected TP53 
mutations in 30 of 59 samples taken from patients with oesophageal 
adenocarcinoma.  They found that tumours with mutations of this gene were 
associated with a markedly poorer prognosis compared those without.  In the 
present study using samples from patients who had survived long enough to 
develop neo-Barrett’s there is likely to have been a selection bias towards 
patients with a better prognosis who potentially are less likely to have had 
tumours with TP53 mutations.  With such small numbers of patients, the lower 
than expected incidence of TP53 mutations observed in this study could be 
entirely due to chance. 
 
Laser capture microdissection allows specimens to be analysed on a crypt by 
crypt basis.  This technique can be used to study clonality of tissues as it is 
possible to reveal mutations present within single crypts or small patches of 
tissue which would be masked by the predominant wild type tissue if a whole 
biopsy or oesophagectomy block specimen were used.  In a tissue of 
monoclonal origin the tissue should be genotypically, as well as phenotypically 
homogenous. 
 
Laser capture microdissection and sequencing of samples from the four 
patients with genetic mutations in the present study demonstrated that the 
observed mutation was present in all crypts dissected from the adenocarcinoma 
epithelium.  This supports the theory that adenocarcinomas are monoclonal.  In 
one case the mutation found in the adenocarcinoma was also present in an 
area of Barrett’s oesophagus present within the same oesophagectomy 
specimen.  This provides a putative link between the two suggesting that the 
tumour arose from this surrounding Barrett’s metaplasia.  Two further patients 
with identifiable mutations in their adenocarcinoma also had areas of Barrett’s 
available to study from the same oesophagectomy specimen.  In neither of 
these cases was the mutation detectable within the Barrett’s specimen.  In 
these cases no link between the Barrett’s oesophagus and the co-existing 
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adenocarcinoma was demonstrable.  An important consideration here is the fact 
that the Barrett’s oesophagus resection blocks were taken from the same 
oesophagectomy specimens but not necessarily from areas adjacent to the 
tumours.  We know that Barrett’s oesophagus is heterogeneous and it may be 
that these tumours arose from surrounding Barrett’s oesophagus but not 
necessarily from the area captured in our specimen block.    
 
Leedham et al (2008) pioneered the use of the techniques described above in 
the study of sporadic Barrett’s oesophagus.  They dissected individual crypts 
from Barrett’s oesophagus biopsies and from oesophagectomy blocks and 
analysed them for both point mutations, as undertaken in the present study and 
for loss of heterozygosity of the tumour suppressor genes CDKN2A, TP53 and 
APC (adenomatous polyposis coli).  In this study it was observed that both 
single biopsies and resection specimens of Barrett’s oesophagus exhibited 
genetic heterogeneity.  The authors suggested a new model for the clonal 
evolution of Barrett’s oesophagus whereby mutations occur in multiple 
progenitor cells.  Each of these mutated progenitor cells gives rise to a separate 
clone of cells and these evolve and compete resulting in a heterogeneous 
mosaic within a Barrett’s oesophagus segment.  Some clones may have a 
selective advantage and consequently expand more widely however there is no 
such thing as an underlying ‘founder mutation’ present throughout a Barrett’s 
oesophagus.   
 
The present study suggests that whilst Barrett’s oesophagus metaplasia may be 
polyclonal in origin, adenocarcinoma arising within Barrett’s oesophagus is 
monoclonal.  None of the mutations detected within the adenocarcinoma 
specimens were detected in the samples of neo-Barrett’s oesophagus from the 
same patients.   
 
There are two potential explanations for the development of neo-Barrett’s 
metaplasia in the oesophageal remnant following sub-total oesophagectomy.  
The first theory is that this is spontaneous metaplasia occurring as a result of 
the profound reflux of acid and bile into the oesophageal remnant following 
surgery.  According to this theory, neo-Barrett’s would therefore develop in 
much the same fashion as sporadic Barrett’s oesophagus.  A second theory is 
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that patients with oesophageal adenocarcinoma have an underlying field 
change present within, and throughout the oesophageal epithelium which 
renders the epithelium unstable and prone to the development of metaplasia 
and subsequent dysplasia.  The present study found no evidence to suggest 
that mutations present in the original tumours were present within the 
oesophageal remnant and therefore found no evidence to support the theory of 
a field change present throughout the oesophagus.   
 
Whilst there is no data to support a theory of oesophageal field change, the 
present study provides insufficient data to exclude this possibility.  The 
mutations detected in the original specimens were detected in areas of 
oesophageal adenocarcinoma and not within adjacent areas of non-neoplastic 
tissue as determined by laser capture microdissection.  These mutations may 
therefore occur late in the metaplasia-dysplasia-adenocarcinoma sequence.  
The post oesophagectomy samples studied did not include any areas of 
dysplasia or adenocarcinoma and this may explain the absence of the 
mutations observed in the oesophagectomy specimens.  It could be argued that 
there may be an undetected persisting mutation, or loss of heterozygosity which 
predisposes to the earliest stages in the conversion of oesophageal squamous 
epithelium to metaplastic columnar epithelium and which underlies both the 
development of the original carcinoma and the subsequent neo-Barrett’s 
oesophagus.    
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Chapter 7. Summary and Discussion 
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This study sought to evaluate the incidence of columnar metaplasia in the 
oesophageal remnant following subtotal oesophagectomy and reconstruction 
with a gastric conduit.  Small studies have suggested that this is a common 
phenomenon occurring in over a third of patients but the present study is the 
largest to address this issue and confirms the high prevalence. 
 
Columnar metaplasia occurred with a similar incidence following surgery for 
both oesophageal adenocarcinoma and squamous cell carcinoma inferring that 
it occurs de novo following surgery rather than being due to residual disease or 
an underlying predisposition of the patient to develop Barrett’s oesophagus.  
Previous studies within the Northern Oesophago-gastric cancer unit have 
demonstrated profound reflux of both acid and bile into the oesophageal 
remnant following oesophagectomy and it is suggested that this is the causative 
mechanism for the development of this neo-Barrett’s metaplasia (Dresner et al., 
2003).  
 
The earliest case of columnar metaplasia in this study was observed only 9 
months following surgery.  This finding suggests that the initial conversion to a 
columnar mucosa can occur much more quickly than has been believed.  While 
patients with Barrett’s oesophagus often have a long history of symptomatic 
reflux, it appears that given the right conditions, oesophageal squamous 
mucosa can transform into a metaplastic columnar epithelium after only a few 
months exposure to the injurious effects of duodeno-gastric reflux.  Gastro 
oesophageal reflux disease (GORD) represents a significant health problem in 
the Western world in particular, with an estimated prevalence of 10 – 20% 
defined by weekly heartburn and/or acid regurgitation (Dent et al., 2005).  The 
vast majority of patients with GORD will have no long term sequelae but the 
association with Barrett’s oesophagus and oesophageal adenocarcinoma is a 
source of concern for health care professionals.  Investigation, with the gold 
standard test being gastroscopy, is relatively expensive and invasive and 
methods to risk stratify those patients at high risk of developing significant 
pathology are urgently required.  Guidelines from the National Institute for 
health and clinical excellence (2004) recommend referral for assessment only 
for patients over the age of 55 who have unexplained or persistent symptoms or 
dyspepsia associated with alarm symptoms.    The present study casts some 
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doubt on the theory that complications of GORD only occur in the context of 
longstanding symptoms and suggests that duration of symptoms may not be as 
significant as previously thought in terms of risk stratification of patients. 
 
One hypothesis of the present study was that neo-Barrett’s metaplasia 
occurring in the oesophageal remnant is an inevitable consequence of subtotal 
oesophagectomy and reconstruction with a gastric conduit.  This hypothesis is 
not proven.  The prevalence of columnar metaplasia increased with time from 
surgery and was over two thirds for patients in whom over eight years had 
elapsed since surgery.  Whether the remaining patients would develop neo-
Barrett’s metaplasia over a longer period of time is unclear.  The present study 
does however confirm that neo-Barrett’s can be expected to develop in almost 
all long term survivors following oesophagectomy.  The other important 
inference of the present study is that the vast majority  of individuals have the 
potential to develop Barrett’s oesophagus in the presence of significant reflux 
disease. 
 
Recent developments in endoscopic techniques have provided less invasive 
options for the treatment of early oesophageal carcinoma in the form of 
endoscopic mucosal resection.  For younger patients one concern has been 
whether further invasive carcinomas may develop as the oesophagus remains 
in-situ following treatment.  Subtotal oesophagectomy has been suggested as 
the treatment of choice for these patients as it removes the vulnerable tissue 
and prevents any future neoplasia which may be associated with recurrence or 
field changes.  The results of the present study suggest that this group of young 
patients with early disease and a good prognosis are at high risk of developing 
columnar metaplasia in the oesophageal remnant over a period of years.  
Surgery perhaps does not offer the absolute guarantee against recurrent 
adenocarcinoma that these patients seek.  Critically, there were no cases of 
dysplasia or adenocarcinoma within the oesophageal remnant of the cohort of 
patients in the present study.  Any risk of this appears small but there is clearly 
a degree of concern given the high prevalence and apparent rapid development 
of the metaplastic epithelium. 
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In the United Kingdom the vast majority of patients undergoing 
oesophagectomy do so for malignant disease.  The median age at the time of 
surgery was 67 in 2009, the latest year for which figures are available.(2010)  
The majority of patients also have relatively advanced disease (stage 2 or 3) 
and will unfortunately die as a result of their disease despite undergoing surgery 
with curative intent.  As a result of these factors the overall 5 year survival 
following oesophagectomy remains significantly under 50% (Dresner SM and 
Griffin SM, 2000).  The absence of any cases of dysplasia in this cohort of 126 
patients is very reassuring.  The median follow up period was 3.6 years and the 
cohort included 47 patients in whom more than five years had elapsed since the 
time of surgery.  These findings suggest that the majority of patients undergoing 
oesophagectomy in the United Kingdom are at very low risk of developing 
dysplasia or adenocarcinoma in their oesophageal remnant during their normal 
lifespan and a finding of neo-Barrett’s is not clinically significant for these 
individuals.   
 
For certain subgroups of patients the propensity to develop neo-Barrett’s may 
be much more relevant.  Patients undergoing surgery for early stage malignant 
disease have a good chance of cure and long term survival.  Paediatric patients 
undergoing surgery for intractable corrosive stricture or oesophageal atresia 
may have a similar reconstruction and in other parts of the world 
oesophagectomy for end stage achalasia remains relatively common.  All of 
these patients might be expected to live for many decades after surgery and the 
risk of malignant progression within neo-Barrett’s epithelium may be much more 
significant.   
 
There are no national guidelines on endoscopic follow up of patients following 
oesophagectomy.  The finding of a high prevalence of neo-Barrett’s in a 
previous study in the Northern Oesophago-gastric Cancer Unit (Dresner et al., 
2003) led to the introduction of routine endoscopic follow up in the unit as 
outlined in Chapter 2.  On the basis of the present larger study, with a 
significant cohort of long term survivors it would appear that this approach is 
unnecessarily cautious.  There appears to be no justification for early routine 
endoscopy at one year.  The policy of routine endoscopy at five years is more 
controversial.  Certainly this seems unlikely to detect dysplasia or 
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adenocarcinoma but it could be argued that this is an appropriate time to screen 
for neo-Barrett’s particularly in younger patients who may benefit from long-term 
endoscopic follow up.  Clearly patient co-morbidities at this time also need to be 
taken into account.  Paediatric patients are an important consideration, they 
may be at the highest risk of malignant progression in neo-Barrett’s due to their 
long post operative life expectancy.  Follow up of these individuals may be 
disrupted when they reach adolescence and transfer to adult services.  The 
present study does not address the issue of neo-Barrett’s in paediatric patients 
but this has been reported elsewhere and endoscopic follow up is 
recommended by some surgeons (Lindahl et al., 1990, Borgnon et al., 2004). 
 
The present study observed that a greater period of time since surgery had 
elapsed for patients with columnar epithelium demonstrating specialised 
intestinal metaplasia compared to those with other forms of columnar 
epithelium.  These observations suggest that the first step in the metaplasia-
dysplasia-adenocarcinoma sequence is conversion to a non-intestinalised 
columnar epithelium.  There has been much debate about the importance of 
specialised intestinal metaplasia in making the diagnosis of Barrett’s 
oesophagus and a lack of concordance remains between guidelines.  North 
American guidelines do not recognise columnar epithelium without specialised 
intestinal metaplasia as Barrett’s oesophagus.  UK guidelines do recognise non-
intestinalised columnar epithelium as Barrett’s oesophagus, providing the 
location of the biopsies is confirmed as being oesophageal in origin.  In post 
surgical patients it is much easier to identify the gastro-oesophageal junction 
and the location of biopsies within the oesophagus is easier to confirm.  The 
present study suggests that patients with cardiac or fundic types of metaplasia 
may simply be at an early stage of the disease process and that these epithelia 
are part of the oesophageal metaplasia sequence rather than a result of 
sampling error and inadvertent gastric biopsy.  This finding has potentially 
important clinical implications.  Patients without intestinal metaplasia are 
unlikely to be offered surveillance and follow up in the United States as they do 
not meet the diagnostic criteria for Barrett’s oesophagus.  The present study 
suggests that these patients may well go on to develop intestinal metaplasia but 
they are likely to have been discharged from clinical follow up. 
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Surveillance programmes for Barrett’s oesophagus are common but there is 
limited evidence to support their efficacy in reducing mortality from oesophageal 
cancer.  The UK based Barrett’s Oesophagus Surveillance Study (BOSS) aims 
to assess the efficacy of surveillance.  This randomised controlled trial will 
compare regular endoscopic surveillance with endoscopy at need for the 
prevention of early mortality from oesophageal adenocarcinoma (Jankowski and 
Barr, 1996).  The study is not due to report for several years but if surveillance 
is shown to confer a survival advantage the issue of how to accurately diagnose 
Barrett’s will become even more important.  The present study would suggest 
that patients without intestinal metaplasia should be included although, as this 
appears to represent earlier stage disease, longer surveillance intervals might 
be appropriate. 
 
   
Studying the development of Barrett’s oesophagus represents a significant 
clinical problem.  It is not possible to accurately identify patients at high risk 
from their demographic profile or symptoms.  The incidence of oesophageal 
adenocarcinoma has increased dramatically over the last three decades and 
despite improvements in chemotherapy regimes and surgical outcomes the 
associated mortality remains high.  It seems likely that real improvements in the 
mortality associated with this condition will come as a result of prevention or 
detection of early disease rather than improvements in the treatment of 
advanced disease.  Barrett’s oesophagus is recognised as the major risk factor 
for oesophageal adenocarcinoma and the prevention of this condition or the 
modification of its malignant potential are key research targets.  Over recent 
years many potential chemopreventive agents and predictive markers of cancer 
progression have been identified but in order to test these a robust high 
throughput model for the development and progression of Barrett’s is required 
(Attwood et al., 2008).  Models allow pre-clinical testing of potential markers and 
treatments without the expense and protracted time periods associated with 
standard trials in humans.  Compounds which show promise in model based 
studies can be fast tracked to human studies and resources allocated 
appropriately.   
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The present study confirms that columnar metaplasia develops in a high 
proportion of patients following subtotal oesophagectomy in an accelerated 
fashion.  These patients represent a possible human model in which 
pharmacological agents which might provide protection from Barrett’s could 
undergo preliminary testing.  If this post-surgical model is compared against the 
characteristics of an ideal Barrett’s model outlined in Chapter 1 some of the 
potential benefits above animal and cell culture models are obvious. 
 
1. Spontaneous metaplasia should occur in the model species 
 
Criteria is fulfilled 
 
2. Model species should be genetically similar to man 
 
Criteria is fulfilled 
 
3. Model should include a lifelike model of reflux 
 
Criteria is partially fulfilled.  Reflux tends to be more severe than in non-surgical 
patients and bile reflux is more significant given the pyloroplasty. 
 
4. Model should represent the complex confounding factors in humans e.g. 
ageing, lifestyle factors and genetic heterogeneity 
 
Criteria is probably fulfilled.  Ageing and lifestyle factors are similar in post 
surgical patients compared to others.  The cohort in the present study included 
a high proportion of patients with adenocarcinoma and it is possible that these 
individuals are not truly genetically representative of the population as a whole. 
 
The absence of any cases of dysplasia in this study suggests that post-
oesophagectomy patients are unlikely to be a good model for the malignant 
progression of Barrett’s oesophagus.  Other studies suggest that progression to 
dysplasia and adenocarcinoma does occur but the numbers involved are 
thankfully small and the timescales appear to be long.  There therefore appears 
to be no advantage in using these ‘model’ patients as opposed to patients with 
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sporadically occurring Barrett’s oesophagus.  The value of the post-
oesophagectomy patient model appears be in demonstrating the development 
rather than progression of columnar metaplasia. 
 
Cellular protein expression as determined by immunohistochemistry allows for 
more detailed examination and comparisons of epithelia than is possible with 
conventional histopathology alone. Cellular proteins have been studied in 
Barrett’s oesophagus by a number of research groups and the present study 
aimed to ascertain whether post-oesophagectomy neo-Barrett’s tissue is 
characterised by the same molecular markers.  Clearly for post-
oesophagectomy patients to be considered as a model for the development of 
Barrett’s oesophagus it is essential that the columnar metaplasia occurring in 
this situation closely resembles that which occurs spontaneously in the general 
population.   
 
The present study demonstrated the recognised ‘classical Barrett’s staining 
pattern’ for cytokeratins 7 and 20 in over two thirds of neo-Barrett’s samples, a 
prevalence which is within the range reported by those investigating sporadic 
Barrett’s oesophagus.  In a subgroup of patients with neo-Barrett’s oesophagus 
with specialised intestinal metaplasia the prevalence of this classical pattern 
was even higher at more than 80%.  This finding provides further support for the 
theory that intestinalised columnar epithelium represents a more advanced 
stage of metaplasia.  The present study also demonstrated the presence of 
neuroendocrine differentiation in neo-Barrett’s tissue in the form of 
Chromogranin A positive cells.  This feature is known to occur commonly in 
sporadic Barrett’s oesophagus and was universal in the neo-Barrett’s samples 
studied. 
 
When considering studies of Barrett’s oesophagus it is important to take into 
account the fact that many different definitions have been used over the years 
and this is likely to contribute to the marked variations in prevalence of 
molecular markers reported.  The results in the present study do not provide 
conclusive proof that post-oesophagectomy neo-Barrett’s is identical to sporadic 
Barrett’s oesophagus but they are certainly similar.  This provides further 
evidence for the theory that this is an appropriate model for the early stages in 
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the development of Barrett’s oesophagus with markers known to be expressed 
in Barrett’s oesophagus frequently present.  There is therefore, now reasonable 
evidence that neo-Barrett’s is endoscopically, microscopically and molecularly 
similar to sporadic Barrett’s oesophagus.   
 
There are drawbacks to the post-oesophagectomy human model for the 
development of Barrett’s oesophagus.  Overall long-term survival after 
oesophagectomy is poor due to the high prevalence of advanced stage disease 
and the average age of patients.  Under 1200 patients are recorded as having 
undergone oesophagectomy in England and Wales in 2009 according to a 
national audit (National Oesophago-gastric Cancer Audit, 2010) and the number 
of patients available for long term follow up is therefore small.  Patients who 
have undergone this type of surgery have often undergone significant physical 
and emotional stress and enrolling them in studies of neo-Barrett’s might cause 
unnecessary anxiety.  This issue would need to be carefully considered by 
researchers and ethics committees particularly given that the present study 
suggests that neo-Barrett’s follows a fairly indolent clinical course for these 
individuals.   
 
The present study also demonstrated the presence of trefoil proteins in neo-
Barrett’s tissue.  This is the first time that these proteins have been studied in 
neo-Barrettt’s tissue.  All three recognised trefoil proteins were expressed to 
varying extents and in a similar pattern to that reported in sporadic Barrett’s 
oesophagus.  Median time from surgery was greater in those patients who 
demonstrated TFF3 expression compared to those who did not express this 
protein suggesting that this trefoil may not be present in very early stage 
Barrett’s oesophagus but becomes more prevalent over time.  Serial biopsies 
from post-oesophagectomy patients would be required to prove this temporal 
association but ethical concerns mean this type of study is unlikely to be 
undertaken.   
 
TFF3 has been proposed as a biomarker which could be used to screen for 
Barrett’s oesophagus.  There are ongoing clinical trials investigating non-
endoscopic screening for Barrett’s oesophagus using a sponge capsule to 
capture oesophageal cells (Kadri SR et al., 2010).  TFF3 staining is used in this 
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study to identify Barrett’s cells with a sensitivity and specificity of over 90% for 
what are deemed clinically relevant segments of 2cm or more.  The results of 
the present study support the use of TFF3 as a biomarker for Barrett’s 
oesophagus but also raise the possibility that early stage disease could be 
missed by this technique if TFF3 has not yet become established in the new 
segment. 
 
Endoscopic screening for Barrett’s oesophagus has been practiced by some 
clinicians, particularly in the United States (Rubenstein et al., 2008).  There is 
no good evidence to support this approach however and it is not currently 
recommended by either American or British guidelines.  At present the only 
routinely available method of screening for Barrett’s is endoscopy.  This is 
expensive, invasive and carries small but not insignificant risks.  Oesophageal 
adenocarcinoma remains relatively rare with less that 6000 cases per year in 
England and Wales.  It is not possible to accurately identify high risk patients as 
gastro-oesophageal reflux is so common and up to 40% of patients with 
adenocarcinoma do not report chronic reflux symptoms (Lagergren et al., 1999).  
Those who undertake screening for Barrett’s argue that it potentially identifies 
individuals who might benefit from surveillance to detect progression to 
adenocarcinoma at an early, treatable stage.  Coupled with the lack of evidence 
for Barrett’s oesophagus surveillance it is unlikely that current methods of 
screening are ever likely to be recommended. 
 
The ongoing work investigating screening with a sponge capsule and TFF3 as a 
biomarker is interesting as it has the potential to change the cost and clinical 
effectiveness balance in favour of screening and surveillance.  The test is easier 
to administer and cheaper than endoscopy and used in combination with other 
biomarkers it might have a role in surveillance.  If new, non-surgical treatments 
for early oesophageal cancer, ablative treatments for Barrett’s and 
chemotherapeutic agents fulfil their promise in long term studies we may in 
future be looking to a situation where we have a cost effective test for an easily 
modifiable condition.  This situation is undoubtedly some way off but is not 
beyond the realms of possibility.  In this context a biomarker to identify patients 
with Barrett’s oesophagus becomes critically important. 
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Oesophageal adenocarcinoma, which develops from Barrett’s oesophagus is 
one of the most lethal malignancies and its incidence is increasing rapidly.  
Future research is needed both in terms of the basic and clinical sciences in 
order to better identify patients at risk, to understand and potentially modify the 
development and progression of the metaplasia-dysplasia-adenocarcinoma 
sequence and to treat patients with invasive adenocarcinoma.  The human 
model for the development of Barrett’s oesophagus provided by post-
oesophagectomy patients is not without limitations but may go some way to 
help with this process. 
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Appendix B – Patient Information leaflet 
 
 
 
 
 
 
 
 
 
 
 
Patient Information Sheet and Consent Form 
      
 
Patient Initials:      Subject Number: 
 
Study Title:  Molecular and genetic changes in Barrett’s 
oesophagus following surgery 
 
 
 
Name of Researchers:  Professor Michael Griffin, Dr. Lorna Dunn 
 
You are being asked to allow the research team to undertake additional 
laboratory tests on samples of tissue which were stored at the time of your 
operation and at your endoscopy tests. Before you decide if you are willing to 
take part, it is important for you to understand the background to this project.  
Therefore please take time to read the following information carefully and 
discuss it with others if you wish.  
 
Ask us if there is anything that is not clear or if you would like more information. 
Take as much time as you want to decide whether or not you wish to take part.  
 
Thank you for reading this. 
 
 
What is the background and purpose of the study? 
 
Barrett’s oesophagus is a condition where the lining of the lower end of the 
gullet (oesophagus) is transformed from its normal lining to one which has a 
more complex nature, similar in many ways to the lining of the stomach.  It is 
believed this condition is caused by acid from the stomach spilling back up into 
the oesophagus (gastro-oesophageal reflux) over many years.  Some patients, 
including you, develop Barrett’s in the remaining part of their oesophagus 
following surgery to remove the rest of the oesophagus. 
 
Many questions remain unanswered about Barrett’s oesophagus.  The process 
by which the normal lining of the oesophagus changes over time is not 
understood.  It is also unclear why some patients develop Barrett’s after their 
surgery whilst others do not. 
 Royal Victoria Infirmary 
Queen Victoria Road 
Newcastle upon Tyne 
NE1 4LP 
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The study which we are performing will hopefully clarify some of the confusion 
in Barrett’s oesophagus, in particular, Barrett’s which occurs following surgery.  
We are seeking volunteers to help us in this study and invite you to take part.  
Our plan is to carry out additional laboratory tests on samples of tissue which 
were routinely stored at the time of your surgery and following your more recent 
endoscopy tests.  These specimens will be analysed under the microscope 
using techniques which are not used routinely but which have proved useful in 
other studies.  By comparing the findings between different groups of patients 
we hope to gain a greater understanding of how Barrett’s develops.  
 
  
Why have I been chosen? 
 
You have been asked to consider taking part in this study because you have 
had an oesophagectomy and have gone on to develop Barrett’s changes in the 
remaining part of your oesophagus.   
 
 
Do I have to take part? 
 
No.  It is up to you to decide whether or not to take part.  If you do, you should 
keep this information sheet to keep and sign and return the consent form. You 
are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard 
of care you receive.  
 
 If you decide not to take part in this study you will not be disadvantaged and 
your medical treatment and care will not be changed in any way. 
 
 
What will happen to me if I take part? 
 
The research team will obtain your old tissue samples and carry out some 
additional laboratory tests on them.  You will not need to undergo any additional 
tests or procedures or attend any additional appointments. 
 
 
What are the possible benefits of taking part? 
 
This study will not directly help you but could lead to more appropriate 
treatments for future generations of patients with the same condition.  The extra 
tests we plan to carry out are for research purposes only and will not affect the 
care you require or receive in the future. 
 
 
What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak 
with the researchers who will do their best to answer your questions (Contact 
0191 2829697).  If you remain unhappy and wish to complain formally, you can 
do this through the NHS Complaints Procedure  
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Complaints can be sent to: 
The Complaints Officer, Freeman Hospital, Newcastle. NE7 7DN 
 
 
Who has reviewed the study?  
This study has been reviewed by the County Durham and Tees Valley 2 
Research Ethics Committee  
 
 
Contact Details: 
 
For further information about the study you can speak to the Clinical Research 
Fellow: 
  
Dr. Lorna Dunn  Tel: 0191 2829697 
 
Thank you for taking the time to read this information sheet.  If you wish 
to participate in this study please complete and return the attached 
consent form. 
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Appendix C. Protocol for processing and paraffin embedding of biopsy 
specimens 
 
 
1. Specimens transferred in 10% neutral buffered formalin 
2. Formalin washed from tissue with tap water 
3. Tissue transferred to 70% ethanol in distilled water for 24 hours 
4. Tissue passed through two changes of 70% ethanol for one hour each 
5. Tissue transferred to 80% ethanol in distilled water for 2 hours 
6. Tissue transferred to 90% ethanol in distilled water for 2 hours 
7. Tissue passed through 3 changes of 100% ethanol each for 2 hours 
8. Tissue transferred to isopropyl alcohol for 2 hours 
9. Tissue transferred to 1:1 isopropyl alcohol:chloroform each for 2 hours 
10. Tissue passed through 2 changes of chloroform each for 2 hours 
11. Tissue passed through 2 changes of molten paraffin wax each for 3 hours 
12. Paraffin wax block allowed to cool embedding tissue 
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Appendix D. Protocol for section cutting and de-waxing and rehydrating 
 
Cutting 
 
1. Paraffin block allowed to cool on ice for 10-15 minutes 
 
2. Block locked in position on microtome and surface apposed to blade 
 
3. 15µm sections trimmed from block until surface of tissue exposed 
 
4. 5 µm sections cut 
 
5. Sections floated and flattened on surface of water bath at 40°C 
 
6. Sections retrieved onto glass slides and allowed to drain 
 
7. Sections dried in oven at 60°C for 45 minutes 
 
8. Sections allowed to cool 
 
 
 
Dewaxing and Rehydrating 
 
Procedure undertaken using Leica Autostainer XL 
 
1. Sections heated in oven at 65°C for 15 minutes 
 
2. Sections soaked in xylene for 1 minute 
 
3. Sections soaked in 2 further changes of xylene for 30 seconds each 
 
4. Sections soaked in 2 changes of absolute alcohol for 30 seconds each 
 
5. Sections soaked in 95% alcohol for 1 minute 
 
6. Sections washed in distilled water for 1 minute 
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Appendix E. Immunohistochemistry staining protocol for Cytokeratins 7 
and 20 
 
Protocol for use with the BenchMark XT automated staining system (Ventana, 
Roche diagnostics, Sussex, UK) 
 
1.  ***** Select EZ Prep ***** 
2.  ***** Start Timed Steps ***** 
3.  ***** Mixers Off ***** 
4. Warm up Slide to 75 Deg C, and incubate for 4 Minutes 
5. Apply EZ Prep Volume Adjust (Ventana, Tucson, Arizona, USA) 
6. Rinse slide 
7. Apply EZ Prep Volume Adjust 
8. Rinse slide 
9. Apply EZ Prep Volume Adjust 
10. Apply Liquid Coverslip (Ventana, Tucson, Arizona, USA) 
11. Warmup Slide to 76 Deg C, and incubate for 4 minutes 
12. Rinse slide 
13. Apply Depar Volume Adjust (Ventana, Tucson, Arizona, USA) 
14. Apply  Liquid Coverslip 
15. Disable slide heater 
16. ***** Mixers On ***** 
17. [ Short - 8 Minute Conditioning ] 
18. Rinse slide 
19. Apply Cell Conditioner #1 (Ventana, Tucson, Arizona, USA) 
20. Apply Liquid Coverslip 
21. ***** Select SSC Wash ***** 
22. Warm up slide to 95 Deg C, and incubate for 8 Minutes 
23. [ Mild - 30 Minute Conditioning ] 
24. Apply Cell Conditioner #1 
25. Apply Liquid Coverslip 
26. Warmup Slide to 100 Deg C, and incubate for 4 minutes 
27. Apply Liquid Coverslip 
28. Apply Cell Conditioner #1 
29. Apply Liquid Coverslip 
30. Apply Cell Conditioner #1 
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31. Apply Liquid Coverslip 
32. Apply Cell Conditioner #1 
33. Apply Liquid Coverslip 
34. Apply Cell Conditioner #1 
35. Apply Liquid Coverslip 
36. Apply Cell Conditioner #1 
37. Apply Liquid Coverslip 
38. [ Standard - 60 Minute Conditioning ] 
39. Apply Cell Conditioner #1 
40. Apply Liquid Coverslip 
41. Apply Cell Conditioner #1 
42. Apply Liquid Coverslip 
43. Apply Cell Conditioner #1 
44. Apply Liquid Coverslip 
45. Apply Cell Conditioner #1 
46. Apply Liquid Coverslip 
47. Apply Cell Conditioner #1 
48. Apply Liquid Coverslip 
49. Apply Cell Conditioner #1 
50. Apply Liquid Coverslip 
51. Apply Cell Conditioner #1 
52. Apply Liquid Coverslip 
53. Disable slide heater 
54. Incubate for 8 minutes 
55. Rinse slide With Reaction Buffer (Ventana, Tucson, Arizona, USA) 
56. Adjust slide volume with Reaction Buffer 
57. Apply Liquid Coverslip 
58. Rinse slide with Reaction Buffer 
59. Adjust slide volume with Reaction Buffer 
60. Apply Liquid Coverslip 
61. ***** Procedure Synchronization ***** 
62. Warm up Slide to 37 Deg C, and incubate for 4 minutes 
63. Rinse slide with Reaction Buffer 
64. Adjust slide volume with Reaction Buffer 
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65. Apply One Drop of UV INHIBITOR (Ventana, Tucson, Arizona, USA) , Apply 
Liquid Coverslip, and incubate for 4 minutes 
66. Rinse slide with Reaction Buffer 
67. Adjust slide volume With Reaction Buffer 
68. Apply Liquid Coverslip 
69. Warm up slide to 37 Deg C, and incubate for 4 Minutes 
70. Rinse Slide with Reaction Buffer 
71. Adjust slide volume with Reaction Buffer 
72. Apply Liquid Coverslip 
73. Apply one drop of primary antibody and Incubate for 32 minutes 
74. Rinse slide with Reaction Buffer 
75. Adjust slide volume With Reaction Buffer 
76. Apply Liquid Coverslip 
77. Warm up Slide to 37 Deg C, and incubate for 4 minutes 
78. Rinse slide with Reaction Buffer 
79. Adjust slide volume with Reaction Buffer 
80. Apply one drop of Ultraview horse radish peroxidase universal multimer 
(Ventana, Tucson, Arizona, USA), apply Liquid Coverslip, and incubate for 8 
minutes 
81. Rinse slide with Reaction Buffer 
82. Adjust slide volume with Reaction Buffer 
83. Apply Liquid Coverslip 
84. Rinse slide with Reaction Buffer 
85. Adjust slide volume with Reaction Buffer 
86. Apply one drop of Ultraview DAB universal chromogen and one drop of 
Ultraview DAB H2O2 (both Ventana, Tucson, Arizona, USA), apply Liquid 
Coverslip, incubate for 8 Minutes 
87. Rinse slide with Reaction Buffer 
88. Adjust slide volume with Reaction Buffer 
89. Apply One Drop of Ultraview copper, apply Liquid Coverslip, and incubate 
for 4 minutes 
90. Rinse slide with Reaction Buffer 
91. Adjust slide volume with Reaction Buffer 
92. Apply one drop of Hematoxylin II counterstain (Ventana, Tucson, Arizona, 
USA), apply Liquid Coverslip and incubate for 8 Minutes 
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93. Rinse slide with Reaction Buffer 
94. Adjust slide volume with Reaction Buffer 
95. Apply Liquid Coverslip 
96. Rinse slide with Reaction Buffer 
97. Adjust slide volume with Reaction Buffer 
98. Apply one drop of Bluing reagent (Ventana, Tucson, Arizona, USA), apply 
Liquid Coverslip and Incubate for 4 Minutes 
99. Rinse slide with Reaction Buffer 
100. Apply Liquid Coverslip 
101. Disable slide heater 
102. ***** Select Optional Wash ***** 
103. ***** Select SSC Wash ***** 
104. ***** Start Timed Steps ***** 
105. Rinse slide with Reaction Buffer 
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Appendix F. Immunohistochemistry staining protocol for chromogranin A 
 
Protocol for use with the BenchMark XT automated staining system (Ventana, 
Roche diagnostics, Sussex, UK) 
 
1. ***** Select EZ Prep ***** 
2. ***** Start Timed Steps ***** 
3. ***** Mixers Off ***** 
4. Warm up slide to 75 Deg C, and incubate for 4 minutes 
5. Apply EZ Prep Volume Adjust (Ventana, Tucson, Arizona, USA) 
6. Rinse slide 
7. Apply EZ Prep Volume Adjust 
8. Rinse slide 
9. Apply EZ Prep Volume Adjust 
10. Apply Liquid Coverslip (Ventana, Tucson, Arizona, USA) 
11. Warm up slide to 76 Deg C and incubate for 4 minutes 
12. Rinse slide 
13. Apply Depar Volume Adjust (Ventana, Tucson, Arizona, USA) 
14. Apply Liquid Coverslip 
15. Disable slide heater 
16. ***** Mixers On ***** 
17. [ Short - 8 Minute Conditioning ] 
18. Rinse slide 
19. Apply Cell Conditioner #1 (Ventana, Tucson, Arizona, USA) 
20. Apply Liquid Coverslip 
21. ***** Select SSC Wash ***** 
22. Warm up slide to 95 Deg C and incubate for 8 minutes 
23. [ Mild - 30 Minute Conditioning ] 
24. Apply Cell Conditioner #1 
25. Apply Liquid Coverslip 
26. Warm up slide to 100 Deg C and incubate for 4 minutes 
27. Apply Liquid Coverslip 
28. Apply Cell Conditioner #1 
29. Apply Liquid Coverslip 
30. Apply Cell Conditioner #1 
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31. Apply Liquid Coverslip 
32. Apply Cell Conditioner #1 
33. Apply Liquid Coverslip 
34. Apply Cell Conditioner #1 
35. Apply Liquid Coverslip 
36. Apply Cell Conditioner #1 
37. Apply Liquid Coverslip 
38. Disable slide heater 
39. Incubate for 8 minutes 
40. Rinse slide with Reaction Buffer 
41. Adjust slide volume with Reaction Buffer 
42. Apply Liquid Coverslip 
43. Rinse slide with Reaction Buffer 
44. Adjust slide volume with Reaction Buffer 
45. Apply Liquid Coverslip 
46. ***** Procedure Synchronization ***** 
47. Warm up Slide to 37 Deg C and incubate for 4 minutes 
48. Rinse slide with Reaction Buffer 
49. Adjust slide volume with Reaction Buffer 
50. Apply one drop of ultraView Inhibitor (Ventana, Tucson, Arizona, USA), 
apply Liquid Coverslip, and incubate for 4 minutes 
51. Rinse slide with Reaction Buffer 
52. Adjust slide volume with Reaction Buffer 
53. Apply Liquid Coverslip 
54. Warm up slide to 37 Deg C and incubate for 4 minutes 
55. Rinse slide with Reaction Buffer 
56. Adjust slide volume with Reaction Buffer 
57. Apply Liquid Coverslip 
58. Apply one drop of primary antibody and incubate for 32 minutes 
59. Rinse slide with Reaction Buffer 
60. Adjust slide volume with Reaction Buffer 
61. Apply Liquid Coverslip 
62. Warm up slide to 37 Deg C and incubate for 4 minutes 
63. Rinse slide with Reaction Buffer 
64. Adjust slide volume with Reaction Buffer 
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65. Apply one drop of ultraView horseradish peroxidise universal multimer, 
apply Liquid Coverslip and Incubate for 8 minutes 
66. Rinse slide with Reaction Buffer 
67. Adjust slide volume with Reaction Buffer 
68. Apply Liquid Coverslip 
69. Rinse slide with Reaction Buffer 
70. Adjust slide volume with Reaction Buffer 
71. Apply one drop of ultraView DAB and one drop of ultraView DAB H2O2, 
apply Liquid Coverslip, incubate for 8 minutes 
72. Rinse slide with Reaction Buffer 
73. Adjust slide volume with Reaction Buffer 
74. Apply one drop of ultraView copper, apply Liquid Coverslip and incubate for 
4 minutes 
75. Rinse slide with Reaction Buffer 
76. Adjust slide volume with Reaction Buffer 
77. Apply one drop of Hematoxylin II counterstain (Ventana, Tucson, Arizona, 
USA), apply Coverslip, and incubate for 8 Minutes 
78. Rinse slide with Reaction Buffer 
79. Adjust slide volume with Reaction Buffer 
80. Apply Liquid Coverslip 
81. Rinse slide with Reaction Buffer 
82. Adjust slide volume with Reaction Buffer 
83. Apply one drop of Bluing reagent (Ventana, Tucson, Arizona, USA), apply 
Liquid Coverslip and incubate for 4 minutes 
84. Rinse slide with Reaction Buffer 
85. Apply Liquid Coverslip 
86. Disable slide heater 
87. ***** Select Optional Wash ***** 
88. ***** Select SSC Wash ***** 
89. ***** Start Timed Steps ***** 
90. Rinse slide with Reaction Buffer 
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Appendix G. Trefoil factor Immunohistochemistry Protocol 
 
1. Sections prepared as described 
2. Endogenous peroxidase activity blocked by soaking in methanol-hydrogen 
peroxide for 10 mins 
3. Slides washed in tris-buffered saline (TBS) for 3 x 5 minutes 
4. Antigen retrieval by heating slides in citrate buffer (pH6) in a pressure cooker 
for 1 minute once full pressure reached. 
5. Slides cooled in running tap water 
6. Slides incubated with avidin/biotin blocking kit (Vector Labs Inc, Ca, USA) 
according to manufacturers instructions. 
7. Slides washed in TBS for 3 x 5 minutes 
8. Slides incubated with normal rabbit serum for 10 minutes 
9. Primary antibodies diluted with normal rabbit serum as follows 
 TFF1  1:10 
 TFF2  1:1000 
 TFF3  1:20 
10. Slides incubated with primary antibodies at room temperature for 1 hour 
11. Slides washed in TBS for 3 x 5 minutes 
12. Slides incubated with bitinylated goat anti-mouse secondary antibody 
(Vector Labs Inc, Ca, USA) for 1 hour. 
13. Slides washed in TBS for 3 x 5 minutes 
14. Slides incubated with avidin-biotin peroxidase complex (Vectastain ABC Kit, 
Vector Labs Inc, Ca, USA) for 30 minutes 
15. Slides washed in TBS for 3 x 5 minutes 
16. Slides stained with 3,3’-diaminobenzidine/hydrogen peroxide 
17. Slides washed in running tap water 
18. Slides counterstained by dipping in haematoxylin for 15 seconds 
19. Slides rinsed in running tap water 
20. Slides soaked in Scott’s tap water for 30 seconds 
21. Slides rinsed in running tap water 
22. Slides dehydrated by immersion in a series of increasing concentrations of 
ethanol, 50%, 75%, 95%, 100%, 100%. 
23. Slides cleared in xylene 
24. Sections mounted under cover slips 
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Appendix H. First round PCR reagent quantities and annealing 
temperatures 
 
Primer MgCl2 Q Solution Annealing 
temperature  
TP53 Exon-5 1 µl 5 µl 55°c 
TP53 Exon-6 2 µl 5 µl 60°c 
TP53 Exon-7 1 µl 5 µl 60°c 
TP53 Exon-8 2 µl 5 µl 60°c 
KRAS 2 µl 5 µl 60°c 
CDKN2A Exon-2 2 µl 5 µl 60°c 
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Appendix I. Second round PCR reagent quantities and annealing 
temperatures  
 
Primer MgCl2 Q Solution Annealing 
temperature  
TP53 Exon-5 1 µl 5 µl 60°c 
TP53 Exon-6 1 µl 0 µl 60°c 
TP53 Exon-7 1 µl 5 µl 60°c 
TP53 Exon-8 2 µl 0 µl 60°c 
KRAS 2 µl 5 µl 55°c 
CDKN2A Exon-2 2 µl 5 µl 60°c 
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